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ABSTRACT 
 
 
 
Background: Alterations in thyroid organogenesis occurs very frequently in 
humans, leading to several conditions responsible for primary congenital 
hypothyroidism. Such alterations, classified as “thyroid dysgenesis” (TD) 
include athyresis, ectopy of the gland, and thyroid hypoplasia. The molecular 
mechanism leading to TD are largely unknown, but, several studies linked 
thyroid dysgenesis to mutations in genes expressed in the developing thyroid, 
such as NKX2-1, NKX2-5, PAX8, FOXE1, rTSH. 
NKX2-1 mutations have been described in several patients with a syndromic 
form of primary congenital hypothyroidism associated to respiratory distress, 
and benign hereditary chorea (Brain–Thyroid–Lung Syndrome, BTLS). 
Methods: we screened 76 patients with persistent CH for mutations in known 
(NKX2-1, NKX2-5, PAX8) and new candidate (DNAJC17) genes by SSCP, or 
HRM. In addition, the NKX2-1 gene was sequenced in the members of a 
Brazilian family with clinical features of BTLS. 
Results: We found no mutations in the PAX8 or NKX2-5 genes in our cohort. 
The only variation observed was an already reported polymorphism 
(rs199939219) within the PAX8 gene that causes a change of the first 
nucleotide of the triplet encoding for serine at position 337 (Ser337Ala). This 
change, functionally tested by in vitro studies, has no effect on the PAX8 
protein activity.  
We also looked for mutations in the DNAJC17 gene, a new candidate gene that 
has been demonstrated to act as phenotype modulator in mouse double 
heterozygous for deletion in Nkx2-1 and Pax8. In DNAJC17 we found a known 
polymorphism c.350A>C.  
Finally, we were able to identify a novel NKX2-1 mutation in the Brazilian 
family with the clinical findings of the BTLS. The mutation is a deletion of a 
cytosine at position 834 (ref. sequence NM_003317) (c.493delC) that causes a 
frameshift with formation of an abnormal protein from amino acid 165 and a 
premature stop at position 196. The last amino acid of the nuclear localization 
signal, the whole homeodomain, and the carboxy terminus of NKX2-1 are all 
missing in the mutant protein, which has a premature stop codon at position 
196 (p.Arg165Glyfs*32). The p.Arg165Glyfs*32 mutant does not bind DNA, 
and it is unable to transactivate the thyroglobulin (Tg) and the surfactant 
protein-C (SP-C) promoters. Interestingly, a dose-dependent dominant negative 
effect of the p.Arg165Glyfs*32 was demonstrated only on the Tg promoter, but 
not on the SP-C promoter. This effect was also noticed when the mutation was 
tested in presence of PAX8 or cofactors that synergize with NKX2-1 (P300 and 
TAZ). The functional effect was also compared with the data present in the 
literature and demonstrated that, so far, it is very difficult to establish a specific 
correlation among NKX2-1, PAX8 and NKX2-5 mutations, their functional 
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consequence, and the clinical phenotype of affected patients, thus suggesting 
that the detailed mechanisms of transcriptional regulation still remain unclear. 
Conclusions: We describe a novel NKX2-1 mutation in a Brazilian family and 
demonstrate that haploinsufficiency may not be the only explanation for BTLS. 
Our results indicate that NKX2-1 activity is also finely regulated in a tissue-
specific manner, and additional studies are required to better understand the 
complexities of genotype–phenotype correlations in the NKX2-1 deficiency 
syndrome. No mutations have been identified in sporadic cases of TD in 
NKX2-5, PAX8 or DNAJC17 genes, suggesting that sporadic cases of TD are 
likely to be caused by epigenetic factors, rather than mutations in thyroid 
transcription factors or genes involved in thyroid development. 
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1. BACKGROUND 
 
 
 
Primary congenital hypothyroidism (CH) is the most frequent endocrine 
metabolic disease in the infancy, with an incidence of about 1/2500 newborns a 
year (Cassio, Corbetta et al. 2013). In absence of an adequate treatment, CH is 
characterized by signs and symptoms of impaired metabolism and by motor 
and mental handicaps. Before the introduction of a neonatal screening program, 
CH was one of the most frequent causes of mental retardation. With the 
exception of the rare cases of central hypothyroidism, CH is characterized by 
the presence of elevated TSH levels at birth in response to reduced thyroid 
hormone production.  
Many human disorders appear to be derived from alterations of the 
morphogenetic events. For instance, severe malformations in foregut-derived 
organs (such as esophageal atresia, trachea esophageal fistula, lung anomalies, 
and congenital stenosis of the esophagus and trachea) are common anomalies 
occurring in one in 2000 to one in 5000 live births (Motoyama J, Liu J et al. 
1998). 
Thyroid gland organogenesis results in an organ the shape, size, and position of 
which are largely conserved among adult individuals of the same species, thus 
suggesting that genetic factors must be involved in controlling these 
parameters.  
In humans, the organogenesis of the thyroid gland is often disturbed, leading to 
a variety of conditions. In the majority of cases (80-85%), CH is due to 
alterations occurring during the gland organogenesis, which results in a thyroid 
gland that is absent (thyroid agenesis or athyreosis), hypoplastic (thyroid 
hypoplasia), or located in an unusual position (thyroid ectopy). All these 
entities are grouped under the term “thyroid dysgenesis” (TD) (De Felice M 
and Di Lauro R 2004).  
In the remaining 15-20% of cases, CH is caused by inborn errors in the 
molecular steps of thyroid hormones biosynthesis, secretion or recycling. 
These forms of CH are indicated with the term “dyshormonogenesis”, and are 
characterized by an enlargement of the gland (goiter), presumably due to 
elevated TSH levels. Thyroid dyshormonogenesis shows classical Mendelian 
recessive inheritance, and the molecular mechanisms in most of these forms 
have been characterized. In addition, mostly thanks to the changes in screening 
strategies for CH of the last years, it has been recently observed an increase 
number of mild forms of CH associated with eutopic thyroid gland. Of these, 
about one third of patients presented a permanent hypothyroidism and need to 
continue LT4 therapy after re-evaluation, and in 8.7% of the studied cases a 
mutation in TSHR gene has been identified (Rabbiosi, Vigone et al. 2013). 
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1.1 Morphogenesis of thyroid gland 
 
The thyroid gland in mammals is located in the neck region. The gland 
produces thyroid hormones and calcitonin in two distinct cell types, the TFCs 
and the parafollicular or C cells, respectively. The TFCs, the most numerous 
cell population in the gland, form the thyroid follicles, spherical structures 
serving as storage and controlled release of thyroid hormones (Mauchamp J, 
Mirrione A et al. 1998). The C cells are scattered in the interfollicular space, 
mostly in a parafollicular position. The two diverse cell types, responsible for 
the dual endocrine function of the gland, originate from two different 
embryological structures: the thyroid anlage is the site of origin of the TFCs 
whereas the ultimobranchial bodies are the source of C cells. The thyroid 
anlage is an area enclosing a small group of endodermal cells, and it is located 
on the midline of the embryonic mouth cavity in its posterior part. The 
ultimobranchial bodies are a pair of transient embryonic structures derived 
from the fourth pharyngeal pouch and located symmetrically on the sides of the 
developing neck. The C cell precursors migrate from the neural crest (Le 
Douarin N, Fontaine J et al. 1974) bilaterally to the fourth pharyngeal pouches 
and become localized in the ultimobranchial bodies (Fontaine J 1979). The 
cells of the thyroid anlage and the ultimobranchial bodies migrate from their 
respective sites of origin and ultimately merge in the definitive thyroid gland. 
In the merging process, both the thyroid anlage and the ultimobranchial bodies 
disappear as individual structures, and the cells contained in them disperse in 
the structure of the adult thyroid gland. The cells originating from the anlage 
continue to organize the thyroid follicles, whereas the C cells scatter within the 
interfollicular space.  
The morphogenesis of the thyroid, like in many endoderm-derived organs, 
begins with an event that recruits a group of cells, in an homogeneous cell 
layer, to the thyroid fate, i.e., to follow all the developmental steps necessary to 
achieve the TFC phenotype. This event is called, in developmental biology 
terms, “specification”, because a group of cells are specified to undertake a 
definite developmental program. The first visible change is a thickening of the 
endodermal epithelium in the foregut, which is referred to as thyroid anlage. 
Thickening in a restricted region of a cell layer, a common event in the 
initiation of organogenesis, has been suggested to be an essential event in the 
generation of signals required for the continuation of organogenesis (Kenyon 
KL, Ranade SS et al. 2003).  
 
In mice, thyroid anlage appears at embryonic day (E) 8-8.5 in the ventral wall 
of the primitive pharynx (Kaufman MH and Bard  J 1999). At E9-E9.5 the 
endodermal cells of the thyroid anlage start to migrate and to proliferate, 
invading the surrounding mesenchyme and forming the thyroid bud. By E10, 
the thyroid primordium appears as a flask-like structure with a narrow neck 
that rapidly becomes a diverticulum. A small hole at the site of origin in the 
pharyngeal floor (the foramen cecum) is the remnant of the anlage, connected 
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with the migrating thyroid primordium by a narrow channel (the thyroglossal 
duct). At E11.5 the thyroglossal duct disappears, and the thyroid primordium 
loses its connections with the floor of the pharynx and begins to expand 
laterally. Two days later the thyroid primordium reaches the trachea, which has 
extended ventrocaudally starting from the primitive laryngotracheal groove. By 
E15–E16 the thyroid lobes expand considerably, and the gland exhibits its 
definitive shape: two lobes connected by a narrow isthmus. The mechanisms 
leading to proliferation of the precursors and to the formation of the lobes 
remain to be elucidated. Surprisingly, TSH signaling, the best known growth 
stimulus for adult thyroid cells, does not appear to be involved (Postiglione 
MP, Parlato R et al. 2002) (Marians, Ng et al. 2002). By E15.5, the first 
evidence of follicular organization appears with many small follicles 
disseminated within the gland. At this time calcitonin-producing C cells, 
derived from the ultimobranchial bodies that have fused with the primitive 
thyroid at around E14, can also be detected among follicles (Cordier AC and 
Haumont 1980). 
The differentiative program of TFCs is completed only when the gland reaches 
its final location. As a result, TFCs express a series of proteins that are typical 
of TFCs and that are essential for thyroid hormone biosynthesis. Because there 
will be no further differentiation event in the life of TFCs, this last 
differentiation could be called terminal or functional differentiation. Genes 
typical of this stage appear according to a given temporal pattern: Tg, TPO, 
and TSH receptor (Tshr) genes are expressed by E14.5 (Lazzaro, Price et al. 
1991) (35); sodium/iodide symporter (NIS) is detected by E16  (Postiglione 
MP, Parlato R et al. 2002). T4 is first detected at E16.5 (Meunier D, Aubin J et 
al. 2003). 
 
In humans, the process of thyroid morphogenesis is very similar, lasting from 
the 3rd to 16th week of gestation (Trueba SS, Auge J et al. 2005). 
 
 
 
1.2 Thyroid dysgenesis 
 
The most critical events in thyroid organogenesis occur during the first 60 days 
of gestation in man and the first 15 days in mice. It is likely that alterations in 
the molecular events occurring during this period can be associated to TD.  
 
 
1.2.1 Athyreosis 
 
The absence of TFC in orthotopic or ectopic location is called athyreosis. This 
condition can either be the consequence of lack of formation of the thyroid bud 
or results from alterations in any of the step following the specification of the 
thyroid bud and determining a defective survival and/or proliferation of the 
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precursors of the TFC. In athyreotic patients, the presence of cystic structures 
resulting from the persistence of remnants of the thyroglossal duct is frequently 
reported (Marinovic D, Garel C et al. 2003). This finding indicates that in these 
subjects some of the early events of thyroid morphogenesis have taken place 
but the cells fated to form the TFCs either did not survive or switched to a 
different fate. In many cases, scintigraphy failed to demonstrate the presence of 
thyroid tissue, but thyroid scanning by ultrasound reveals a very hypoplastic 
thyroid. 
 
 
1.2.2 Ectopia 
 
The ectopic thyroid is the consequence of a failure in the descent of the 
developing thyroid from the thyroid anlage to its definitive location in front of 
the trachea. An ectopic thyroid can be found in any location along the path of 
the developing gland migration from the foramen caecum to the mediastinum. 
In the majority of cases, the ectopic thyroid appears as a mass in the back of 
the tongue (lingual thyroid, usually functioning). Sublingual ectopic tissues are 
less frequent; in this case, thyroid tissue is present in a midline position above, 
below or at the level of the hyoid bone. Ectopic thyroid tissues within the 
trachea have also been reported (Brandwein M, Som P et al. 1998). In a few 
cases thyroid tissue in the submandibular region has been described (Kumar R, 
Gupta R et al. 2000) (Feller KU, Mavros A et al. 2000). Some authors, on the 
assumption that TFCs derive from both a median thyroid and a lateral thyroid 
bud (i.e., the ultimobranchial body), hypothesize that this aberrant thyroid 
tissue originates from a defective lateral thyroid component that cannot migrate 
and fuse with the median thyroid anlage. However, the hypothesis that TFCs 
can be derived from the ultimobranchial bodies appears to be questionable. 
Studies in animal models did not offer any conclusive demonstration that cells 
of ultimobranchial bodies are fated to differentiate toward typical TFCs. 
Furthermore, in the majority of subjects with an ectopic thyroid located along 
the midline, no other thyroid tissue is detectable either in paratracheal or in 
tracheal areas. If the thyroid did originate from two different buds, a higher 
number of cases where, in addition to the ectopic median thyroid, another 
thyroid mass derived from the lateral component should also be present. 
Because this finding has never been reported, we should conclude that ectopic 
submandibular thyroid tissues, also, are the result of an aberrant migration of 
the median thyroid anlage  (De Felice M and Di Lauro R 2004). 
Developmental defects other than abnormal migration of the thyroid bud 
should be taken into account to explain the presence of thyroid tissue in 
locations distant from the path of migration of the embryonic gland. The origin 
of intracardiac ectopic thyroids could be due to disturbances occurring early in 
embryogenesis, when the thyroid anlage is in close contact with the embryonic 
heart (Casanova JB, Daly RC et al. 2000). In the case of sub diaphragmatic 
locations such as the duodenum wall (Takahashi T, Ishikura H et al. 1991), 
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gallbladder (Harach HR 1998), or porta hepatis, either aberrant migration or 
heterotopic differentiation of uncommitted endodermal cells could be 
hypothesized (Ghanem N, Bley T et al. 2003). 
 
 
1.2.3 Hypoplasia 
 
Orthotopic and hypoplastic thyroid is reported in 5% of CH cases. Thyroid 
hypoplasia is probably a genetically heterogeneous form of thyroid dysgenesis. 
It could be due to defects in any of the genes that control the number of thyroid 
cells (De Felice M and Di Lauro R 2004). 
The relative proportions of the main TD phenotypes vary in different studies, 
depending on the methodology used to detect the presence of the gland. 
According to 
99
Tc scintigraphy (Olivieri, Stazi et al. 2002), (Devos, Rodd et al. 
1999), (Connelly JF, Coakley JC et al. 2001), more sensitive but exclusively 
dependent on metabolic activity, ectopy of the thyroid is the most frequent type 
of dysgenesis (48–61% of cases), whereas athyreosis is the cause of 15–33% of 
cases of TD. The scintigraphic analysis could either not reveal the frequency of 
thyroid hypoplasia, or most likely underestimated it at only 5% of CH patients. 
It is conceivable that these studies included in athyreosis some non functioning 
thyroids and counted as hypoplasia only the smallest glands. In a study based 
on ultrasound diagnosis, which is independent from metabolic activity but not 
as sensitive as scintigraphy, athyreosis was found in 48% of CH patients, 
ectopy in 18%, and hypoplasia in 17%. This technique most likely included in 
athyreosis some very small, ectopic thyroids. From these data it could conclude 
that the most frequent form of TD is thyroid gland ectopy and that a 
combination of ultrasound sonography and 
99
Tc scintigraphy might resolve a 
precise relative proportion of these phenotypes. However, cost-benefit 
considerations should be carefully evaluated before performing 
99
Tc 
scintigraphy in cases of CH (De Felice M and Di Lauro R 2004). 
 
 
1.2.4 Hemiagenesis 
 
Thyroid hemiagenesis is a rare congenital abnormality, in which one of the 
thyroidal lobes fails to develop. Thyroid hemiagenesis is often associated with 
mild and or transient hypothyroidism but several patients were found to be in 
euthyroid state (both serum TSH and thyroid hormone levels are within the 
normal range). Thyroidal hemiagenesis is predominantly seen in females with 
an incidence to 0.2% in healthy children. In the large majority of the cases, it is 
the left lobe to be absent (Maiorana, Carta et al. 2003). The causes of thyroid 
hemiagenesis are still unclear and it is unknown whether the disturbance of the 
lobulation process is due to interference of environmental factors or to genetic 
abnormality. In addition, the occurrence of some cases of thyroid hemiagenesis 
among members of the same family (Rajmil HO, Rodriguez-Espinosa J et al. 
1984) suggests that genetic factors could be involved in this anomaly. The 
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molecular mechanisms leading to the formation of the two thyroid symmetrical 
lobes, which are impaired in the case of hemiagenesis, are not known. In the 
mouse embryo, by E12, the midline-located thyroid bud begins to expand 
laterally, and at E15 the bilobed shape of the gland is evident. The genetic basis 
of the lobulation process is finally beginning to be understood. Indeed, either a 
non lobulated gland or hemiagenesis of the thyroid (Fagman H, Grände M et 
al. 2003) have been described in Shh
-/-
 mice embryos. Hemiagenesis has also 
been reported in double heterozygous Titf1
-/-
 Pax8
-/- 
mice  (De Felice, Macchia 
PE et al. 2002). However, in humans, candidate genes responsible for the 
hemiagenesis of the thyroid have not yet been described. 
 
 
1.3 Molecular basis of thyroid organogenesis 
 
 The molecular basis of thyroid gland development began to be investigated 
with the discovery that the transcription factor Nkx2-1, identified as 
responsible for the thyroid-specific expression of Tg and TPO, is expressed not 
only in functioning thyroid cells but also in their precursors (Lazzaro, Price et 
al. 1991). Subsequently, the transcription factors Foxe1, Pax8, and Hhex were 
also found to be expressed both in mature thyroid cells and in their precursors. 
The expression of these factors in the thyroid anlage, at the very beginning of 
thyroid morphogenesis, immediately suggested that these genes might play an 
important role in the organogenesis of the thyroid gland. These factors are also 
present in other embryonic tissues, but all four are coexpressed only in the 
thyroid anlage. 
In the primitive pharynx, Nkx2-1 is present exclusively in the thyroid anlage, 
and its appearance coincides with specification of the anlage. Nkx2-1 remains 
expressed in the TFC during all stages of development and in adulthood. In 
differentiated TFC, Nkx2-1 controls thyroglobulin and thyroperoxidase 
expression (Civitareale, Lonigro et al. 1989). Nkx2-1 is also present in the 
trachea and lung epithelium (Figs. 1 and 2) and in selected areas of the 
forebrain, including the developing posterior pituitary (Lazzaro, Price et al. 
1991). After birth and in adult organisms, Nkx2-1 is still present in the thyroid 
and lung epithelium and in the posterior pituitary (Guazzi, Price et al. 1990), 
whereas its expression in the brain is restricted to the periventricular regions 
and some hypothalamic nuclei (Nakamura K, Kimura S et al. 2001). The 
expression of Nkx2-1 in the hypothalamus is reduced in the adult compared 
with the embryonic brain; however, it increases transiently but markedly before 
the first endocrine manifestations of puberty (Lee BJ, Cho GJ et al. 2001). 
Like Nkx2-1, Pax8 is detected in the developing thyroid from E8.5, i.e., at the 
time of specification. In the endoderm Pax8 mRNA is present only in the 
thyroid anlage (Fig. 1). Expression of Pax8 is maintained in TFCs during all 
stages of development (Fig. 2) and in adulthood.  
Foxe1 mRNA is detected at E8.5 in all the endodermal cells of the floor of the 
foregut, including the thyroid anlage. Hence, at variance with Nkx2-1 and 
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Pax8, the expression of which in the pharynx is strictly limited to the thyroid 
anlage, Foxe1 has a wider domain of expression. However, the expression of 
Foxe1 is limited posteriorly because no Foxe1 mRNA is present in the lung 
(Fig. 1). It has also been noted that at E8.5 Foxe1 seems to be much more 
evident in a region of the pharynx posterior to that of the thyroid precursor 
cells (Zannini, Avantaggiato et al. 1997). Expression of Foxe1 in the thyroid 
cell precursors is maintained during development (Fig. 2) and persists in adult 
TFCs. At later stages of development Foxe1 is expressed in the tissues derived 
from the pharyngeal arches and pharyngeal wall: thyroid, tongue, epiglottis, 
palate, and esophagus. 
Also Nkx2-5 is expressed in the thyroid primordium during development 
(Kasahara, Bartunkova et al. 1998). NKX2-5 transcripts were identified in the 
pharyngeal endoderm at stage E8.5 to E9.5 in a subset of cells that start to 
differentiate and migrate antero-ventrally to constitute the thyroid gland. At 
later stages, pharyngeal expression of NKX2-5 is limited to the area 
corresponding to the thyroid primordium (Chen and Schwartz 1995) and is 
undetectable thereafter. 
 
 
 
 
De Felice M and Di Lauro R. Endocr ine Reviews 2004 
 
 
Fig. 1. Gene expression in the thyroid region at the beginning of organogenesis. The 
expression domains on relevant genes are indicated in red in a schematic frontal view 
of the entire pharynx of an E9 mouse embryo. Pp, Pharyngeal pouch; Pa, pharyngeal 
arch. 
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Thus, the small number of cells in the primitive pharynx fated to become TFCs 
already at E8.5 are univocally characterized by the simultaneous expression of 
Nkx2-1, (Lazzaro, Price et al. 1991) Foxe1 (Zannini, Avantaggiato et al. 1997), 
Pax8 (Plachov D, Chowdhury K et al. 1990), and Hhex (Thomas PQ, Brown A 
et al. 1998). When the thyroid diverticulum forms and begins its migration, the 
expression of these factors is restricted to the thyroid primordium as they are 
never expressed in the thyroglossal duct. For the rest of its life, a thyroid cell 
will be hallmarked by the simultaneous presence of Nkx2-1, Foxe1, Pax8, and 
Hhex (Fig. 1). The expression of these four factors is required for the early 
stages of thyroid morphogenesis. Therefore, alterations in any of these genes 
can be responsible for an abnormal thyroid gland morphogenesis and thyroid 
dysgenesis. 
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Fig. 2. Gene expression in the thyroid region after completion of organogenesis. The 
expression domains on relevant genes are indicated in red in a schematic frontal view 
of the trachea esophagus region of an E17 mouse embryo. 
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1.4 Genes involved in thyroid dysgenesis 
 
Because familial occurrence of TD is rare, this condition was considered a 
sporadic disease resulting mainly from nongenetic causes such as 
environmental factors or stochastic events during embryogenesis. But, a 
genetic cause of the disease has been demonstrated in about 5% of the reported 
cases. TD presents a clear female prevalence (Castanet, Polak et al. 2001). One 
report (Devos, Rodd et al. 1999) suggested that the female prevalence is 
significant for ectopy but not for athyreosis.  Epidemiological studies 
demonstrated a different incidence of the disease in different ethnic groups 
(Lorey FW and Cunningham GC 1992), (Castanet, Polak et al. 2001) 
suggesting that the genetic background plays a role in this affection. 
Furthermore, in populations where consanguineous marriages are common, the 
incidence of CH is increased (Ordookhani A, Mirmiran P et al. 2003). Other 
evidence in favor of the relevance of genetic factors in CH with TD is the 
finding of a small but significant proportion of familial cases. It has been 
reported that 2% of patients had an affected relative (Castanet, Polak et al. 
2001). This frequency is 15-fold higher than the frequency expected on the 
basis of chance alone, indicating that the involvement of genes required for 
correct thyroid morphogenesis is very likely in these familial forms. 
Interestingly, in some familial cases the affected members show either 
athyreosis or ectopy. This finding supports the hypothesis that athyreosis and 
thyroid ectopy could have common underlying mechanisms, as strongly 
suggested by the observation that mice deprived of Foxe1 gene products show 
either ectopy with a very small thyroid or no thyroid at all (De Felice M, Ovitt 
C et al. 1998). In addition, among the first-degree relatives of patients with 
sporadic TD, there is a significantly higher rate of asymptomatic thyroid 
developmental anomalies compared to the normal populations. Indeed, the 
prevalence of these anomalies is less than 1% in the control population, 
whereas it is 8% in first-degree relatives of patients with CH. This suggests the 
hypothesis that both severe forms of TD and heterogeneous asymptomatic 
alterations (including hemiagenesis or ectopy of the thyroid, thyroglossal duct 
cysts, pyramidal lobe) could originate from the same genetic defects during 
thyroid morphogenesis. Interestingly, in asymptomatic anomalies there is no 
female preponderance (Leger J, Marinovic D et al. 2002). By contrast, against 
the notion of heritable TD is the finding reported by Perry et al., showing a 
discordance for TD in 12 of 13 monozygotic twin pairs (Perry, Heinrichs et al. 
2002). This finding suggests that postzygotic events must be evoked in the 
pathogenesis of many cases of TD. However, it is most likely that the targets of 
such events are the same genes responsible for normal thyroid development. 
De Felice and Di Lauro, suggest that the function of genes involved in normal 
thyroid development can be interfered with by either mutations or epigenetic 
events. In both cases the result is TD, which would be inheritable, of course, 
only in the case of genetic mutations. According to different reports (Olivieri, 
Stazi et al. 2002), (Roberts HE, Moore CA et al. 1997), (Devos, Rodd et al. 
18 
 
1999), (Lazarus and Hughes 1988), TD is associated with other major birth 
defects in 5–16% of cases. It is conceivable that, in the cases presenting 
multiple congenital anomalies, the defective mechanism or gene could be 
involved in the morphogenesis of the thyroid and of the other embryonic 
structures altered. In this respect, it is of great interest that the malformations 
most frequently associated with TD are cardiac malformations. The preferential 
association of thyroid malformations with those of the heart is consistent with 
the hypothesis that signals generated in the heart primordium are necessary for 
normal thyroid development. 
It should be stressed, however, that studies on thyroid development in normal 
and mutated mouse embryos indicate the simultaneous presence of Pax8, 
Nkx2-1, Foxe1, and Hhex and that these factors are required for thyroid 
morphogenesis. Indeed, thyroid dysgenesis is present in animal models with 
mutations in these genes, and mutations in the same genes have been identified 
in patients with congenital hypothyroidism associated with TD. 
 
 
1.4.1 NKX2-1 
 
NKX2-1 (also known as NKX2-1) is a transcription factor containing a 
homeodomain. It belongs to the NK2 class of homeobox proteins that have a 
tyrosine residue at amino acid 54 of the homeodomain and a conserved 23-
amino-acid NK2-specific domain (Chen and Schwartz 1995). The human gene 
maps to chromosome 14q13 and it is formed by 3 exons. NKX2-1 contains 
three functional domains: an N-terminal transactivation domain, a DNA-
binding domain (HD), and a C-terminal transactivation domain (De Felice M, 
Damante G et al. 1995). There is compelling evidence that NKX2-1 functions 
by forming complexes with other transcription factors on the regulatory regions 
of target genes. NKX2-1 interacts with retinoic acid receptors and associated 
cofactors (Yan, Naltner et al. 2001), nuclear factor 1, members of the AP-
1family, and BR22. It has been suggested that NKX2-1plays a central role in 
the stabilization of these complexes. 
 In vitro NKX2-1 activates transcription of cotransfected Tg and TPO 
promoters in non thyroid cells (Damante and Di Lauro 1994), which suggests 
that NKX2-1 is important for the transcriptional activation of thyroid specific 
genes. Interestingly, the presence of the NKX2-1 protein does not invariably 
correlate with active transcription of the Tg and TPO genes in thyroid 
development (Damante G, Tell G et al. 2001). From embryonic day 8.5 (E8.5) 
on, NKX2-1 is present in the thyroid bud together with the other thyroid 
transcription factors TTF-2 and Pax-8, whereas Tg and TPO do not appear 
before E13. In lung cells it is responsible for the production of the surfactant 
proteins and in the hypothalamus NKX2-1 acts as transcriptional regulator of 
genes encoding neuromodulators and hypophysiotrophic peptides, controlling 
circadian oscillations in GnRH gene transcription (Matagne, Kim et al. 2012). 
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Gene-inactivation experiments have revealed some important functions of 
Nkx2-1 in vivo. Nkx2-1 null mice die at birth. They are characterized by 
impaired lung morphogenesis, lack of thyroid and pituitary, and severe 
alterations in the ventral region of the forebrain (Kimura, Hara et al. 1996). 
Other studies, performed at earlier stage of development demonstated that in 
Nkx2-1
-/-
embryos the thyroid primordium forms in its correct position but 
subsequently undergoes degeneration and eventually disappears. At E10.5 the 
thyroid primordium already appears much smaller in size in comparison with 
wild type, and at E11 no thyroid cells are detectable; these data and the 
presence of apoptotic cells suggest that Nkx2-1 is required to prevent the 
initiation of an apoptotic process (Kimura S, Ward JD et al. 1999). Hence, 
Nkx2-1 is essential for the survival of thyroid cells precursor, but it is not 
necessary for their initial formation. The Nkx2-1
-/- 
mouse has been of great 
relevance because it demonstrates two important concepts: the first is that 
athyreosis might be due to the inability of the TFC precursors to survive rather 
than to lack of their specification; the second consists in the proof of the 
concept that athyreosis can be due to a single, heritable genetic lesion. Nkx2-1 
is also implicated in epithelial/mesenchymal signaling. In Nkx2-1
-/- 
mice a 
reduction of the number of cartilage rings of the trachea (Minoo P, Su G et al. 
1999) was observed. Because there is no Nkx2-1 in the cartilage, it is very 
likely that the tracheal rings defect is the result of a defective signaling process, 
which is normally controlled by Nkx2-1 in the tracheal epithelium and which is 
necessary for the normal development of tracheal cartilage. These interactions 
represent a necessary step in the morphogenesis of trachea and lungs (Yuan B, 
Li C et al. 2000). Supporting this hypothesis are studies carried out on 
defective anatomical structures in Nkx2-1
-/- 
mice, showing that the expression 
of some well-known signaling molecules is controlled by this transcription 
factor. Bone morphogenetic protein (Bmp)4, a TGFβ-related peptide growth 
factor, expressed in the growing tip of the branching lung epithelium in a 
normal embryo, is undetectable in the lungs of Nkx2-1
-/-
 embryos; hence, 
Nkx2-1 controls, directly or indirectly, Bmp4 expression, and it is very likely 
that the absence of this growth factor is responsible for the alteration in lung 
morphogenesis in the mutant. 
Because the initiation of Nkx2-1 expression is coincident with specification, 
elucidation of these mechanisms might shed some light on the specification 
process itself. In mice, an inductive signaling by the axial mesendoderm 
(Shimamura K and Rubenstein JL 1997) could be implicated in the initial 
activation of Nkx2-1 in the prosencephalic neural plate. Sonichedgehog (Shh) 
is relevant for the ventralizing signal, and Nkx2-1 is expressed in patterns that 
are either coincident or adjacent to domains of Shh expression. Analysis of 
Shh
-/-
 embryos has revealed that Nkx2-1 is indeed regulated by this factor only 
in the forebrain. Indeed, in Shh-deficient embryos no Nkx2-1 is observed in the 
brain, whereas normal levels of the protein are detected in the thyroid and lung 
anlage (Pabst O, Herbrand H et al. 2000). On the basis of in vitro studies, it 
was proposed that the zinc finger factor Gata6 regulates the transcription of 
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Nkx2-1 However, analysis of Gata6
-/-
 chimeric lungs has demonstrated that 
Nkx2-1 is localized normally in epithelial cells of both wild type and mutated 
lungs (Keijzer R, Van Tuyl M et al. 2001). In conclusion, Nkx2-1 appears as a 
protein that is highly regulated in a strict cell-specific manner, because it 
regulates different genes in different cell types. Furthermore, some genes 
appear to depend on Nkx2-1 for expression in some cells, whereas they are 
independent from it in others, as in the case of Bmp4 in lung and posterior 
pituitary. In the thyroid cells themselves, Nkx2-1 clearly plays radically 
different roles during development, as it controls survival at the beginning of 
organogenesis and the expression of TFC-specific genes in adult life. 
 
Early studies searching for NKX2-1 mutations in humans affected by CH were 
disappointing. In viable newborns, it could be difficult to find homozygous 
loss-of function mutations in the NKX2-1 gene; the essential role of Nkx2-1 in 
lung and brain development, assessed in the animal model, made it possible to 
anticipate that such mutations should cause death immediately after birth. 
Subsequently, a heterozygous deletion encompassing the NKX2-1 locus in an 
isolated infant (Devriendt, Vanhole et al. 1998) and in two siblings (Iwatani, 
Mabe et al. 2000) was reported. Finally, the analysis of some large families 
(Breedveld, van Dongen et al. 2002) provides strong evidence that NKX2-1 
defects are directly responsible for benign hereditary chorea, an autosomal-
dominant movement disorder. When tested in vitro, the corresponding mutated 
forms of Nkx2-1 show neither functional activity nor a dominant-negative 
effect on the wild-type form. These data suggest that the haploinsufficiency is 
responsible for the pathological phenotype. On the contrary, Nkx2-1
+/- 
mice are 
considered normal, on the basis of anatomical and morphological studies 
(Kimura, Hara et al. 1996). NKX2-1 mutations have been described in several 
patients with primary CH, respiratory distress and benign hereditary chorea, 
which are manifestations of the “Brain-Thyroid-Lung Syndrome” (BTLS, 
OMIM # 610978) (Table 7). In the majority of cases haploinsufficiency has 
been considered to be responsible for the phenotype (Ferrara, De Michele et al. 
2008). Only few mutations produce a dominant negative effect on the wild type 
NKX2-1 (Guillot, Carre et al. 2010), (23Nettore, Ferrara et al. 2013) and among 
those in two cases it has been reported a promoter-specific dominant negative 
effect (Moya, Perez de Nanclares et al. 2006), (Nettore, Ferrara et al. 2013). 
All the published NKX2-1 mutations have variable functional effects, even if 
the mutations occur in similar regions of the protein. The clinical features of 
the patients carrying NKX2-1 mutations are reported in Table 7. Phenotypes are 
very variable and there is no correlation between the clinical manifestations 
and the molecular alterations (Ferrara, De Michele et al. 2008). Both the 
incomplete penetrance and the variability of the phenotype could be due to the 
effect of other modifier genes as well as of environmental factors. Furthermore, 
when the disease is associated with a large chromosomal deletion, we cannot 
exclude that the loss of other genes is contributing to variability of the 
phenotype. 
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1.4.2 PAX8 
 
PAX8 is a transcription factor belonging to the mammalian family of PAX 
proteins, characterized by the presence of a 128 aminoacid DNA binding 
domain (paired domain, Prd). Within this family, composed of nine members 
(Mansouri, Chowdhury et al. 1998)  Pax8, on the basis of a higher sequence 
similarity, forms a subfamily with Pax2 and Pax5 (Walther C, Guenet JL et al. 
1991) (Dorfler P and Busslinger M 1996). The human gene maps to 
chromosome 2q12-q14 encoding for PAX8 protein of 450 aminoacids even if 
different isoforms have been characterized for alternative splicing. The Full-
length form, Pax8a, consists of 12 exons and is the most protein species 
present. The Pax8b isoform lacks exon 9, while the isoform Pax8c presents a 
frameshift of reading from exon 9, which generates a region rich in proline and 
termination premature transcript (Poleev A, Wendler F et al. 1995). Several 
mechanisms may be involved in regulation of the levels of cytoplasmic protein 
such as sumoylation  and the inactivation by the redox state (De Felice M, 
Ovitt C et al. 1998),  (Cao, Kambe et al. 2005).  
Pax8 is expressed in alla stages of thyroid development and in adulthood. In 
the nervous system, Pax8 mRNA is transiently expressed in the 
myelencephalon and through the entire length of the neural tube. No signals are 
detected in the brain at later stages of the development, nor are they present in 
the adult brain. In the excretory system, Pax8 mRNA is present in the 
nephrogenic mesenchyme, which gives rise to the epithelial structures of 
nephrons as a consequence of the instructive interactions of the growing 
nephric duct and ureter. 
Analysis of Pax8
-/-
 mice revealed the role of this transcription factor during 
embryonic life. Whereas no phenotype has been detected in heterozygous 
Pax8
-/-
 mice, homozygous Pax8
-/- 
mice are alive at birth but show growth 
retardation and die within 2-3 weeks if not treated with thyroid hormones 
(Mansouri, Chowdhury et al. 1998). These mice do not display any apparent 
defects in the spinal cord, midbrain/hindbrain boundary, or kidneys. On the 
contrary, the thyroid gland in these mice is severely altered and no follicles and 
TFC can be detected, while calcitonin-producing C cells are present. 
Hypothyroidism is the cause of death of the mutated animals: the 
administration of T4 to Pax8
-/-
 
 
mice allows the animals to survive. A detailed 
study during the early steps of thyroid morphogenesis shows that in Pax8 null 
embryos the thyroid diverticulum is able to evaginate from the endoderm, but 
Pax8 is required for further development. In the absence of this transcription 
factor, at E11.5, thyroid primordium appears smaller (hypoplastic thyroid) than 
in wild-type mice, and at E12.5 follicular cells are essentially undetectable, 
indicating that Pax8, similarly to Nkx2-1, is required for the survival of thyroid 
cell precursors but not for their specification (Pasca di Magliano M, Di Lauro 
R et al. 2000). Furthermore, in the thyroid anlage of Pax8
-/- 
mice the expression 
of Foxe1 and Hhex is strongly down-regulated (Parlato R, Rosica A et al. 
2000). In addition to these important roles in morphogenesis of the TFC 
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component of the thyroid gland, it has been shown, in cell culture systems, that 
Pax8 is a master gene for the regulation of the thyroid-differentiated 
phenotype.  
In conclusion, Pax8 not only is required for the survival of the thyroid 
precursor cells but also holds a specific upper role in the genetic regulatory 
cascade, which controls thyroid development and functional differentiation. 
These functions of Pax8 in thyroid development are consistent with the 
findings that in other organs Pax genes have a relevant role both in initiating 
and maintaining the tissue-specific gene expression program (Nutt SL, Heavey 
B et al. 1999), (Bouchard M, Souabni A et al. 2002). 
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Fig. 3. Both Titf1 and Pax8 are required for thyroid development. Sagittal sections of 
wild-type (A), Pax8
-/-
 (B), and Titf1/Nkx2-1
-/- 
C) E15.5 mouse embryos stained with an 
anti-Titf1/Nk2-1 antibody are shown. In wild-type embryo, the developing thyroid 
(arrow) is positioned dorsal to the cricoid cartilage. In both the mutated embryos the 
thyroid tissue is undetectable (arrowhead).  
 
 
 
The involvement of PAX8 has been described in sporadic and familial cases of 
CH with TD (Table 6). So far, loss-of-function mutations in the DNA binding 
domain of PAX8 have been identified in two subjects with isolated CH and in 
the affected members of four families (Table 6); when tested in a transfection 
assay, these mutated proteins are unable to drive transcription from TPO 
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promoter, a target of this transcription factor. All affected individuals are 
heterozygous for the mutations and, in the familial cases, transmission is 
autosomal dominant. The different phenotypes described varied from mild to 
severe hypoplasia of the thyroid also among the affected members of the same 
family (Macchia, Lapi et al. 1998). Furthermore, the same heterozygous 
mutation been detected in both a patient with CH hypoplasia and in her mother 
with no signs of hypothyroidism (Congdon T, Nguyen LQ et al. 2001), 
indicating incomplete penetrance. Even if, in the majority of cases CH is due to 
thyroid hypoplasia, three patients with athyreosis and two with thyroid ectopy 
have been described (Table 6). However, to explain the severe hypoplasia 
described in some patients, the mutant gene should be preferentially expressed. 
Moreover, such monoallelic expression of PAX8 should be a specific 
mechanism in humans and could be a explanation of this phenomenon. 
Alternatively, the TD observed in PAX8
+/-
 patients could be due to a gene 
dosage requirement (haploinsufficiency). This indicates that in humans, 
contrary to mice models, both PAX8 alleles are necessary for correct thyroid 
morphogenesis, and a reduced dosage of the gene product (haploinsufficiency) 
causes dysgenesis. This phenomenon has already been observed in other 
systems (Bi W, Huang W et al. 2001), (Lindsay EA, Vitelli F et al. 2001) 
included for other Pax genes (van Raamsdonk CD and Tilghman SM 2000), 
(Wilm B, Dahl E et al. 1998). The protein acts properly within a concentration 
range that is sensitive to a 2-fold change. The knockout of the gene, in mice, 
leads to the disappearance of the thyroid primordium, whereas the reduced 
amount of Pax8 in these patients is not sufficient to support the normal 
development of the gland. The influence of other modifier genes could explain 
the variable penetrance of the phenotype. According to this hypothesis, the 
discrepancy between humans and mice could be related to the genetic 
background of the mouse line used in generating the corresponding animal 
models.  
The molecular mechanisms by which PAX8 mutations lead to TD are still 
unclear. A recent work describes and functionally characterizes two novel 
PAX8 mutations leading to TD by two different mechanisms. Both mutations 
(S54R and R133Q) determined a significant reduction in the transcription 
induction of thyroglobulin and thyroperoxidase promoters, but while the S54R 
mutant presented an impaired DNA binding, the DNA-binding properties of 
R133Q mutation are not affected and the R133Q has no dominant negative 
effect on the WT protein in vitro (Hermanns, Grasberger et al. 2013).  
Hemiagenesis of the thyroid is a frequent observation in mice double 
heterozygous for Nkx2-1
+/–
 and Pax8
+/–
 (Amendola, De Luca et al. 2005) but, 
to date, in humans no genetic alterations have been found in patients with 
thyroid hemiagenesis. 
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1.4.3 FOXE1 
 
FoxE1, also called TTF-2, is a transcription factor containing a forkhead 
domain and a polialanine stretch of variable length (Macchia, Mattei et al. 
1999; Macchia 2007; Santarpia, Valenzise et al. 2007). While Foxe1 is located 
on mouse chromosome 4, the human gene maps to chromosome 9q22 and 
encodes for a 42 kDa protein.  
Foxe1 has a wider domain of expression.  In ectoderm-derived structures, at an 
early stage of development, Foxe1 is present in the posterior stomatodeum, in 
the buccopharyngeal membrane, and in the cells of the roof of the oral cavity 
indenting to constitute Rathke‟s pouch, which will form the various 
components of the anterior pituitary. At later stages, Foxe1 mRNA expression 
in the pituitary is down-regulated (Zannini, Avantaggiato et al. 1997), whereas 
it appears in the secondary palate, in the definitive choanae, and in the 
whiskers and hair follicles (Dathan N, Parlato R et al. 2002). In the adult, 
Foxe1 is still present in the thyroid, whereas the expression in the esophagus is 
faint. 
In humans, FOXE1 mRNA is also detected in adult testis (Clifton-Bligh RJ, 
Wentworth JM et al. 1998) and several other tissues (Chadwick BP, Obermayr 
F et al. 1997). However, in the latter case, additional mRNAs of different size 
have been reported. Homozygous FoxE1 knock-out mice are born at the 
expected ratio but die within 48 h. These mice have no thyroid in its normal 
location and absence of thyroid hormones. Furthermore, the mice show a 
severe cleft palate, probably responsible for the perinatal death, and elevated 
TSH levels in the bloodstream (De Felice M, Ovitt C et al. 1998). Studies of 
the early stages of thyroid morphogenesis demonstrate that the budding of the 
thyroid primordium does not require Foxe1, because the anlage can be easily 
detected by the expression of Nkx2-1 and Pax8, and a normal primordium is 
formed. However, at E9.5 in Foxe1 null embryos, thyroid precursor cells are 
still on the floor of the pharynx, whereas in wild-type embryos they are 
detached from the pharynx cavity and begin to descend (Fig 4). At later stages 
of development, in the absence of Foxe1, mutant mice exhibit either a small 
thyroid remnant still attached to the pharyngeal floor or no thyroid gland at all. 
The variable expressivity of the phenotype could be due to stochastic events 
during thyroid morphogenesis. In addition, it is possible that either the 
individual genetic background or sex-related factors are responsible for the 
variability of the phenotype of the Foxe1 null mice. It is worth noting that the 
non-migrating thyroid cells are able to complete their differentiation process as 
demonstrated by the presence of thyroglobulin. Hence, FoxE1 plays an 
essential role in the control of the migration of TFC precursors whereas both 
Nkx2-1 and Pax8 seem to be relevant in the survival and/or differentiation of 
these cells. Furthermore, the data that found that in 50% of Foxe1 null mice the 
thyroid disappears indicate that this gene, too, is implicated in the control of 
the survival of thyroid cells at a step different from those controlled by Nkx2-1 
and Pax8. The role of Foxe1 in the adult gland is still a matter of study. 
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Functional studies in cell cultures have demonstrated that Foxe1 can act as a 
promoter-specific transcriptional repressor (Perrone L, Pasca di Magliano M et 
al. 2000). Because the Foxe1 null mice die at birth, only the creation of an 
animal model with a thyroid-specific, conditional knockout of Foxe1 will 
permit elucidation of the role of this factor in the physiology of the gland. 
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Fig. 4. Foxe1 is required for thyroid precursor cells migration. Sagittal sections of 
Foxe1-/- (A) and Foxe1-/- (B) E11 mouse embryosstained with an anti-Titf1/Nk2-1 
antibody. The arrows point to the thyroid bud. In the mutated embryo, the thyroid bud 
is still on the floor of the primitive pharynx. 
 
 
 
FOXE1 within its coding sequence contains a polyalanine tract of variable 
length, ranging from 11 to 19 alanines (Amiel, Trochet et al. 2004; Carre, 
Castanet et al. 2007). The studies of other genes containing polyalanine 
stretches demonstrated that changes in polyAla result in a less severe 
phenotype when compared to causative point mutations at the same locus 
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(Amiel, Trochet et al. 2004). A few studies have pointed to the potential role of 
FOXE1-polyAla length polymorphism in determining the susceptibility to TD 
(Carre, Castanet et al. 2007), (Hishinuma, Ohyama et al. 2001), (Tonacchera, 
Perri et al. 2004).  
A recent study, report that the length of FOXE1-polyAla varied from 12 to 18 
alanines, compared to previuos reports. In the population studied, in the 
patients with the familial form of TH, a significantly higher incidence of longer 
variants (>16 codons) of FOXE1-polyAla was noted in comparison to the 
control group as well as the patients with the sporadic form of TH. All patients 
with the familial form were heterozygous or homozygous for the longer variant 
of FOXE1-polyAla. The length of FOXE1-polyAla in the patients with the 
sporadic form of TH and the control subject did not differ significantly 
(Szczepanek E 2011).  
Homozygous mutations in FOXE1 gene have been reported in patients affected 
by Bamfort‟s syndrome. This syndrome is characterized by cleft palate, 
bilateral choanal atresia, spiky hair and athireosis (Bamforth JS, Hughes IA et 
al. 1989). Even if defects in choanae and hair follicles have not yet been 
investigated in Foxe1 null mice, Foxe1 is expressed in both these structures 
(Dathan N, Parlato R et al. 2002). Indeed, two homozygous mutations in 
FOXE1 gene have been described in two pairs of siblings affected by this 
syndrome (Clifton-Bligh RJ, Wentworth JM et al. 1998), (Castanet M, Park 
SM et al. 2002). All the affected members carry homozygous missense 
mutations in conserved amino acids of FOXE1, and the mutant proteins, when 
tested in vitro, show a reduction in both DNA binding and transcriptional 
activity. While in mice the absence of FoxE1 causes either athyreosis or 
ectopia (De Felice M, Ovitt C et al. 1998), in humans, FOXE1 mutations have 
never been associated to the thyroid ectopy. 
 
 
1.4.4 NKX2-5 
 
In addition to Nkx2-1, other genes of the Nkx2 family are present in the 
primitive pharynx and the thyroid anlage, such as Nkx2-3, Nkx2-5, Nkx2-6. 
Nkx2-5, which is a homeodomain-containing protein, originally identified as a 
potential vertebrate homologue of the Drosophila gene tinman (Komuro and 
Izumo 1993).  The gene encoding NKX2-5 in humans is located on 
chromosome 5q34 and consists of two exons encoding for a 324 aminoacids 
protein. Nkx2-5 plays a crucial role in heart morphogenesis (Chen and 
Schwartz 1995). Its transcripts are found in the heart (Kasahara, Lee et al. 
2000), in heart progenitor cells (Lints TJ, Parsons LM et al. 1993), in 
mammary gland during lactation (Dentice, Luongo et al. 2004), and in the 
thyroid primordium during development (Kasahara, Bartunkova et al. 1998). In 
Nkx2-5
-/-
 embryos the thyroid bud is smaller when compared to the wild type, 
suggesting that Nkx2-5 is required for thyroid development (Dentice, 
Cordeddu et al. 2006). In humans, NKX2-5 is essential for normal heart 
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morphogenesis, myogenesis, and function (Tanaka M, Schinke M et al. 2001), 
and several loss of function mutations in NKX2-5 have been described in 
patients with congenital heart diseases (Hirayama-Yamada, Kamisago et al. 
2005). Transmission is autosomal dominant, with incomplete penetrance 
(Benson, Silberbach et al. 1999; Tanaka T, Inazu T et al. 1999).  
Heterozygous mutations in NKX2-5 have been associated to the human ectopic 
thyroid (Dentice, Cordeddu et al. 2006). Functional studies demonstrated that 
these mutants exhibited a significant functional impairment, with reduction of 
transactivation properties and dominant negative effect (Table 8). Because 
Nkx2-5 acts as a homodimer through its homeodomain, dimerization is 
impaired by some disease-causing mutants that are dominant negative over the 
wild-type counterpart.  Recently, it has been reported a girl with athyreosis 
presenting heterozygous mutations in both NKX2-5, and PAX8 genes 
(Hermanns, Grasberger et al. 2011). Haploinsufficiency, monoallelic 
expression, or imprinting could all have an impact on the phenotype (Vassart 
and Dumont 2005) and again patients carrying NKX2-5 mutations show a 
phenotypic variability in both heart and thyroid phenotype. However, the role 
of Nkx2-5 in thyroid development remains poorly understood. 
 
 
1.4.5 TSHR 
 
In late stage of thyroid organogenesis, at E15.5, the thyrotropin receptor (Tshr) 
starts to be expressed in TFC. Tshr is a protein of 765 aminoacids long both in 
humans and in mice and belongs to the superfamily of G protein-coupled 
receptors. TSH binds to the extracellular portion of the receptor, a long amino-
terminal extracellular domain that includes a succession of leucine-rich repeats. 
The COOH portion of Tshr forms the transmembrane and intracellular domains 
involved in transducing signals (Parmentier M, Libert F et al. 1989), (Misrahi 
M, Loosfelt H et al. 1990). Tshr, localized on chromosome 14q31 in humans 
(Rousseau-Merck MF, Misrahi M et al. 1990), (Libert F, Passage E et al. 1990) 
and chromosome 12 in mice (Taylor BA, Grieco D et al. 1996), spreads over 
60 kb and is split into 10 exons. The extracellular amino-terminal domain is 
encoded by nine exons, whereas the transmembrane domain and cytoplasmic 
tail are encoded by a single large exon (Gross B, Misrahi M et al. 1991). It is 
interesting to note that other G protein-coupled receptors (such as adrenergic or 
muscarin receptor genes) are devoid of intron; therefore, Tshr seems to have 
evolved from an intronless protoreceptor fused to a set of duplicated genes 
coding for a leucine-rich sequence. The expression of Tshr mRNA is detected 
in rat thyroid at E15 (Brown RS, Shalhoub V et al. 2000) (corresponding to 
E13.5–E14 in mice) and strongly increases by E17. Hence, Tshr mRNA is 
detected in the developing thyroid after the completion of the migration of the 
primordium, before the first evidence of follicular organization in the gland. 
The way the activation of Tshr regulates both proliferation and functioning of 
adult thyroid cells has already been exhaustively reviewed (Dumont JE, Lamy 
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F et al. 1992), (Kimura T, Van Keymeulen A et al. 2001). The analysis of 
thyroid development in mice carrying spontaneous (Beamer, Eicher et al. 1981) 
or induced (Marians, Ng et al. 2002) alterations in the Tshr gene has provided a 
powerful tool in the exploration of the role of the TSH/Tshr pathway during 
embryonic life. The role of the TSHR in thyroid differentiation was first 
identified in Tshr
hyt/hyt 
mice, affected by primary hypothyroidism with elevated 
TSH and hypoplastic thyroid, as a consequence of a loss of function mutation 
in the fourth transmembrane domain of TSHR (pro556Leu), which abolishes 
the cAMP response to TSH (Stuart, Oates et al. 1994). As the Tshr
hyt/hyt 
mice, 
also the Tshr null mice display a severe hypothyroidism, associated with 
thyroid hypoplasia in adult life. However, at birth, in both these mutants, the 
size of the thyroid does not appear to be affected, and the gland displays only 
some alterations in its structure. A detailed analysis performed at the end of the 
organogenesis, at E17, has revealed that in the absence of a functional Tshr, the 
size and the follicular structure of the thyroid are not affected, and the amount 
of Tg does not change, whereas the expression of both TPO mRNA and NIS is 
strongly down-regulated (Postiglione MP, Parlato R et al. 2002). These data 
indicate that, during embryonic life, the TSH/Tshr signaling is required to 
complete the differentiative program of the TFC, but, unlike what happens 
during adult life, this signaling is not relevant in controlling the growth of the 
gland.  
The first genetic errors associated with CH with TD have been identified in the 
gene coding for TSHR. In 1968, Stanbury et al. observed that TSH 
unresponsiveness could be a cause of CH in the absence of goiter. The 
identification of Tshr
hyt/hyt 
mice (Beamer, Eicher et al. 1981), affected by a 
primary hypothyroidism with elevated TSH and hypoplastic thyroid, offered a 
useful model for this autosomal-recessive form of CH. The first mutations were 
identified in three siblings (Sunthornthepvarakui, Gottschalk et al. 1995)(194) 
characterized by high TSH and normal thyroid hormone levels in the serum. 
The siblings were compound heterozygous, carrying a different mutation in 
each of the two alleles, one allele derived from each parent. After this report 
other mutations in the TSHR gene have been identified in patients affected by 
CH with thyroid hypoplasia and increased TSH secretion. The different 
phenotypes described range from asymptomatic hyperthyrotropinemia to 
severe CH with a profound hypoplasia of the thyroid. Part of the variability of 
the phenotype can certainly be explained by the diverse residual activity of the 
mutated TSHR molecules. However, the affected members of the same family 
show occasionally diverse expressivity of the hypothyroid phenotype, too, thus 
suggesting that other genes are capable of influencing the TSHR activity. Until 
now, patients with ectopic thyroid have never been described. This is expected 
because the TSHR-induced pathway is not involved in the migration of the 
embryonic thyroid. Subjects heterozygous for loss-of-function mutations in the 
TSHR genes are euthyroid; in the familial forms, consistently, the diseasis 
inherited as an autosomal-recessive trait. However, in many heterozygous 
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relatives of the affected members, the serum TSH values fluctuate above the 
upper limit of the normal range (Russo D, Betterle C et al. 2000). 
 
 
1.4.6 Other genes-DNAJC17 
 
TD is a multigenic disorder. This hypothesis is consistent with the finding that 
there is no clear Mendelian transmission of TD in families with more than one 
affected member (Castanet, Polak et al. 2001). Furthermore, in familial cases 
of TD associated with mutations in either the NKX2-1 or PAX8 gene, the 
disease is characterized by incomplete penetrance and variable expressivity, 
thus suggesting the contribution of additional genes to the phenotype (De 
Felice M and Di Lauro R 2004). The study of multigenic diseases in humans is 
difficult. Studies on mouse models indicate that the pool of genes, mostly 
transcription or growth factors, involved in thyroid development is rather large, 
and defects in these genes or in their yet unidentified targets could be relevant 
for the pathogenesis of TD in humans. It is known that, neither Pax8 nor Nkx2-
1 heterozygous null mice show overt thyroid defects. But, the combination of 
two heterozygous null mutations, in Nkx2-1 and Pax8, results in a severe 
hypothyroidism characterized by thyroid hypoplasia and increased incidence of 
thyroid hemiagenesis. This model has been named DHTP, for double 
heterozygous for Nkx2-1 and Pax8. Interestingly, the severe hypothyroidism is 
present only in the C57BL6/J (B6) genetic background, whereas it is 
completely absent in both 129/SvPasCrl (Sv) and DHTP/B6-Sv F1 hybrids. 
These data suggest that homozygosity for B6-specific alleles, in the presence of 
null mutations in both Nkx2-1 and Pax8, is involved in the emergence of TD. 
Genetic linkage analysis in a DHTP backcross population identified two 
potential loci linked to the hypothyroid phenotype, with one of them having the 
major effect. On the basis of a single-nucleotide polymorphism (SNP) that 
causes a non synonymous aminoacid change in a highly conserved protein 
domain between B6 and Sv strains, it was identified Dnajc17, as a candidate 
modifier gene for hypothyroidism. Indeed, Dnajc17 presents a phenylalanine 
residue at position 273 in the B6 mice, but it shows a tyrosine at the same 
position in all other mouse strains. Even though the phenylalanine-tyrosine 
change is a conservative missense mutation, tyrosine273 is conserved in 
Dnajc17 ortholog genes throughout the evolution from metazoans (Fig. 5). It is 
worth noting that in humans, disease-associated mutation soccur often at sites 
that are conserved in evolution. In addition, analysis performed with NetPhos 
2.0 software predicts that tyrosine
273
 is very likely to be phosphorylated, 
suggesting that the absence of this post translational modification could be 
responsible for an impaired function of the protein. 
The gene coding for DNAJC17 maps on chromosome 2 of mouse and human 
chromosome 15. It consists of 11 exons and encodes a protein of 304 amino 
acids, belonging to the family of heat-shock-protein-40 type III. Dnajc17 is 
expressed from the early stage of embryonic life in the developing thyroid 
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(E10.5) (Fig.6) and remains expressed in the adult thyroid as well as in 
differentiated thyroid follicular cells in culture. In addition, the findings that 
Dnajc17 is expressed in thyroid and it is localized in the nucleus are consistent 
with a role of this protein in modulating the transcription of some thyroid-
specific genes. Studies in vivo of this protein demonstrated that Dnajc17
+/-
 
mice appeared normal, while Dnajc17
-/- 
pups were never observed postnatally, 
indicating that theDnajc17 null mutation is recessive embryonic lethal. 
Furthermore it found Dnajc17
-/- 
two-cell embryos, but no homozygous embryos 
were recovered after the morula stage. These findings indicate that Dnajc17
-/-
 
embryos were developmentally arrested before implantation and indicate an 
essential role of this gene in early mouse development. An additional aspect 
that support the candidacy of Dnajc17 as a modifier gene of the DHTP 
phenotype is the observation that the hypothyroid phenotype in this model is 
associated with an impaired transcription of the Tg gene, well known target of 
Nkx2-1 and Pax8. Consistent with this are the data indicating that Dnaj 
proteins interact, via a highly conserved domain (J domain), with Hsp70 
chaperone proteins and regulate the activity of these chaperones (Qiu, Shao et 
al. 2006). It has been reported that chaperone proteins can control the 
disassembly of transcriptional complexes (Freeman and Yamamoto 2002) and 
can act as regulators in gene expression processes in Drosophila melanogaster  
as well as in mammalian cells. Hsp70proteins, the partners of Dnaj, are 
involved in a number of biological processes, and since Dnajc17 has a nuclear 
localization, disturbances in Hsp40-Hsp70 interactions could have pleiotropic 
effects, including alterations in the regulation of the transcriptional activity of 
Nkx2-1 e/o Pax8.  
 
 
 Species  Alignment 
 
Mus muris (B6 strain) RDFESLVMMRMRQAAERQQLIAQMQQED—EGRPT 
Mus muris (Sv strain) RDYESLVMMRMRQAAERQQLIAQMQQED—EGRPT 
Rattus norvegicus RDYESLVMMRMRQAAERQQLIAQMQQED—EGRPT 
Homo sapiens RDYESLVMMRMRQAAERQQLIARMQQEDQ–EGPP 
Macaca mulatta RDYESLVMMRMRQAAERQQLIARMQQEDQ–EGPPT 
Monodelphis domestica RDYESLVMMRMRQAAERQQLIEQMQREDE–EGLPT 
Danio rerio RDYESVVLMRLRQAEERKRLIEQMKREEEDDTA 
Anophelesgambiae RDYESLVLRQLRQAEERKRLIEQMMKEEAEAEGETTAQ 
Drosophila melanogaster TDYEDLVMRKLRQAEERKRLIEQMMKDE—EGE 
 
 
Fig. 5. Alignment of the deduced amino acid sequence of the C-terminal region of 
Dnajc17 orthologous genes among different species. Tyrosine 273 residue is in bold. 
 
 
 
 
 
 
32 
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Fig. 6. Dnajc17 expression in mouse embryo. A and C, Sagittal sections of E10.5 wild 
type mouse embryo were immunostained with an anti-Dnajc17 (A) or anti-Nkx2-1 (C) 
specific antibody (magnification x50). B and D, Higher magnification (x200) of the 
boxed areas in A and C, respectively. The expression of Nkx2-1 is used as a 
molecular marker to identify the thyroid bud. Dnajc17 has a robust expression in 
developing thyroid 
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2. AIM OF THE STUDY 
 
 
 
The objective of the this work was to study the role of thyroid transcription 
factor (NKX2-1, NKX2-5, PAX8) already known to be involved in thyroid 
organogenesis as well as the possible association of thyroid dysgenesis (TD) 
with other genes not previously linked to the disease in humans.  
In the last years, several genes playing a major role in thyroid development 
have been identified. Alterations of the thyroid morphogenesis have been 
associated with disturbances in the function of some of these genes, suggesting 
that genetic mechanisms can be responsible for TD.  
Several mutations in NKX2-1, NKX2-5, FOXE1 and PAX8 genes, have been 
found in patients with congenital hypothyroidism (CH) due to TD. In 
particular, NKX2-1 mutations were associated with the “Brain-Thyroid-Lung 
Syndrome”, which combines Congenital Hypothyroidism (CH), neurological 
symptoms (hypotonia evolving to benign hereditary chorea (BHC) after 
infancy), and pulmonary symptoms.  
The phenotypic variability and incomplete penetrance observed in familial 
cases of patients with TD carrying mutations in either NKX2-1 or PAX8 genes 
supported the possibility that other interacting genes may modulate the 
phenotype. Among these, it has been demonstrated that Dnajc17 is highly 
expressed in the thyroid bud and has an essential function during development. 
In order to better understand the complexities of the genotype–phenotype 
correlation in TD and to identify novel genetic alterations in patients with TD, 
we sequenced the entire coding region of NKX2-1 in a family from Curitiba, 
affected by Brain-Lung-Thyroid Syndrome. We also screened by SSCP and 
HRM analysis known genes (NKX2-1, NKX2-5, PAX8), and DNAJC17, a new 
candidate gene, in 76 patients with persistent CH. 
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3. MATERIAL AND METHODS 
 
 
 
3.1 Patients 
 
Our study included 76 patients with persistent CH identified by the Italian 
screening program for congenital hypothyroidism.  
The group was composed as follows: 17 patients had agenesis; 19 
hemiagenesis; 31 ectopy; 4 hypoplasia of the thyroid gland and 5 patients CH 
with normal thyroid. 100 normal volunteers with no thyroid abnormalities were 
used as controls.  
In addition we had the opportunity to study a family living in Curitiba, Brazil 
with five affected patients showing the clinical manifestations of brain–
thyroid–lung syndrome (BTLS) (Fig. 7). Clinical informations are reported in 
the next paragraph. 
Informed consent was obtained from all the studied patients or their parents. 
 
 
 
3.2 The “Brazilian Family” 
 
The family included five affected patients in three generations (Fig. 7).  
 
 
 
 
 
Nettore et al. Thyroid 2014 
 
 
Fig.7 Pedigree of the studied family. The family members carrying the c.493delC 
mutation (p.Arg165Glyfs*32) and showing the clinical manifestation of brain–thyroid–
lung syndrome (BTLS) are in black. The proband (III-6) is indicated by an arrow. 
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Collection of clinical information was difficult because the members of the 
family live in different towns; therefore, some of the clinical characteristics 
were missing. The proband (III-6) was the fifth child of non consanguineous 
parents. He was born at term with a birth weight of 2820 g, but a delay in 
motor development was soon evident: he took his first steps at 24 months of 
age. During infancy, the proband showed moderate generalized choreiform 
movements and cerebellar ataxia that remained stable thereafter, accompanied 
by several episodes of respiratory insufficiency that were diagnosed either as 
asthma or pneumonia. Routine blood chemistry and hematology tests and 
electrocardiograms were normal. Brain MRI, electromyography, and muscle 
biopsy were also normal. When the proband was 13 years old, his thyroid 
function tests (TFTs) revealed subclinical hypothyroidism: serum thyrotropin 
(TSH) was 9.1mU/L (normal range 0.35–4.94 mU/L), free thyroxine (FT4) was 
1.07 ng/dL (normal range 0.7–1.48 ng/dL) and triiodothyronine (T3) was 
127.55 ng/dL (normal range 58–159 ng/dL). Serum antithyroid antibodies tests 
were negative. The proband‟s mother (II-1) presented with short stature, mild 
generalized choreiform movements since infancy, subclinical hypothyroidism 
(TSH 8.51 mU/L, FT4 1.07 ng/dL, T3109.46 ng/dL), and episodes of 
respiratory insufficiency (diagnosed as asthma) in childhood. Subject III-2, a 
brother of the proband, presented with cervical dystonia, moderate generalized 
choreiform movements, and hypothyroidism (TFT not available) at the age of 
22 years. Subject III-4 (the oldest sister of the proband) was diagnosed with a 
mild choreiform movement disorder at the age of 17 years. At that time, 
subclinical hypothyroidism (TSH8.13 mU/L, FT4 1.1 ng/dL, T3 122.08 ng/dL) 
was also noticed. She was treated with 25 lg/d of L-thyroxine, which 
normalized serum TSH levels. The proband‟s youngest sister (III-5) presented 
with moderate generalized choreiform movements, mild cognitive deficit, and 
subclinical hypothyroidism (TSH 5.43 mU/L, FT41.19 ng/dL, T3 126.60 
ng/dL) at the age of 14 years. All the other members in the family (I-1, I-2, II-
2, II-3, III-1,III-3, III-7, III-8, III-9) had normal TFTs and normal thyroid 
morphology on ultrasound examination. 
 
 
 
3.3 DNA samples 
 
Genomic DNA was extracted from peripheral blood leukocytes according to 
the manufacturer‟s instructions (FlexiGene DNA Kit, Qiagen, Hilden, 
Germany) and stored at 4°C until used.  
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3.4 PCR conditions 
 
PCR were performed using the thermostable recombinant DNA polymerase 
(VWR, Geldenaaksebaan, Belgium). PCRs were run in a Thermo Cycler-One 
Gradient (EuroClone, Milano, Italy). Negative controls were always included. 
Exons 1 to 3 of the NKX2-1 gene, exons 3 to 10 of the PAX8 gene, exons 1 to 5 
of the NKX2-5 gene and exons 1 to 11 of the DNAJC17 gene were amplified in 
a 15 -µl reaction using the primer pairs shown in Table 1 to 4. In the tables also 
the annealing temperature each PCR product are given.  
PCR buffer cointaned 10 mM Tris-Hcl pH 8.3, 50 mM KCL, 1,5 mM MgCl2, 
10% DMSO, 200 µM dNTPs, The following PCR conditions were used: initial 
denaturation for 2 min at 95 °C, then 35 cycles with 1 min at 94  °C, 1 min at 
the temperature specific for each primer pair and 1 min at 72 °C, followed by a 
5 min incubation at 72 °C.  
The products mixed with a loading dye were run on a 1–1.5% agarose gel 
(SeaKem LE Agarose, Lonza, Rockland, ME USA) stained with ethidium 
bromide and visualized under u.v. light with AlphaImager Mini 
(CellBiosciences, Santa Clara USA). 
 
 
 
 
Table 1. NKX2-1 Primers and annealing temperatures 
 
 
Exon Sequence Tm Lenght bp 
Ex1F GTGGCTGCCTAAAACCTG  
60.4°C 
 
700 bp 
Ex1R GGCCGCCCTCCCTGATGC  
Ex2Q CCAGAACCACCGCTACAAAATGAAG 
64.5°C 
 
300 bp 
Ex2R GGCGCCACCGCTGCCCACGGAGATG 
Ex2G GCGCGGAAAACAGGGGTGGC  
64.5°C 
 
400 bp 
Ex2H GCTGCGCCGCCTTGTCCTTG  
Ex3aF GGGGCTGTGAGCGCTCCAGTACAGCC 
68.1°C 
 
800 bp 
Ex3aR CCTGGCTGGTGGCCCGGGTGTGCGCCAA 
Ex3bF TGGCGGTGCCGGTCCTGGTGAAAGA 
55°C 
 
458 bp 
Ex3bR CCAGGTTGTTAAGAAAAGTCG  
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Table 2. PAX8 Primers and annealing temperatures 
 
 
 
 
 
 
 
 
Table 3. NKX2-5 Primers and annealing temperatures 
 
 
 
 
 
Exon Sequence Tm Lenght bp 
Ex3F CATAGCTAATCCCCACCCAAAC  
58°C 
 
259 bp 
Ex3R GCCTGCGGTGAATTTCG 
Ex4F ATTGGGTAATTCTTTGGGATTC  
59°C 
 
314 bp 
Ex4R CCAGGCCTTTCTTGTCTCTT  
Ex5F AGGGGTGTCAAAAAGGCGACTG 
61°C 
 
241 bp 
Ex5R TGGGTATGCTGAAGGGGAGGTG  
Ex6F TCTCCCTCTCCCCCACTG  
58°C 
 
255 bp 
Ex6R GCAGAGCCCCTACAAAGTCC  
Ex7F GAGCATGAATGATAGGTCCC  
58°C 
 
304 bp 
Ex7R CACAGGCTCATTTGGAGAAT  
Ex8F GTCTCTGTGCGCTGACTTCT  
59°C 
 
232 bp 
Ex8R CACACCTTCCGCCTGAC  
Ex9F CCTCCCCGCCATCTCACACC  
61°C 
 
290 bp 
Ex9R TCCCACCCGCCGCCATAG  
Ex10F GCCCCCATGGTCCAACTGAC  
61°C 
 
220 bp 
Ex10R TGCCTCTGCTCCTTGTGTCCAC  
Exon Sequence Tm Lenght bp 
Fr1F CACCATGCAGGGAAGCTG 
59,1°C 250 bp 
Fr1R CCTCTGGCTTGAAGGCG 
Fr2F AGCTCTCTGCCCGCCTG  
55,5°C 300 bp 
Fr2R AGTTTCTTGGGGACGAAAGC 
Fr3F AGGTCAAGCCGCTCTTAC 
58°C 218 bp 
Fr3R TTCGGGGGCCGACAGGTA  
Fr4F AGGCGCAGGTCTATGAGC 
64,5°C 430 bp 
Fr4R CCATCGCGCACCAGCACT 
Fr5F GCGGCAGGACCAGACTCT 
64,7°C 300 bp 
Fr5R TGTTGGCGGCGGCAGTGG 
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Exon Sequence Tm Length bp 
J 1F AGAACACAATTCCCAGAGGG 
60.9 °C 266 bp 
J 1R AGAGCGGATGCCAGCAG 
J 2F ATTCCCCTTACCCATTGAGC 
62 °C 253 bp 
J 2R GCTTACACCCCACAGCACTC 
J 3aF TTTTGAGGGAGCACACCATT 
56.7 °C 156 bp 
J 3aR ATTCCGATGAAGGAGGCTGT 
J 4aF CCGGGGCTCTGTCTTTACTC 
60.9 °C 222 bp 
J 4aR. GCTTCAGGTGAGGGAGATGA 
J 5F TGATTGAGACTTTGGGGAGG 
60.9 °C 272 bp 
J 5R CTCTCTAGCCACGGCGAC 
J 6aF TGGACCTGCACAGAATTGTC 
60.9 °C 163 bp 
J 6aR ATAGGCGGGGTGATAGACCT 
J 7aF CTTCTTGCTCTGGGCTGCAT 
60.9 °C 207 bp 
J 7aR CGAGCCACAGGAAGCATCTAT 
J 8F GAGGGTGGGAGGATGTCTG 
62.7 °C 266 bp 
J 8R AGGGAAGTTCAGGCATTGAG 
J 9F GTAGCCCAGGCTTGTCTCTG 
60.9 °C 266 bp 
J 9R TCCCTAGGAGTGCAGACCAC 
J 10aF GGACAGGACTAGATGCTGTGTTTG 
60.9 °C 223 bp 
J 10R TTGGAAGGAAAGAGCCTGAG 
J 11F CTCGGCACCGTACTCGG 
60.9 °C 310 bp 
J 11R GCCCAGCACCTTATACCTATG 
 
Table 4. DNAJC17 Primers and annealing temperatures 
 
 
 
3.5 Mutational Screening 
 
3.5.1 SSCP analysis 
 
PCR products of PAX8 and NKX2-5 gene, were diluted 1:1 in a denaturing 
solution (99% formamide, 1 % xylene-cyanol solution and bromophenol blue), 
denatured at 95 °C for 5 min and thereafter diretly placed on ice to prevent 
reanniling of the single stranded product. PCR products were loaded in non – 
denaturing gels 12% Polyacrylamide (GeneGel Excel 12.5/24 Kit, GE 
Healthcare Bio-Sciences AB, Sweden) using the GenePhor Electrophoresis 
Unit (GE Healthcare Bio-Sciences AB, Sweden). 
The gels were run at 8 °C and a constant Voltage of 650 V, Current of 30 mA, 
Power of 15 W, for 3 hours (until bromophenol blue reaches the anode buffer 
strip). 
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SSCP bands were detected with the PlusOne DNA Silver Staining Kit (GE 
Healthcare Bio-Sciences AB, Sweden) contained Fixing Solution, Staining 
Solution, Sodium Carbonate Solution, Formaldehyde 37%, Sodium 
Thiosulphate 2% and Stopping Solution. Then, the gels were air dried. Samples 
showing an abnormal mobility pattern within the matrix when compared with 
the wild-type control, were submitted to direct sequencing. 
 
 
 
3.5.2 High Resolution DNA Melting 
 
Mutation screening of exons 1 to 10 covering the DNAJC17 coding region was 
performed by High Resolution Melt Analysis. Primers for HRM curve analysis 
were similarly designed to flank the coding regions and to be annealed at 60°C 
using Primer Express software to calculate the "Tm" (Applied Biosystems, 
Foster City, CA). Real-time PCR and subsequent high-resolution melt analysis 
were performed in 20-µl mixture on StepOne Plus (Applied Biosystems, Foster 
City, CA USA). The MeltDoctor HRM Master Mix (Applied Biosystems, 
Foster City, CA USA) contains magnesium chloride, dNTPs, MeltDoctor™ 
HRM Dye and AmpliTaq Gold 360 DNA Polymerase at a 2x concentration. 
The  Melt Doctor™ HRM dye is a stabilized form of the SYTO®9 dye, a next-
generation ds DNA-binding dye developed by Molecular Probes that delivers 
sharp, clean melt profiles. Simplest to use is MeltDoctor™ HRM Master Mix; 
it requires only the addition of template DNA and a PCR primer pair before 
starting the PCR. We used 200 nM of each PCR primer and 20 ng of genomic 
DNA in 20 µL PCR reactions. 
PCR conditions and primer sequences are shown in table 4. 
Melting-curve data were generated by increasing the temperature from 72 °C to 
95 °C at 0.3 °C/ and recording fluorescence in the green channel. HRM curve 
analysis was performed using StepOne Software (Version 2.3). The software 
was used to calculate the derivative of the intensity of fluorescence at different 
temperatures (dF/dT). The reference strains were included in each run to 
facilitate inter-run comparisons. All samples were tested in duplicate to ensure 
reproducibility of the melt curves. The HRM curves were derived by first 
selecting two normalization regions, one occurring prior to the melting of the 
double stranded product and one following complete separation of the two 
strands. If a sample showed an aberrant melting curve pattern, the PCR product 
was purified with ExoSAP and sequenced for both forward and reverse strands 
with ABI Genetic Analyzer 3100 (Applied Biosystems, Foster City, CA USA) 
according to the standard protocol. All mutations were also verified on PCR 
products directly using genomic DNA as a template. 
 
 
 
 
40 
 
3.5.3 Direct DNA sequencing 
 
The three exons of the NKX2-1 gene were direct amplified by polymerase 
chain reaction (PCR) as previously described for all Brazilian family‟s 
members. PCR products were purified with Antarctic Phosphatase - 
Exonuclease I (NewEngland BioLabs, Ipswich, MA) at 37 C° for 15 minutes 
and 80 C° for 15 minutes for the enzyme activation and inactivation 
respectively and the products were bidirectionally sequenced with a 377 ABI 
sequencer (Applied Biosystems, Foster City, CA). The genes encoding PAX8, 
NKX2-5 were also amplified and sequenced as previously described. To 
exclude the presence of polymorphysms, 100 normal subjects were also 
screened as controls. 
All the samples resulted abnormal to either SSCP or HRM PCR were also re-
amplified and sequenced with the same technique. 
 
 
 
3.6 Mutagenesis 
 
The mouse Nkx2-1 gene from the p3XFLAG-CMV-10-NKX2-1 vector was 
mutagenized by QuikChange Site-Directed Mutagenesis kit (Agilent 
Technologies, La Jolla, CA) according to the manufacturer‟s procedure, using 
as template in a PCR the sense primer 5‟-
CCGCCGGAAGCGCGGGTGCTCTTCT-3‟ and the antisense primer 5‟-
GAGAAGAGCACCCGCGCTTCCGGC-3‟ for the NKX2-1 c.493delC. 
For the PAX8 c.T1009G, the mouse Pax8 gene from the p3XFLAG-CMV-
pax8 vector was mutagenized using the same protocol. It was used as template 
in a PCR the sense primer 5‟ AGCAAGTCGGCGCCGGGGTCCCG 3‟- and 
the antisense primer 5‟ CGGGACCCCGGCGCCGACTTGCT 3‟ 
The presence of both mutations in the obtained vectors was confirmed by direct 
sequencing.  
 
 
 
3.7 Cell culture and in vitro functional assays 
 
HEK293 and HeLa cells were maintained in Dulbecco‟s modified Eagle‟s 
medium supplemented with 2mM L-glutamine, 4.5 g/L D-glucose, 50 U/mL 
penicillin, 50 µg/mL streptomycin, and 10% fetal bovine serum under 
humidified 5% carbon dioxide/95% air at 37C° and grown in 24-well plates to 
70%–80% confluence (i.e., ˜5 x 104 cells per well). HeLa cells were transfected 
with the reporter plasmid (0.1 µg of pTg-Luc, 0.3µg of SP-C-Luc 0.32) plus 3 
ng of CMV-Ren as an internal control vector, and different doses of effector 
plasmids. HEK293 cells were transfected with 0.1 µg of the reporter pTg-Luc 
plasmid and 1.5 ng of CMV Ren internal control vector plus different doses of 
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effector plasmids. In each set of transfection experiments, the total amount of 
transfected DNA was normalized using an empty vector. Transfections were 
performed with the TurboFect in vitroTransfection Reagent (Fermentas Life 
Sciences, Pittsburgh, PA), using a DNA/Turbofect ratio of 1:2 in all 
experiments. Cells were harvested after 36–48 hours and analyzed sequentially 
for firefly and Renilla luciferase activities (Dual-Luciferase Reporter Assay 
System, Promega, Madison, WI). The ratios between the measured firefly and 
Renilla luciferase activities were expressed relative to the ratios obtained in 
cells transfected with the reporter and an empty expression vector (CMV-Flag) 
only. Transfection experiments were performed in duplicate and repeated at 
least three times. Data are shown as mean ±SD. Statistical analysis was 
performed using Student‟s t-test.  
 
 
 
3.8 Western blot 
 
For western blot, cells (5 x 10
6
) were plated on 100-mmdiameter culture dish 
24 h before transfection. HEK293 cells were transiently transfected with 10 ng 
of either wild-type (WT)-Nkx2-1 or c.493delC-Nkx2-1 plasmids using the 
FuGene 6 Transfection Reagent (Roche, Indianapolis, IN) according to the 
manufacturer‟s instructions. After 48 hours, cells were scraped in phosphate-
buffered saline (pH 7.4) and centrifuged at 1792 g for 5 minutes at 4C°. Pellets 
were frozen and stored at -80C° until used to prepare nuclear or total extracts. 
To obtain nuclear extracts, the frozen pellets of the transfected HEK293 cells 
were resuspended in low-salt buffer (10mM HEPES, pH 7.9; 10mM KCl; 
1.5mM MgCl2; 0.1mM EGTA [pH 7]; 0.5mM dithiothreitol [DTT]; pepstatin, 
4mg/mL; 2mM benzamidine; aprotinin, 20 mg/mL; 10mM leupeptin; and 1mM 
phenylmethylsulfonylfluoride) and centrifuged for 3 minutes at 4 °C at 2000 
rpm. The pellets were resuspended in low-salt buffer and passed through a 25-
gauge needle for 15 times. Nuclei were pelleted by centrifugation at 5000 rpm 
for 3 minutes at 4 °C and resuspended in 100 µL of extraction buffer (10mM 
HEPES, pH 7.9; 0.4 M NaCl; 1.5mM MgCl2; 0.1mM EGTA [pH 7]; glycerol 
5%; 0.5 mM DTT; pepstatin, 4mg/mL; 2 mM benzamidine; aprotinin, 20 
mg/mL; 10 mM leupeptin; and 1mM phenylmethylsulfonylfluoride) and 
incubated for 30 minutes at 4 °C. After centrifugation at 12,000 rpm for 30 
minutes at 4 °C, the supernatant was quantified by BioRad Assay. 
Total extracts of transfected HEK293 cells were prepared as follows: frozen 
pellets of the transfected HEK293 cells were resuspended in 1mL Busslinger 
Lysis Buffer plus proteases inhibitors (20mM TRIS, pH 7.9; 120mM KCl; 
5mM MgCl2; 0.2mM EDTA; 0.2% NP-40; 10% glycerol; DTT 100x; NaF40x; 
β- glycerophosphate 40x; and NaV [1000x]) and chilled on ice for 15 minutes. 
After centrifugation for 10 minutes at 12,000 rpm, the supernatant was frozen 
at -80 °C. Prior to use, the protein content of each sample was quantified by 
BioRadAssay. Ten micrograms and 40 µg each of nuclear and total extracts 
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were boiled in Laemmli buffer and resolved on a 12% SDS PAGE gel. The gel 
was blotted on Immobilon P (MilliporeCorp., Bedford, MA) for 90 minutes at 
a constant current of 100 mA. Immunodetection of NKX2-1 was performed by 
using a monoclonal anti-FLAG antibody (M2; Sigma, St.Louis, MO) diluted 
1:3000 in Tris-buffered saline containing 5% nonfat milk (Bio-Rad 
Laboratories, Inc., Richmond, CA), and the filter was treated with a 1:3000 
dilution of goat antimouse IgG conjugated to horse radish peroxidase (Bio-
Rad). 
 
 
 
3.9 Electrophoretic mobility shift assay 
 
We evaluated the binding of Nkx2-1 to DNA in the presence of Nkx- 
c.493delC  by electrophoretic mobility shift assay (EMSA) using double-
stranded end-labeled oligonucleotides C for the Tg promoter as described 
(Santisteban P, Acebron A et al. 1992), and double-stranded end-labeled 
oligonucleotide C2 for the surfactant protein C (SP-C) promoter.  
Antisense oligonucleotides were labeled with a T4 polynucleotide kinase (New 
England Biolabs, Boston, MA) and radioactive [-32P] ATP. Double-stranded 
oligonucleotides were purified by passing them through nick columns 
containing Sephadex G-50DNA grade resin (Amersham-Pharmacia). Nuclear 
extracts were prepared as previously described  from transfected HeLa cells. 
EMSAs were performed with 30-µl reaction mixtures at room temperature at a 
final concentration of 20 mM Tris-HCl, pH 7.5, 75 mM KCl, 1 mM 
dithiothreitol, 10% glycerol, and 1 mg/ml poly (dI-dC). Binding reaction 
mixtures containing 1 µg of nuclear extracts and 10 fmol of the probe were 
equilibrated for 30 min at room temperature and separated by electrophoresis 
through a 6% polyacrylamide gel containing 0.5x Tris-borate-EDTA. Binding 
specificity was assessed by competition with a 100-fold molar excess (or as 
indicated) of cold competitors incubated with proteins 15 min before the probe 
was added. 
 
 
 
3.10 Review of the literature 
 
We performed a systematic review of the literature by a MEDLINE search 
using the key words „congenital hypothyroidism‟, „benign hereditary chorea‟, 
„thyroid transcription factor 1‟, „NKX2-1‟, „TITF1‟, „TTF1‟ and „mutation‟. 
Inclusion criteria for the analysis were (i) patients with documented mutational 
analysis and (ii) individual clinical data on thyroid, lung and neurologic 
disorders. All patients with NKX2-1 gene defects reported in the literature 
were reviewed. Clinical features (age at diagnosis of CH, IRDS, CILD and 
BHC), data on laboratory and imaging investigations (result of neonatal 
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screening, TSH, T4, T3, thyroid ultrasound or scintigraphy, cerebral MRI) 
were entered in a database. All patients with isolated BHC without documented 
thyroid function were excluded.  
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4. RESULTS 
 
 
 
4.1 Mutational screening of genes 
 
4.1.1 Mutational screening of NKX2-1 
 
Single Strand Chain Polymorphism (SSCP) was used to screen for 
mutations in the NKX2-1 coding sequence using specific primer-pairs (Table 1) 
in 48 patients affected by CH (Table 5). No abnormal bands were detected in 
any of the studied patients. 
Direct sequencing was used as first screening method in the patients of 
the Brazilian family showing the clinical features of the BTL syndrome. 
Sequencing of the NKX2-1 coding region of the proband‟s DNA in the 
Brazilian family revealed a new monoallelic deletion of the cytosine at position 
834 (accession no. NM_003317.3) (Fig. 8). The mutation is responsible for a 
frameshift that produces an abnormal protein from amino acid 165. The last 
amino acid of the nuclear localization signal (NLS), the whole homeodomain, 
and the carboxy-terminus of NKX2-1 are all missing in the mutant protein, 
which has a premature stop codon at position 196 (p.Arg165Glyfs*32). The 
mutant protein has an approximate molecular weight of 20 kDa. The same 
mutation (TRANSNP_1331899076), never described before, was present in all 
the affected members of the family but in none of the unaffected members of 
the family and in 100 normal controls. 
 
 
4.1.2 Mutational screening of PAX8 
 
SSCP was used as first approach to screen for mutations the entire 
PAX8 coding sequence using the specific primer-pairs (Table 2) in 48 patients 
affected by CH (Table 5). 
An abnormal band was observed in the migration pattern of exon 9 of 
PAX8 gene in a 12yo girl affected by thyroid ectopy (sublingual thyroid). She 
was diagnosed at birth as congenital hypothyroidism and received substitutive 
treatment since she was 17 days old. No family history of thyroid disease has 
been reported. The mother of the patient has been adopted. 
Sequencing of the abnormal sample identified by SSCP revealed an 
heterozygous mutation at position 1009 of the PAX8 (c.T1009G, reverse 
strand). The mutation is responsible for a change of the first nucleotide of the 
triplet encoding for serine at position 337 (Ser337Ala). The mutation was not 
present in 100 DNA samples of normal controls, but sequencing of the family 
of the patient demonstrated that it was inherited from the mother (Fig. 9). 
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  Mutational screening 
CH Patients N. of cases (76) 
SSCP (NKX2-1, 
NKX2-5, PAX8) 
HRM (DNAJC17) 
Athyreosis 17 7 10 
Ectopia 31 17 14 
Hypoplastic 4 / 4 
Hemiagenesis 19 19 19 
Normal thyroid 5 5 / 
 
Table 5. Resume of N. of cases with CH and mutational screening techniques 
used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Electopherogram showing a NKX2-1 mutation. The c.493delC mutant  
produces a frameshift with a premature termination of the protein at the 196 aminoacid 
(p.Arg165Glyfs*32). The mutation is present in all affected members of the family. 
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Fig. 9 Electropherogram of PAX8 exon 9. We identified a variant c.1009T>G 
(p.Ser337Ala) in a patient with thyroid ectopia. 
 
 
 
 
 
 
4.1.3 Mutational screening of NKX 2-5 
 
Single Strand Chain Polymorphism  (SSCP) was used to screen for 
mutations in the NKX2-5 coding sequence using specific primer-pairs (Table 3) 
in 48 patients affected by CH (Table 5). No abnormal bands were detected in 
any of the studied patients. 
 
 
4.1.4 Mutational screening of DNAJC17 
 
High Resolution DNA Melting Analysis (HRM) was used as first 
approach to screen for mutations in the DNAJC17 coding sequence using 
specific primer-pairs. Forty-five patients with permanent CH (19 with 
emiagenesis, 9 with athyreosis, 4 with hypoplasia, 13 with ectopia) and 8 
controls were included in the study. Analysis of the HRM data shows 
normalised plots and difference plots of each  mutant compared to wild-type 
controls for amplicons for exons 1 to 12 of DNAJC17 . The majority of the 
melt profiles were clearly distinguishable on difference plots from wild-type by 
amplitude and/or by shape. In particular, among all the samples studied we 
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observed the presence of aberrant melt profiles in some cases with changes in 
melting curve shape in DNAJC17 exons 5 (Fig.10). 
Direct sequencing of samples resulted abnormal to HRM analysis (ex. 5) 
revealed the presence of a sequencing variant only in exon 5. In particular, we 
identified a substitution of adenine to citosine in exon 5 (c.350A>C) of 
DNAJC17 in a patient affected by athyreosis. 
 
 
 A 
 B      
 
 
Fig. 10 HRM (A) and electropherogram (B) of DNAJC17 exon 9. We did not identify 
any base change in a patient with ectopia. 
 
 
 
 
 
 
4.2 SNPs Data Base 
 
The identified NKX2-1 (c.493delC), DNAJC17 (c.350A>C) and PAX8 
(c.1009T>G) variants were queried into the NHLBI GO Exome Sequencing 
Project (ESP) database, to estabilish if they were new mutation or previously 
reported polymorphisms. This database includes some of the largest well-
phenotyped populations in the United States, representing more than 200,000 
individuals.  
The c.350A>C-DNAJC17 mutant was present in the database as 
polymorphism. The nucleotide at position 350 of DNAJC17 was reported as 
adenine in 99% of the alleles, while the citosine has a frequency of 1%. The 
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prevalence of cytosine is higher in European population, where it represents the 
3% of the cases. 
Also the c.1009T>G-PAX8 on Ensemble Genome Browser 
demonstrated that this variant is a known SNP (rs199939219) (Fig. 11), while 
the search of the c.493delC-NKX2-1 produced no results, indicating that this is 
a de novo mutation associated with the brain–thyroid–lung syndrome (BTLS) 
(Fig. 12). 
 
 
 
 
 
Human       GGG------------------ACCCCGGAGCCGACTTGC 
Chimpanzee  GGGACCGAGGCACCGGCTGGGACCCCGGAGCCGACTTGC 
Gorilla     GGGACCGAGGCACCGGCTGGGACCCCGGAGCCGACTTGC 
Orangutan   GGGACCGAGGCACCGGCTGGGACCCCGGAGCCGACTTGC 
Macaque     GGGACCGAGGCACCGGCTGGGACCCCGGAGCCGACTTGC 
Marmoset    GGGACCGAGGCACCGGCTGGGACCCCGGAGCCGACTTGC 
 
 
Fig. 11. Philogenetic context of rs199939219 SNP (c.1009T>G PAX8). The alignment 
of 6 primates shown variants (including SNPs and indels) imported from dbSNP. The 
A/C (ancestral of T/G) is conserved in species. 
 
 
 
 
 
 
 
 
Human       AAGAGCACCCGGCGCTTCCTG 
Chimpanzee  AAGAGCACCCGGCGCTTCCTG 
Gorilla     AAGAGCACCCGGCGCTTCCTG 
Orangutan   AAGAGCACCCTGCGCTTCCTG 
Macaque     AAGAGCACTCGGCGCTTCCTG 
Marmoset    AAGAGCACCCGGCGCTTCCTG 
 
GCGCCGCGCAGGAAGCGCCGGGTGCTCTTCTCGCAGGCGCAGGTGTACGAGCTGGAGCGA    
GCGCCGCGCAGGAAGCGCCGGGTGCTCTTCTCGCAGGCGCAGGTGTACGAGCTGGAGCGA     
-A--P--R--R--K--R--R--V--L--F--S--Q--A--Q--V--Y--E--L--E--R 
 
 
Fig. 12. NKX2-1 Sequence conservation (ancestral)  via cross-species alignments. 
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4.3 PAX8 Functional characterization 
 
As indicated, the c.1009T>G was present as rare polymorphism in the 
tested databases. Since no functional data were available for this variant and in 
order to exclude a possible role of this polymorphism ass co-factor in the 
pathogenesis of thyroid dysgenesis, we performed functional studies on the 
c.1009T>G-PAX8. To this aim, the c.1009T>G-PAX8 was inserted by site 
directed mutagenesis in an expression vector and transfection experiments have 
been performed to test the functional effect of the mutation. The mutant protein 
had the same activity of the WT-PAX8, did not produced a dominant negative 
effect and the activity in presence of NKX2-1, TAZ or P300 is similar to the 
activity measured for the wild type. This data confirmed that the c.1009T>G – 
PAX8 has no functional effect on PAX8 function anc can be considered as a 
simple polymorphism with no clinical relevance. 
 
 
 
4.4 NKX2-1 functional characterization 
 
4.4.1 Nuclear localization 
 
Since the c.493delC mutation occurs in the codon encoding for the last amino 
acid of the NLS of NKX2-1, we tested the effect on the nuclear localization. To 
this aim, HeLa cells were transfected with either the WT-Nkx2-1 or the 
c.493delC-Nkx2-1. After 24 hours, both nuclear and cytoplasmatic proteins 
were extracted from transfected cells and Western blot results are shown in 
Fig. 13. As expected, WT-NKX2-1 was synthesized and migrated into the 
nucleus, disappearing from the cytosolic extracts. Despite the alteration of the 
nuclear localization signal, thec.493delC was able to migrate into the nucleus. 
These results indicate that the p.Arg165Glyfs*32 was synthesized and was 
capable of migrating into the nucleus. 
 
 
 
 
 
Fig. 13. Nuclear Localization. Western blot analysis with the anti-FLAG antibodies of 
cytosolic and nuclear extract of the cells transfected with both wild-type (WT) and 
c.493delC (p.Arg165Glyfs*32) cloned into the p3XFLAG-CMV-10 plasmid. The 
c.493delC is normally synthesized and able to migrate into the nucleus. 
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4.4.2 DNA binding capacity 
 
DNA binding properties of the c.493delC mutant were also analyzed by EMSA 
using a short DNA stretch correspondingto the NKX2-1 binding site within the 
Tg promoter (oligo C)  and the SP-C promoter (oligo C2). The results are 
shown in Fig. 14. A retarded band could be detected with the WT, while the 
c.493delC NKX2-1 was, as expected, unable to bind to DNA because of the 
absence of the homeodomain. Moreover, the addition of the same or double 
amount of c.493delC extracts did not reduce the binding of WT-NKX2-1. This 
indicates that c.493delC-NKX2-1 was unable to physically interact and 
modulate WT-NKX2-1 binding to DNA. The specificity of all the observed 
complexes was demonstrated in competition experiments adding a 100-fold 
excess of cold oligos. 
 
 
 
 
 
 
 
 
Fig. 14. DNA binding capability of the c.493delC mutant (p.Arg165Glyfs*32). 
Electrophoretic mobility shift assay (EMSA) was performed with nuclear extracts of 
HEK293cells transfected with WT and c.493delC constructs on the thyroglobulin (Tg) 
promoter (A) and surfactant protein C (SP-C) promoter (B). Arrowheads indicate the 
bound NKX2-1 to the oligos. The co-transfection of the WT-Nkx2-1 with the same 
(+/+) or double (+/++) amount of the mutant c.493delC does not reduce the binding of 
the WT. Extracts were also incubated with a large excess (100-fold) of cold oligos as a 
competitor that produced a significant displacement of the bound labeled probe. 
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4.4.3 Transactivation capacity of mutated and WT NKX2-1 proteins 
 
The transcriptional properties of both WT- and c.493delC NKX2-1 were 
investigated by co-transfection assays as previously described. As expected, 
the c.493delC mutant was unable to activate both the Tg and the SP-C 
promoters. Thereafter co-transfection experiments were performed using both 
WT and the c.493delC mutant on the same promoters. Interestingly we were 
able to demonstrate a dose dependent dominant negative effect of the 
c.493delC mutant on the WT-NKX2-1 when used with the Tg promoter 
(Fig.15A), but no dominant negative effect could be demonstrated on the SP-C 
promoter (Fig. 15B), indicating that the c.493delC mutant produced a 
dominant-negative effect on the wild-type NKX2-1 in a promoter-specific 
manner. To further understand the dominant-negative action and investigate the 
c.493delC effects, co-transfection experiments were performed with PAX8, 
P300, and TAZ on the Tg promoter.  
 
 
 
 
 
 
 
Fig. 15. Transcriptional activation of Tg and the SP-C promoters.(A) Effects of 
transfection of WT-NKX2-1 and c.493delC-NKX2-1 on the Tg promoter. Addition of 
increasing amounts (12.5, 25, 50 ng) of c.493delC to a constant amount (50 ng) of the 
WT produced a significant decrease in the promoter activity (***p < 0.001). (B) Effects 
of transfection of WT-Nkx2-1 and c.493delC-Nkx2-1 on the SP-C promoter. Contrary 
to what was observed for Tg, addition of increasing amounts (12.5, 25, 50 ng) of 
c.493delC to a constant amount (50 ng) of the WT did not reveal a dominant negative 
effect. 
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PAX8 (Paired Box Gene 8) is a transcription factor expressed in the thyroid but 
not in the lung. It synergizes with NKX2-1 to stimulate Tg and thyroperoxidase 
promoter activities (Di Palma, Nitsch et al. 2003). P300 (E1A-Binding 
Protein), a general transcriptional coactivator, plays a pivotal role in the 
activity of many transcription factors, either by bridging sequence-specific 
DNA binding factors with elements of the basal transcriptional machinery, 
such as transcription factor IIB and polymerase 2, or by its intrinsic histone 
acetyl transferase activity. NKX2-1, PAX8, and P300 physically interact with 
each other (Di Palma, Nitsch et al. 2003), and the functional synergism may 
involve the direct cooperation of all three factors. The addition of P300 
increases the transactivation properties of PAX8, NKX2-1, and both factors 
together. TAZ (transcriptional co-activator with a PDZ-binding motif, also 
known as WWTR1) is also present in thyroid tissue and in differentiated 
thyroid cell lines, thus acting as a potent co-activator for both PAX8 and 
NKX2-1 (Park, Whitsett et al. 2004). As previously shown (Di Palma, Nitsch 
et al. 2003), we were able to demonstrate that PAX8 synergized with the WT 
protein and increased Tg promoter activity. The cotransfection with the 
c.493delC did not modify the PAX8 basal activity, and the dominant negative 
effect was also present when both WT and c.493delC proteins were transfected 
with PAX8 (Fig. 16). 
To further study the interplay of P300, PAX8, and both WT and c.493delC 
proteins, cotransfection experiments were performed in HEK293 cells, since 
these cells lack the endogenous P300. Again, if the c.493delC was added to the 
cells, there was no increase in the activation produced by PAX8 and/or P300, 
suggesting that this truncated protein did not interfere with the complex. 
Finally, when all four factors were present (WT, c.493delC, PAX8 and P300), 
a slight decrease in the activity could be observed compared with the 
multiprotein complex of NKX2-1/PAX8/P300 (Fig. 17). These results indicate 
that the dominant negative effect can also be observed when a multifactorial 
complex is present, and PAX8 or P300 are unable to rescue the effect of the 
mutation. Similar results were obtained when the coactivator TAZ was used in 
HeLa cells. 
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Fig. 16. Synergism with PAX8. Transcription activation of the Tg promoter by WT-
NKX2-1 and c.493delC-NKX2-1 in the interaction with PAX8. HeLa cells have been 
transfected with 50 ng of each plasmid and 100 ng of the reporter. The addition of WT 
produced a significant (***p < 0.001) increase in the PAX8 activity, while the addition 
of the c.493delC hadno effect. If both WT-Nkx2-1 and c.493delC-Nkx2-1 were 
transfected, the dominant negative effect of the mutant on the WT protein was still 
present. The presence of PAX8 did not rescue the dominant negative effect on the Tg 
promoter. 
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Fig. 17. Effect of P300. HEK293 cells were co-transfected with WT-Nkx2-1 (50 ng), 
c.493delC-Nkx2-1 (50 ng), PAX8 (50 ng), and P300 (300 ng) expression vectors, and 
the pTg-Luc reporter (100 ng) in the indicated combinations. The addition of P300 
significantly increased the activity of the Tg promoter in response to WT-NKX2-1 and 
PAX8, but had no effects on the activity of c.493delC. The cooperation between WT, 
PAX8, and P300 produced an additional increase in the activity, while the activation of 
the complex c.493delC/PAX8 did not differ from the activation observed when PAX8 
was co-transfected with P300 alone. Finally, when all the factors were present, there 
was a reduction of the activation compared with the WT+ PAX8 complex, as a 
consequence of the dominant negative effect of the c.493delC mutant on the WT. 
Significant differences between the samples with and without P300 are indicated: ***p 
< 0.001. 
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5. DISCUSSION 
 
 
 
The development of the thyroid gland is a complex process of organ induction 
in the pharyngeal endoderm, early budding of the organ anlagen, tissue 
relocalisation and growth. Defects at any of these steps of the thyroid 
organogenesis can lead to thyroid dysgenesis (TD). With this term, several 
alterations of the gland are indicated, including the complete absence of thyroid 
tissue (athyreosis), the presence of an ectopic organ or hypoplasia of the gland. 
The molecular basis of thyroid development have only recently been studied 
with the identification of several genes playing a crucial role in the thyroid 
organogenesis.  
Comparative and functional studies in different animal models have provided 
interesting hypotheses for the mechanisms by which the developing thyroid 
anlagen is correctly positioned in the anterior neck region (De Felice M and Di 
Lauro R 2004). Alterations of the thyroid morphogenesis, at least in some 
cases, have been associated with disturbances in the function of genes that 
regulate several aspects of thyroid development, suggesting that TD can be a 
heritable genetic disease. However, in the majority of patients, the search for 
mutations in the known genes produced no results.  
In order to further identify genetic defects in thyroid dysgenesis we performed 
a sequencing study of all coding exons of NKX2-1 in a family from Curitiba, 
affected by Brain-Lung-Thyroid Syndrome. We also screened 76 patients with 
persistent CH for known and new candidate genes (NKX2-1, NKX2-5, PAX8, 
DNAJC17) by SSCP or HRM.  
Mutations in NKX2-1 have been demonstrated to be responsible for several 
cases of BTLS, and in our study we describe a novel mutation in the gene 
encoding for NKX2-1 in a family with the clinical manifestations of benign 
hereditary chorea, hypothyroidism, and respiratory distress. The mutation 
c.493delC results in a truncated protein of 196 amino acids. The mutant protein 
contains a frameshift and differs from the WT beginning at position 165, which 
corresponds to the last amino acid of the NLS. Transfection experiments with 
the mutant protein demonstrate that the c.493delC protein is synthesized and 
translocates into the nucleus, but it is unable to bind DNA since it completely 
lacks the homeodomain. The c.493delC mutant was responsible for a clear 
dose-dependent dominant negative effect on the WT NKX2-1 when tested on 
the Tg promoter, whereas when functional assays were performed on the lung 
SP-C promoter, the c.493delC mutant showed no dominant negative effect. 
Several mutations in NKX2-1 have been reported (Table 7), and in the majority 
of cases haploinsufficiency has been considered to be responsible for the 
phenotype, as also suggested by the finding of motor abnormalities and mild 
hyperthyrotropinemia in the Nkx2-1 heterozygous knockout mice (Pohlenz, 
Dumitrescu et al. 2002). Only a few mutations (Table 7) produce a dominant 
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negative effect on the WT NKX2-1 (Carre, Szinnai et al. 2009) (Guillot, Carre 
et al. 2010), and there is only one case among them describing a promoter-
specific dominant negative effect (Moya, Perez de Nanclares et al. 2006). In 
this last case, contrary to what was observed for the c.493delC, the mutant 
protein contained the homeodomain and could bind to DNA. The authors 
suggested that the possible interference of the mutant NKX2-1 (p.P275fs*74) 
with the cooperative interaction between NKX2-1 and PAX8 or NKX2-1 and 
other cofactors on the Tg promoter is the cause of the promoter-specific 
dominant negative effect. Since our mutant did not bind to DNA, it is probable 
that the amino terminus of NKX2-1 binds to other factors that are relevant for 
its activity on the Tg promoter, thus excluding them from the tissue-specific 
transcriptional regulation is achieved by the combined interaction among 
transcription factors, co-regulators, and other components regulating basal 
transcription. In the thyroid, NKX2-1 physically interacts with both PAX8 (Di 
Palma, Nitsch et al. 2003) and TAZ (Di Palma T 2009). In addition P300, a 
ubiquitous transcriptional cofactor, has been demonstrated to play an important 
role for the NKX2-1/PAX8 synergy (Grasberger, Ringkananont et al. 2005) 
(De Leo R 2000). PAX8, P300, and TAZ were tested to see whether they could 
influence the transactivation of NKX2-1 on its target promoters. The presence 
of these cofactors increased the activation of the Tg and SP-C promoters, but 
did not change the thyroid-specific dominant negative effect. In addition, no 
rescue of the NKX2-1/PAX8 synergism was observed, contrary to what was 
previously reported in the case of a PAX8 mutation (Grasberger, Ringkananont 
et al. 2005). It has been suggested that NKX2-1 binds to DNA as a dimer 
(Arnone MI 1995) and that the interaction with PAX8 occurs via the amino 
terminus of the NKX2-1 protein (Di Palma, Nitsch et al. 2003). Several other 
factors, most of which not yet defined, may be involved in the regulation of 
transcription. We believe that the truncated NKX2-1 mutant described here 
interferes with the activity of WT NKX2-1, decreasing the activity of the 
multiprotein transcriptional complex. It is likely that PAX8 plays a critical role 
in modulating this effect in thyroid cells. In lung cells, where PAX8 is absent, 
the dominant negative effect cannot be observed. Even if HeLa cells do not 
express PAX8, it has been previously suggested that other proteins with a 
similar activity may replace the function of PAX8 on the Tg promoter (Moya, 
Perez de Nanclares et al. 2006). Very recently Silberschmidt and coworkers 
(Silberschmidt, Rodriguez-Mallon et al. 2011) produced mice lacking one of 
the two redundant activation domains of Nkx2-1, or having defective 
phosphorylation of the protein. They demonstrated that each mutant shows a 
distinct phenotype. They also revealed a level of complexity that could not be 
predicted by experiments carried out in cultured cells and stressed the 
discrepancy between the results in the cell models and in those that can be 
obtained in whole organisms (Silberschmidt, Rodriguez-Mallon et al. 2011). In 
this context, the major molecular effect of our mutation on the Tg promoter is 
dominant, while hypothyroidism is only mild (subclinical) in all the affected 
members of our family. This discrepancy can be the consequence of different 
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mechanisms of action of the mutation in the different tissues, but also of the 
complex interactions between other genetic and/or environmental factors that 
may modulate the phenotype. All the reported NKX2-1 mutations (summarized 
in Table 7) have variable functional effects, even if the mutations occur in 
similar regions of the protein. Indeed, the clinical features of the affected 
families and family members described in the literature are very variable, and 
there is no correlation between the clinical and the molecular phenotype. 
Mutations that produce major alterations in the protein structure may be 
associated with only minor neurological signs (Pohlenz, Dumitrescu et al. 
2002) (Provenzano, Veneziano et al. 2008), while primary hypothyroidism has 
been linked to NKX2-1 mutations in 81% of the cases (25/31) (Table 7).  
In conclusion, a novel NKX2-1 mutation in a family presenting the clinical 
findings of the BTLS is described. The c.493delC mutant migrates into the 
nucleus but is not able to transactivate the Tg or SP-C promoters. These results 
indicate that NKX2-1 activity is finely regulated by the interaction of several 
factors that are still largely unknown. The mechanisms regulating gene 
expression are different in each tissue. Additional studies are required to better 
understand the complexities of the genotype–phenotype correlation in the 
NKX2-1 deficiency syndrome. Both the incomplete penetrance and the 
variability of the phenotype could be due to the effect of other modifier genes 
as well as of environmental factors. Furthermore, when the disease is 
associated with a large chromosomal deletion, we cannot exclude that the loss 
of other genes is contributing to variability of the phenotype. 
 In addition to NKX2-1, several other genes have been associated to TD. In 
our study, the NKX2-1, PAX8 and NKX2-5 genes were also studied in a cohort 
of 76 patients with TD. Mutations in these genes have been previously 
described in cases of athyreosis, ectopia, and hypoplasia (Tables 6-8) with a 
very high variability in the clinical manifestations. 
Dominantly inherited NKX2-5 mutations are known to cause heart defects, but, 
despite several mutations have been associated to TD (Dentice, Cordeddu et al. 
2006) (Table 8), the involvement of NKX2-5 in TD in humans is still a matter 
of debate.  
Hermanns and co-authors, reported a girl with TD who is heterozygous for two 
mutations, each encoding a transcription factor important for the development 
of the thyroid gland, respectively NKX2-5 and PAX8 genes. The NKX2-5 
S265R is located in a highly conserved region of the gene and it is not a 
common polymorphism. It binds normally to the target sequences because the 
mutation is located outside the homeobox domain of NKX2-5, but presented a 
reduced transcriptional activity when compared to the WT. Furthermore, 
S265R-NKX2-5 exerts a dominant negative effect, thus been likely to have an 
impact on thyroid organogenesis, even though genetically affected family 
members did not have TD or heart defects (Hermanns, Grasberger et al. 2011). 
In addition, in the same patient, it was identified a heterozygous mutation in 
the PAX8 gene promoter (-456). The mutated PAX8 gene promoter showed a 
reduced ability to activate a reporter gene and does not bind nuclear extracts. 
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So, it could be contribute to the pathogenesis of TD. It is surprising the 
observation that a younger sibling of patient, also heterozygous for both NKX2-
5 and PAX8 promoter mutations, had no manifestation of thyroid dysfunction. 
Whether this phenotypic variability is due to a variable penetrance or 
expressivity of the mutant gene or whether the genetic background plays a role 
remains unclear. Haploinsufficiency, monoallelic expression, or imprinting 
could all have an impact on the phenotype (Vassart G 2005). 
We found no mutations in the PAX8 or NKX2-5 genes in our cohort of 
patients. The only variation we observed was SNP rs199939219 
(www.ncbi.nlm.nih.gov/snp) within the PAX8  gene, that causes for a change 
of the first nucleotide of the triplet encoding for serine at position 337 
(Ser337Ala). However, we do not believe this SNP to be related to TD since 
the frequency of the SNP within patients and controls was not significantly 
different. 
It is worth to note that the mutations scored in known candidate genes (NKX2-
1, NKX2-5, PAX8 and TSHR) in TD patients are certainly an underestimate, 
considering that mutations have been searched mostly in the coding region and 
mutations in introns or in regulatory regions may have gone unnoticed, and the 
same limitations also apply to our study. So far a mutation in one of these 
candidate genes has been identified in only 3% of patients with thyroid 
dysgenesis. Moreover a recent report has shown only few non-informative 
chromosomal aberrations in a cohort of thyroid dysgenesis patients by 
comparative-genome-hybridization-array (Array-CGH) (Kuhnen, Turan et al. 
2014) excluding DNA copy number variations (CNVs) as a frequent cause of 
thyroid dysgenesis. Epidemiological data collected in a large neonatal 
screening study of patients with congenital hypothyroidism due to thyroid 
dysgenesis revealed a striking sporadic occurrence. There was no seasonal or 
geographic influence, but there was remarkable discordance observed in pairs 
of monozygotic twins. Furthermore, even in the cases in which mutations in 
known genes are clearly associated with the disease, a great variability in the 
phenotype has been observed, even in individuals with the same mutation. 
Phenotypic variability observed in patients affected by mutations in either 
NKX2-1 or PAX8 genes supports the possibility that other interacting genes 
may modulate the phenotype. A recent study extends the variable clinical 
spectrum of patients with SLC26A4 mutations and points out the necessity to 
analyze the SLC26A4 gene in patients with “apparent” thyroid dysgenesis in 
addition to the known candidate genes TSHR, PAX8, NKX2.1, NKX2.5 and 
FOXE1. In this work, a homozygous missense mutation (p.Leu597Ser) in the 
SLC26A4 gene has been identified in a patient with hypoplastic thyroid tissue, 
who was otherwise healthy. Based on the unexpected identification of the 
SLC26A4 missense mutation in one patient with TD, the SLC26A4 gene was 
screened for mutations in a cohort of 94 patients with TD who had already 
been examined for known thyroid dysgenesis candidate genes and CNVs. The 
authors observed a second case with a homozygous missense mutation 
(p.Gln413Arg) in the SLC26A4 gene, who was additionally affected by severe 
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hearing problems. Both mutations were previously described as loss-of-
function mutations in patients with Pendred syndrome and non syndromic EVA 
(enlarged vestibular aqueduct), but now for the first time have been reported in 
patients with structural thyroid defects (Kuhnen, Turan et al. 2014). This work 
confirms the possibility that other interacting genes may modulate the 
phenotype. A possible multigenic origin for TD was previously suggested in 
the DHTP mice produced by Amendola and coworkers. To date, several mouse 
models carrying loss-of-function mutations in thyroid-specific genes have been 
generated, providing some similarities with the human situation. Recently, a 
polygenic animal model of congenital hypothyroidism which fulfills all 
essential criteria of this disease in humans has been described. These mice 
presented elevated TSH, reduced thyroid hormones, decreased body weight 
accompanied by thyroid hypoplasia, and increased incidence of thyroid 
hemiagenesis. The model, characterized by heterozygous null mutations in the 
genes encoding the transcription factors Nkx2-1 and Pax8, has been named 
DHTP, for double heterozygous for Titf1 and Pax8. Interestingly, the 
hypothyroid phenotype is present only when DHTP mice are produced in the 
B6 strain, whereas it is completely absent in both Sv and DHTP/B6-Sv F1 
hybrid mice (Amendola, De Luca et al. 2005).  Next, using both association 
studies and linkage analysis, the authors identified two potential loci linked to 
the phenotype and finally Dnajc17, which encodes for a type III member of the 
group of Hsp40 (Qiu, Shao et al. 2006) was recognized as a modifier of the 
thyroid phenotype in DHTP mice (Amendola, Sanges et al. 2010). Dnajc17 
presents a phenylalanine residue at position 273 in the B6 mice, but at the same 
position in all other mouse strains it shows a tyrosine. Even though the 
phenylalanine-tyrosine change is a conservative missense mutation, the 
tyrosine residue at position 273 is conserved in all the Dnajc17 ortholog genes 
throughout the evolution from metazoans (Fig. 5) 
Dnajc17 is expressed from the early stage of embryonic life in the developing 
thyroid and remains expressed in the adult thyroid as well as in differentiated 
thyroid follicular cells in culture. It has been reported that DnaJ proteins 
interact, via a highly conserved domain (J domain), with Hsp70chaperone 
proteins and regulate the activity of these chaperones (Qiu, Shao et al. 2006). 
Chaperone proteins can control the disassembly of transcriptional complexes  
(Freeman and Yamamoto 2002) and can act as regulators in several gene 
expression. Since Dnajc17 has a nuclear localization, it could be involved in 
the regulation of the transcriptional activity of Nkx2-1 and/or Pax8. 
Furthermore, in a heterologous cellular system, it has been demonstrated not 
only that Dnajc17 is able to interfere with Tg transcription but also that this 
activity is sensitive to the replacement of tyrosine by a phenylalanine residue at 
position 273 (Amendola, Sanges et al. 2010). This result, albeit obtained in an 
artificial system, suggests that Dnajc17 has the potential to affect transcription 
of thyroid-specific genes via an interference on Nkx2-1 and thus is in full 
agreement with its suggested role as modifier of the DHTP phenotype and, 
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more in general, as one of the genes involved in the multigenic origin of 
thyroid defects.  
All these observations allow to hypothesize a possible role of DNAJC17 also in 
the thyroid development. In our work, the entire coding region of the 
DNAJC17 gene was screened for mutations in patients with CH due to thyroid 
dysgenesis in order to evaluate the potential role of this gene in the 
pathogenesis of TD using HRM technique.  
We decided to use HRM because this technique is a simple, rapid and cost 
effective technique could be used for detection of SNPs in clinical specimens. 
For constitutional variants, Tindall et al. found that 100% (26/26) of the 
samples with one or more heterozygous loci were distinguished from wild type 
by high resolution melting. This compares well to a recent compilation of 19 
studies with an overall sensitivity of 99.3% and a specificity of 98.8% (Farrar 
et al., 2009). 
Despite our efforts, we were not able to demonstrate mutations in the 
DNAJC17 coding sequence in 45 patients with TD as well as in 100 healthy 
normal controls. One of the three abnormal melting curve at HRM that we 
sequenced was determined by the presence of an already known polymorphism 
c.350A>C. This polymorphism occurs with a frequency of 3% in European 
normal population as demonstrated by the comparison of the sequence with the 
NHLBI GO Exome Sequencing Project database. 
The absence of DNAJC17 mutations in our patients well correlate with the 
complex phenotype observed in Dnajc17 knock-out mice, that die between the 
morula and blastocyst stages, data suggesting that this gene could be critical in 
the early development steps of the mouse embryo. Thus it is possible to 
hypothesize that alterations in this gene are not compatible with life also in 
humans as well as in mice. Our results do not exclude the potential role of 
DNAJC17 in the pathogenesis of TD, since we screened a low number of 
patients with TD (only 45) and it necessary to increase the number of patients 
in order to completely rule out the possible DNAJC17 role TD. 
 
In conclusion, our search of alterations in already known and novel candidate 
genes for thyroid dysgenesis resulted in the identification of a novel NKX2-1 
mutation in a Brazilian family were the affected members presented the clinical 
findings of the BTLS. The c.493delC-NKX2-1 mutation has been functionally 
characterized and we demonstrated that the mutant protein migrates into the 
nucleus but is not able to transactivate the Tg or SP-C promoters. In addition, a 
dose-dependent dominant negative effect of the p.Arg165Glyfs*32 was 
demonstrated only on the Tg promoter, but not on the SP-C promoter. These 
results indicate that NKX2-1 activity is finely regulated by the interaction of 
several factors that are still largely unknown. The mechanisms regulating gene 
expression are different in each tissue.  
 
As a result, no conclusive hypothesis for the pathogenesis of thyroid 
dysgenesis could be formed. The sporadic occurrence and discordance in 
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monozygotic twins argue against a classic genetic defect while the stable 
incidence, even in the presence of opposing environmental conditions, suggests 
that exogenous pathogenic factors do not play a critical role. It is possible that 
postmeiotic genetic alterations such as somatic mutations or epigenetic 
alterations are responsible. Further investigation will hopefully link the 
different forms of thyroid dysgenesis with specific molecular defects within the 
regulatory pathways of thyroid development. 
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Mutation 
Region Effect of the mutation 
Thyroid 
Phenothype DNA Protein 
c.-456C > T (*) p.0? Promoter Loss of protein binding capacity on the mutant promoter and decreased transcriptional activity Athyreosis 
c.287G>A p.R31H 
Paired domain 
Completely lack of DNA binding and transcriptional activity on TPO promoter Hypoplasia 
c.286C>T p.R31C Decreased binding to DNA Severe Hypoplasia 
c.119A>C p.Q40P Completely lack of DNA binding and transcriptional activity on TPO promoter Hypoplasia 
c.143C>T p.S48F No p300 recruitment and decreased transcriptional activity on Tg promoter 
Normal or 
Athyreosis 
c.155G>C p.R52P Completely lack of binding to Tg promoter Hypoplasia 
c.160A>G(**) p.S54G Decreased binding to TPO promoter and reduced synergism with NKX2-1 on Tg promoter Hypoplasia 
c.162C>G  p.S54R Decreased DNA binding and transcriptional activity on Tg and TPO promoter Severe Hypoplasia 
c.165T>G p.H55Q Decreased transcriptional activity on Tg promoter Hypoplasia 
c.170G>A p.C57Y Completely lack of transcriptional activity on TPO promoter Hypoplasia 
c.380T>G p.L62R Decreased DNA binding and transcriptional activity on TPO promoter Hypoplasia 
c.238_252dup p.K80-A84dup Decreased DNA binding and transcriptional activity on Tg promoter Hypoplasia 
c.517C>T p.R108* Completely lack of DNA binding and transcriptional activity on TPO promoter 
Hypoplasia and 
Ectopia 
c.398G>A p.R133Q Decreased transcriptional activity on Tg and TPO promoter Severe Hypoplasia 
c.674C>T p. T225M 
C-terminus 
 
NO Decreased transcriptional activity on Tg promoter Ectopia 
c.1006G>A p.G336S NO Decreased transcriptional activity on Tg promoter Athyreosis 
c.989-992delACCC p.T277fs*1 Decreased transcriptional activity on CP5-CAT promoter  
Normal or 
Hypoplasia 
 
Table 6. PAX8 mutations in patients with thyroid dysgenesis (Nettore IC 2013).
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Mutation Type of 
mutation 
Mechanism of action of the mutation Thyroid Phenothype Other disorders 
DNA Protein 
2.6-Mb deletion 
p.0 
 
 
Deletion 
 
Not tested Absent Respiratory problems and  psychomotor delay 
Large deletion 
Haploinsufficiency 
 
Primary hypothyroidism 
associated with 
hypoparathyroidism and 
osteoporosis. 
Multisistem disorder of the basal ganglia, 
salivary glands, bowels and teeth. Respiratory 
problems and  psychomotor delay 
del 14q11.2q13.3 CH (Hypoplasia)  Respiratory problems and  psychomotor delay 
del 14q12-13.3 CH  (Normal thyroid) 
Respiratory problems, severe developmental 
delay and psychomotor delay 
del 14q12-13.3 Absent Psychomotor delay 
del 14q13-21 
CH (Normal thyroid) 
 
Respiratory problems and  psychomotor delay 
c.374-1G >A 
p.0? 
 
Splice site 
mutation 
 
Not tested CH (Hypoplasia)  Respiratory problems and  psychomotor delay 
c.376-2A>G Haploinsufficiency 
CH (Athyreosis)  Respiratory problems 
CH (Hemiagenesis)  Respiratory problems 
CH (Normal thyroid) Respiratory problems and  psychomotor delay 
c.255insG p.G86fs*322 Frameshift 
Haploinsufficiency; Reduced binding and 
transactivation of Tg 
CH (Normal thyroid)  Respiratory problems and  psychomotor delay 
g.1302C>A p.C87* 
Non sense Haploinsufficiency 
CH (Agenesis),  Respiratory problems and  psychomotor delay 
c.609C>A p.S145* CH (Normal thyroid) Respiratory problems and  psychomotor dela 
c.470_479delinsGCG p.P157fs*196 Frameshift Haploinsufficiency CH (Normal thyroid) Respiratory problems and  psychomotor delay 
c.493C>T p.R165W Missense 
Dominant positive on SP-C; 
Reduced transactivation of Tg   
CH (Normal thyroid) Respiratory problems 
c.493delC p.R165Gfs*32 Frameshift 
Decreased binding of Tg 
Reduced transactivation of Tg and SP-C;  
Dom negative only on Tg but not on SP-C  
Subclinical 
Hypothyroidism 
Respiratory problems and  psychomotor delay 
g.2519C>A p.S169* 
Non sense 
Haploinsufficiency CH (Hypoplasia)  Psychomotor delay 
c.523G>T p.E175* Not tested 
CH (Hypoplasia/ 
Hemiagenesia) 
Respiratory problems and  psychomotor delay 
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Table 7. Molecular features of NKX2-1 mutations and clinical characteristics of the patients (Nettore IC 2013).  
 
c.526C>G p.L176V Missense Dom. negative on Tg CH (Hypoplasia)   Psychomotor delay 
c.532C>T p.R178* Non sense 
Decrease binding and reduced transactivation 
of Tg;  not dominant negative on Tg 
Absent Psychomotor delay 
g.2595_2597insGG p.A195fs*4 Frameshift Haploinsufficiency CH (Normal thyroid) Psychomotor delay 
c.605C>T p.P202L 
Missense 
 
Reduced transactivation of Tg;  rescue of 
activity by co-trasfection with Pax8 
CH (Normal thyroid)  Psychomotor delay 
g.2626G>T p.V205F Decreased DNA binding on Tg CH (Hypoplasia)  Respiratory problems and  psychomotor delay 
c.613G>T p.V205F Not tested CH (not defined) Psychomotor delay 
c.619A>T p.I207F 
Reduced transactivation, dom. negative and 
decreased DNA binding capacity on Tg and 
SP-B 
CH (Normal thyroid) Respiratory problems 
c.621C>G p.I207M Not tested CH (Normal Thyroid) Respiratory problems 
c.629A>C p.Q210P Reduced transactivation of Tg CH (Hypoplasia) Psychomotor delay 
c.650C>A p.S217* Non sense Not tested CH (not defined) 
Respiratory problems, psychomotor delay and 
psychosis 
c.713G>T p.W238L 
Missense 
Haploinsufficiency CH (not defined) Psychomotor delay 
c.727C>A p.R243S Haploinsufficiency Absent Psychomotor delay 
c.745C>T p.Q249* Non sense Not tested Absent Psychomotor delay 
c.786_787del2 p.L263fs 
Frameshift 
Dom. negative on SP-B and SP-C CH (Normal thyroid) 
Respiratory problems and  mild  psychomotor 
delay 
c.825delC p.P275fs*74 Dom. negative on Tg but not on SP-C CH (Normal thyroid) Psychomotor delay 
c.859_860insC p.Q287fs*121 Not tested CH (not defined) Respiratory problems and  psychomotor delay 
c.908_909delG p.G303fs*77 Haploinsufficiency Absent Psychomotor delay 
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Mutation 
Mechanism of action of the mutation Congenital heart defect 
Thyroid 
phenotype DNA Protein 
c.73C>T p.R25C Reduced transactivation on thyroid promoter and dominant negative on WT. No cardiac malformation Ectopy/Athyreosis 
c.355G>T p.A119S 
Reduced transactivation, dominant negative effect and reduced DNA binding on 
thyroid promoter. 
No cardiac malformation Ectopy 
No functional effects Congenital hearth defects Normal 
c.482G>C p.R161P 
Reduced transactivation, dominant negative effect and reduced DNA binding on 
thyroid promoter. 
Minor mitral valve 
insufficiency 
Ectopy 
c.795A>C p.S265R (*) 
30-40% reduced transactivation of the Tg and TPO promoter and dominant 
negative effect. Normal binding to NKE-2, DIO, Tg and TPO promoter. 
No cardiac malformation Athyreosis 
 
Table 8. NKX2-5 mutations in patients with thyroid dysgenesis. (*) The patient carrying the p.S265R mutation also has a PAX8 
promoter (-456C>T) mutation (Nettore IC 2013). 
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6. CONCLUSIONS 
 
 
 
Mutations in NKX2-1 have been demonstrated to be responsible for several 
cases of BTLS. To further identify genetic defects in thyroid dysgenesis we 
performed a sequencing study of all coding exons of NKX2-1 in a family from 
Curitiba, affected by Brain-Lung-Thyroid Syndrome. We also screened 76 
patients with persistent CH for known genes (NKX2-1, NKX2-5, PAX8) since 
these are transcription factors involved in thyroid embryogenesis, and new 
candidate gene, DNAJC17. Mutations in the transcription factors NKX2-1, 
NKX2-5, PAX8 have been previously described in cases of TD, while there are 
many observations allow to hypothesize a possible role of DNAJC17 also in the 
thyroid development. By SSCP analysis, we found no mutations in the PAX8 or 
NKX2-5 genes in our cohort. The only variation we observed was SNP 
rs199939219 (www.ncbi.nlm.nih.gov/snp) within the PAX8  gene, that causes 
for a change of the first nucleotide of the triplet encoding for serine at position 
337 (Ser337Ala). We also performed a functional study for this mutation, but 
the mutant protein had the same activity of the WT-PAX8, did not produced a 
dominant negative effect and the activity in presence of NKX2-1, TAZ or P300 
is similar to the activity measured for the wild type. This data confirmed that 
the c.1009T>G PAX8 was a rare and not pathological polymorphism.  
By HRM analysis we screened DNAJC17 gene, but found only a known 
polymorphism c.350A>C. Since Dnajc17 knock-out mice, die between the 
morula and blastocyst stages, we can hypothesize that alterations in this gene 
are not compatible with life also in humans as well as in mice.  
The sequencing study of all coding exons of NKX2-1 in a family from Curitiba, 
affected by Brain-Lung-Thyroid Syndrome, revelead the presence of novel 
mutation in all members of family. The mutation c.493delC results in a protein 
of 196 amino acids. The mutant protein contains a frameshift and differs from 
the WT beginning at position 165, which corresponds to the last amino acid of 
the NLS. Transfection experiments with the mutant protein demonstrate that 
the c.493delC protein is synthesized and translocates into the nucleus, but it is 
unable to bind DNA since it completely lacks the homeodomain. The 
c.493delC mutant was responsible for a clear dose-dependent dominant 
negative effect on the WT NKX2-1 when tested on the Tg promoter, whereas 
when functional assays were performed on the lung SP-C promoter, the 
c.493delC mutant showed no dominant negative effect. 
Our results demonstrate the rare genetic etiology in sporadic cases of TD, at 
least in genes known to be involved in the formation and migration of follicular 
cells. Several previously studies in different ethnic populations with TD did not 
find mutations, either, particularly in sporadic cases (Ramos, Nesi-Franca et al. 
2009) (Macchia, Lapi et al. 1998) (Al Taji, Biebermann et al. 2007). It is likely 
that other epigenetic factors determine TD, such as differential gene 
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expressions or methylation. This finding make it necessary to carry out further 
molecular analyses, to better understand the complexities of the genotype–
phenotype correlation in the TD. 
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Summary
Selenium (Se) is a trace element that plays a criti-
cal role in several processes for human health.
The thyroid is the organ with the highest Se con-
tent per gram of tissue; in thyroid follicular cells,
Se acts as antioxidant by contrasting the produc-
tion of the reactive oxygen species that are gener-
ated during thyroid hormones biosynthesis. In ad-
dition, Se is part of the active site of the deoidinas-
es, the enzymes responsible for thyroid hormones
activation and inactivation.
Herein, the effects of Se supplementation in pa-
tients with thyroid related disorders have been re-
viewed on the basis of the studies published on
this issue.
KEY WORDS: thyroid, selenium, autoimmunity, an-
tioxidant.
Introduction
Selenium (Se) (from the Greek word “Selene” mean-
ing Moon) is an essential trace element, that was dis-
covered in 1817 by the Swedish chemist Jons Jacob
Berzelius (1). Two hundred years later, Se was recog-
nized as a fundamental micronutrient that plays a crit-
ical role in several processes for human health (2-4):
in 1957 Schwarz discovered that traces of Se can pre-
vent liver necrosis in vitamin-E-deficient rats (5) and
some years later, in 1973, Rothruck demonstrated the
biological function of Se as a cofactor of glutathione
peroxidase (GPX) (6). 
Se is the most powerful antioxidant agent present in the
human body (7), it acts as a growth factor, contributes to
the regulation of thyroid hormone biosynthesis, it is a
modulator of cardiovascular health, is important in the
prevention of neurodegenerative diseases and cancer,
and its optimal serum concentrations are required for a
correct immune response and fertility (8, 9).
Se plays an important role in human physiology, and it is
a basic element for many biological processes. Its most
important function is likely to be as a fundamental com-
ponent of the selenoproteins (4). Selenoproteins are a
group of proteins, encoded by at least 25 human genes
(10), presenting in their catalytic site in the amino acid
selenocysteine (Se-Cys). 
The functions of several of the selenoproteins are now
known and approximately half of them have been shown
to protect the cell against the action of reactive oxygen
species (ROS) (10, 11). Selenocysteine-containing pro-
teins influence several biological processes and exhibit
a wide range of functions including free radical catabo-
lism, immune response and carcinogenesis (9, 11). 
A severe Se deficiency is associated with serious en-
demic diseases such as Kashin-Beck disease (an os-
teoarthropathy reported in north-east Asia and Tibet),
Keshan disease (a cardiomyopathy encountered in
some regions of China), but also mixed ematous cre-
tinism as reported in some areas of central Zaire (12).
Se is present in nature in both inorganic and organic
forms (13). Most of the human Se intake originates from
diet, but other sources of Se are the drinking water, the
environmental pollution, and dietary supplementation. In
particular, cereals, organ meats and seafood contains
considerable levels of Se in forms of selenocysteine and
selenomethionine (14).
Se status varies significantly across different popula-
tions and different ethnic groups (4), ranging from se-
vere deficiency to toxic levels (2, 4). The quantity and
the type of Se in foods are not constant all over the
world (15) and the high variability in Se intake is deter-
mined not only by the different Se concentration in the
soil (i.e., volcanic grounds have lower Se content), but
also by other factors that influence the availability of Se
to the food chain or the presence of ions that can com-
plex with Se (2, 4). 
The optimal Se intake is still very debate (16) since it
has been reported that if a low serum Se can contribute
and worsen chronic diseases also Se excesses are as-
sociated with toxicity (17-21). 
Currently, a definition of the optimal Se intake is based
on its role in the modulation of anti-oxidase activity, and
the optimal nutritional level are those necessary to max-
imize the activity of the glutathione peroxidase 1
(GPX1). The optimal intake should bring Se plasmatic
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concentration around 95 μg/L. (range 89-114) (2, 16).
This corresponds to an intake of 75 and 60 μg/day for
men and women, respectively (3, 16). In the US, seleni-
um intake ranges from 60-220 μg/day (21, 22). Se in-
take in Europe is lower than in the US, with large vari-
ability across different countries, ranging from adequate
or marginally adequate intakes in Western and Central
Europe (30-90 μg/day) to low or deficient intakes in
Eastern European countries (7-30 μg/day) (22).
Role of selenium in thyroid physiology
The thyroid gland has the highest content of Se per
mass unit (23) compared to all other endocrine organs
and tissues (4, 10), and the understanding of the funda-
mental role of Se in the thyroid has been increased sig-
nificantly during the past few years (10). 
Several selenoproteins are expressed in thyroid follicu-
lar cells (24-26). Among these, two isoforms of iodothy-
ronine 5ʼ-deiodinase (type1 and type2, DIO1 and DIO2),
which produce active thyroid hormone (4); the thioredox-
in reductase type 1 (27); the selenoprotein P (27); and
three isoforms of glutathione peroxidase, two of which
(GPX1 and GPX4) protect thyroid follicular cells from hy-
drogen peroxide generated by thyroid peroxidase (4),
and the third (GPX3) which is present into the lumen,
where seems to modulate hydrogen peroxide levels
(28).
It is well known that thyroid physiology is closely de-
pendent from the oxidative changes (29): during thyroid
hormone biosynthesis, H2O2 is constantly produced in a
considerable amount, thus exposing the thyroid follicular
cells to high concentrations of H2O2 and ROS (1). The
peroxidative damage is decreased by the action of the
selenoenzymes systems which may be involved in the
regulation of hormone biosynthesis (30). Of note, the
amount of H2O2 produced in thyrocytes is similar to the
amount that can be produced in activated leukocytes
(31), however, while an activated leukocyteʼs has a life
of a few hours, adult human thyrocyteʼs life spans al-
most seven years (32). Such a long life requires a very
efficient anti-oxidative response process against H2O2
excess and this protective system is represented by se-
lenoproteins with GPX3 in first line (31, 33, 34). Intra thy-
roidal Se concentrations are critical for GPXs activity
and unbalances in this process as consequence of re-
duced Se concentrations can increase the oxidative
stress and produce damages to the thyroid follicular
cells. These damages can determine, to the very end,
cell death and hypothyroidism.
Selenium and autoimmune thyroiditis
Chronic autoimmune Hashimotoʼs thyroiditis (HT) is the
most common thyroid disorder and it is the main cause
of acquired hypothyroidism in iodine-sufficient areas
(23). All over the world it has a very high prevalence, af-
fecting about 3% of the population (35). HT is character-
ized by the presence of auto-antibodies directed to the
thyroid epitopes (thyroglobulin and thyroperoxidase),
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which are closely associated with thyroid dysfunction as
consequence of a progressive thyroidal damage and
lymphocytic inflammation (36). 
HT etiology is still unknown but several aspects are in-
volved in its pathogenesis including genetic predisposi-
tion, endogenous and environmental factors, including
Se deficiency. A role of Se deficiency was hypothesized
by the observation of an higher incidence of HT in areas
with severe Se deficiency (37).
Several studies have investigated the possible therapeu-
tic effects of Se administration in patients with HT (12).
In 2002, Gartner et al. conducted a randomized, place-
bo-controlled, blinded trial on 70 female patients in Ger-
many, an area with mild Se and iodine deficiency. The
endpoint of the study was to investigate the effects of a
short-term Se supplementation on the natural corse of
HT. The patients, all under T4 treatment at substitutive
doses, were split in two groups: 36 patients received
200 μg of sodium selenite for 3 months, and 34 patients
received placebo. In the supplemented patients, serum
Se levels increased from 0,87 to 1,09 μM and at the
same time anti-TPO antibodies levels dropped by 37%
(37).
The same author followed up some of patients for a fur-
ther 6 months with a further decrease of TPO-Ab levels
(38).
In 2003, Duntas et al. reported a 46% drop in thyroid an-
tibodies levels after administration for three months of
200 μg/day of selenomethionine, and a 55,5% drop of
antibodies levels after 6 months of treatment (39). Simi-
lar results have been reported by Mazokopakis in 2007
with the administration for one year of 200 μg/day of se-
lenomethionine (40).
In 2006, Turker et al. compared the efficacy of 100 μg
and 200 μg of selenomethionine supplementation, con-
cluding that a better effect in maximize GPX activities
and suppress autoimmune activity is obtained using the
higher dose (41).
In contrast with the previous studies, Karanikas et al.
found no significant reduction in anti-TPO antibodies af-
ter 3 months of Se supplementation with 200 μg/day of
sodium selenite in a series of Austrian patients with HT
(42).
In 2009, Nacamulliʼs study focused mainly on the effect
of a year-long course of Se supplementation in Italian
patients with early-stage HT and a normal thyroid func-
tion or mild hypofunction not receiving substitutive L-T4
therapy. 46 patients were treated with 80 μg/day of sodi-
um selenite for 12 months, while 30 patients were given
no treatment. TPO-Ab or Tg-Ab level decreased signifi-
cantly (30% and 19%, respectively) after 12 months in
the Se-treated group, but not in the control group (43).
More recently, Krysiak and Okopien conducted a ran-
domized clinical trial involving a group of 170 euthyroid
women with recently diagnosed and previously untreat-
ed Hashimotoʼs thyroid and 41 matched healthy sub-
jects. The primary endpoint was to evaluate the effects
of L-T4, Selenomethionine, or their combination on sev-
eral inflammatory markers (TNF-alpha, IL-1B, IL-6,
MCP-1, IL-2, INF-G, and high sensitivity CRP). The
study demonstrated that L-T4 treatment reduces mono-
cyte release of TNF-A, IL-1B, IL-6, and MCP-1, where-
as selenomethionine inhibits lymphocyte release of IL-2,
INF-G, TNF-alpha, and plasma CRP levels. The de-
crease in cytokines was even strongest when both
drugs were administrated together (44).
In 2011, Balazs analyzed IFN-γ-induced HLA-DR ex-
pression in cultured human thyrocytes at various con-
centrations of sodium selenite. Se has a dose-depend-
ent inhibitory effect on the expression of HLA-DR and
this effect shows an inverse correlation with anti-oxida-
tive capacity, suggesting that this can be one of the
mechanisms associated with the efficacy of Se supple-
mentation in HT (45).
Finally, very recently Anastasilakis et al. described 86
patients with HT and supplemented with 200 μg/day of
Se or placebo. No changes in TSH, FT4, FT3 and TPO-
Ab levels were detected in Se supplemented patients,
while a significant drop in Anti-Tg level (p=0,001) was
observed after a 6 months treatment (46).
Results on efficacy of Se supplementation in HT are still
not univocal, however it seems that Se may improve the
inflammatory activity in patients with HT. Such effect is
more evident in areas of mild Se deficiency, but whether
this effect is specific for HT or may also be effective in
other endocrine autoimmune diseases has yet to be in-
vestigated.
Selenium and post-partum thyroiditis 
Pregnancy is a period characterized by profound alter-
ations in the biochemical parameters of thyroid gland
and thyroid gland, on the other hand, influences the
pregnancy. Thyroid autoimmunity is associated with
an increased risk of miscarriage, women with elevated
TPO-Ab are prone to develop hypothyroxinemia dur-
ing pregnancy and thyroid dysfunction after delivery
(47-49). 
Recurrent abortions have been associated with lower
serum Se levels (50), and during the 3rd trimester of
gestation plasma Se levels drop significantly, returning
to baseline after delivery with a risk, for pregnant
women of Se deficiency. 
Negro et al. reported the effect of Se supplementation
on postpartum thyroid status in TPO-Ab positive preg-
nant women (51). The results indicate that Se supple-
mentation reduced the incidence of post-partum thy-
roiditis and permanent hypothyroidism, and treated
patients showed a significant decrease in the titer of
TPO-Ab in the postpartum period, suggesting that se-
lenium administration is effective in prevention of post-
partum thyroiditis (PPT). Nevertheless, no other stud-
ies so far reported similar results and study replica-
tions are required before confirming the efficacy of Se
supplementation in prevention of PPT (52).
Selenium and Graves’ disease
Gravesʼ Disease (GD), similarly to HT, is organ-specif-
ic autoimmune-inflammatory disease with a complex
pathogenesis. GD is characterized by lymphocytic in-
filtration of the thyroid gland with the production of an-
tibodies that bind to the thyrotropin receptor, miming
the TSH action (53). The hyperstimulation of the TSH
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receptor causes an increase of thyroid hormone
biosynthesis with H2O2 over production. This increas-
es ROS production and oxidative stress of the thyroid
follicular cell (3). It is now a common view that H2O2 is
implicated in the pathogenesis of GD with an imbal-
ance of the antioxidant/oxidant status, as suggested
by several authors (3, 54, 55).
In this view, adequate serum Se levels are fundamental
to contrast the inflammatory processes: low serum Se
levels have been reported in patients with hyperthy-
roidism and Gravesʼ disease (56) being associated with
the hyperthyroidism, since the administration of antithy-
roid drugs can increase plasma Se (34, 57). The effica-
cy of Se supplementation in GD has been suggested by
Vrca et al., that demonstrated that patients with GD re-
ceiving in addition to methimazole also a supplementa-
tion with and antioxidant mixture of Se, beta-carotene,
and vitamins C and E, led to euthyroidism faster than
patients treated with methimazole alone (58).
Selenium and Graves’ ophthalmopathy
Gravesʼ orbitopathy (GO) is caused by inflammation in
the orbital connective tissue leading to an enhanced
adipogenesis and overproduction of glycosaminogly-
cans. This causes an increase in orbital volume and fi-
brosis of the extra ocular muscles (59). Oxidative
stress is involved in the pathogenesis of GO (60) as
suggested by the results of studies reporting the effi-
cacy of antioxidant treatment in GO.
In 2000, Bouzas et al. demonstrated that 9 of 11 (82%)
patients treated with oral antioxidants showed an im-
provement of mild to moderately severe Gravesʼ oph-
thalmopathy while improvement was observed only in
3 of 11 (27%) patients in the untreated group (P < .05)
(61).
A recent study conducted by Marcocci et al. compared
the effects on GO of Se administration compared to an
anti-inflammatory agent, pentoxifylline, and placebo
(62). The results demonstrated that Se treatment was
associated with an improved quality of life, less eye in-
volvement and slower progression of GO, compared
to placebo and to pentoxifylline. In addition, Se sup-
plementation is associated with less side effects. The
study has two limitations: the authors did not meas-
ured the effects on plasma Se concentration of Se ad-
ministration, and the study was conducted in areas of
moderate Se deficiency, which may potentiate the ef-
fects of Se supplementation. 
In addition, no confirmatory studies have been report-
ed, and further trials are necessary to define Se sup-
plementation in the treatment of mild and moderate
GO (60).
Conclusions
In this review the role of the trace element Se was an-
alyzed for its effects on thyroid metabolism and dis-
eases.
Se supplementation seems to produce benefits in the
management of autoimmune thyroid disorders (Tab.
1). Se reduces anti-thyroid antibodies levels and im-
proves thyroid morphology at ultrasound in patients
with Hashimotoʼs thyroiditis, the administration of Se
in addition to methimazole seems to be associated
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with a faster normalization of hyperthyroidism in pa-
tients with Gravesʼ disease, and, finally, Se has been
proposed as treatment for mild or moderate Gravesʼ
orbithopathy. 
Table 1 - Clinical studies using selenium supplementation in patients with autoimmune thyroid disorders.  
Disease Country Follow-up Study 
Gruop 
Se dose Major outcome Author 
HT 
Germany 3 months 70 
patients 
(F) 
200 μg/day 
(Se selenite) 
Drop in TPO-Ab (-63.3% ) (37) 
Germany 6 months 47 
patients 
(F) 
200 μg/day 
(Se selenite) 
Major decrease in TPO-Ab in 
patients continuing 
supplementation 
(38) 
Greece 6 months 65 
patients  
(56 F/9 
M) 
200 μg/day 
(SeMe) 
Drop in TPO-Ab  
(-46% at 3 months;  
-55,5% at 6 months) 
(39) 
Turkey 9 months 88 
patients 
(F) 
100 or 200 μg/day 
(SeMe) 
Drop in TPO-Ab, major effects 
with 200 μg/day 
(41) 
Greece 6 + 6 months 80 
patients 
(F) 
200 μg/day 
(SeMe) 
Drop in TPO-Ab  
(-20% at 12 months) 
(40) 
Austria 3 months 36 
patients 
(F) 
200 μg/day 
(Se selenite) 
No effect on TPO-Ab (42) 
Italy 12 months 76 
patients  
(65 F/11 
M) 
80 μg/day 
(Se selenite) 
Drop in TPO-Ab (43) 
Poland 6 months 165 
patients 
200 μg/day 
(SeMe) 
Reduction in cytokines 
product?on 
(44) 
Greece 6 months 86 
patients  
(53 F/33 
M) 
200 μg/day 
(SeMe) 
Drop in TPO-Ab  
(not significant) 
(46) 
PPT 
Italy Pregnancy and 
post partum 
232 
patients 
(F) 
200 mcg/day 
(Seme) 
Evaluation of the prevalence 
of PPTD and hypothyroidism 
(51) 
GD 
Croatia 3 months 57 
patients 
Vitamin C and E, 
Beta carotene and 
Selenium 
Attainment of Euthyroidism  (58) 
GO 
Italy 6?+?6 months 159 
patients 
200 mcg/day 
(Selenium) 
Improvement GO (62) 
  HT: Hashimotos thyroiditis; PPT: post-partum thyroiditis; GD: Graves disease; GO: Graves ophthalmopathy. 
However, the story is not completely clarified yet and
additional studies are required to better define doses
and modality of Se supplementation. 
In addition, other limitations in understanding the role
of Se in thyroid autoimmune diseases are associated
with the observation that intrathyroidal Se levels not
directly correlate with serum Se concentrations, and,
in addition, it should be considered that serum Se as-
say are expensive and not recommended in routine
practice. 
Finally, it should be considered that selenium supple-
mentation in subjects with normal selenium levels was
associated with an increased risk of type 2 diabetes,
and an elevated serum selenium levels were linked to
peripheral vascular disease and all-cause mortality in
several population studies (20, 21, 63). Although
these findings need to be confirmed, long-term seleni-
um supplementation should not be viewed as harm-
less and a possibly healthy way to prevent illness, at
least in patients with normal/high Se income.
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ABSTRACT. Background: Congenital hypothyroidism (CH) is
a frequent disease occurring with an incidence of about
1/2500 newborns/year. In 80-85% of the cases CH is caused
by alterations in thyroid morphogenesis, generally indicated
by the term “thyroid dysgenesis” (TD). TD is generally a spo-
radic disease, but in about 5% of the cases a genetic origin
has been demonstrated. In these cases, mutations in genes
playing a role during thyroid morphogenesis (NKX2-1, PAX8,
FOXE1, NKX2-5, TSHR) have been reported. Aim: This work
reviews the main steps of thyroid morphogenesis and all the
genetic alterations associated with TD and published in the
literature.
(J. Endocrinol. Invest. 36: 654-664, 2013)
©2013, Editrice Kurtis
INTRODUCTION
Primary congenital hypothyroidism (CH) is the most fre-
quent endocrine metabolic disease in the infancy, with
an incidence of about 1/2500 newborns a year (1). In ab-
sence of an adequate treatment, CH is characterized by
signs and symptoms of impaired metabolism and by mo-
tor and mental handicaps. Before the introduction of a
neonatal screening program, CH was one of the most
frequent causes of mental retardation. With the excep-
tion of the rare cases of central hypothyroidism, CH is
characterized by the presence of elevated TSH levels at
birth in response to reduced thyroid hormone produc-
tion.
In the majority of cases (80-85%), CH is due to alterations
occurring during the gland organogenesis, which results
in a thyroid gland that is absent (thyroid agenesis or
athyreosis), hypoplastic (thyroid hypoplasia), or located
in an unusual position (thyroid ectopy). All these entities
are grouped under the term “thyroid dysgenesis” (TD)
(2). In the remaining 15-20% of cases, CH is caused by
inborn errors in the molecular steps of thyroid hormones
biosynthesis, secretion or recycling. These forms of CH
are indicated with the term “dysormonogenesys”, and
are characterized by an enlargement of the gland (goi-
ter), presumably due to elevated TSH levels. Thyroid
dyshormonogenesis shows classical Mendelian recessive
inheritance, and the molecular mechanisms in most of
these forms have been characterized.
In addition, mostly thanks to the changes in screening
strategies for CH of the last years, it has been recently
observed an increase number of mild forms of CH asso-
ciated with eutopic thyroid gland. Of these, about one
third of patients presented a permanent hypothyroidism
and need to continue LT4 therapy after re-evaluation, and
in 8.7% of the studied cases a mutation in TSHR gene
has been identified (3).
THYROID DEVELOPMENT
Thyroid morphogenesis starts with the recruitment, in
the thyroid anlage, of a group of cells that will form the
thyroid follicular cells (TFC). The TFC are the most nu-
merous cells of the thyroid gland that form the thyroid
follicles, spherical structures serving as storage of thy-
roid hormones (4). In mice, thyroid anlage appears at
embryonic day (E) 8-8.5 in the ventral wall of the prim-
itive pharynx (5). At E9-E9.5 the endodermal cells of the
thyroid anlage start to migrate and to proliferate, in-
vading the surrounding mesenchyme and forming the
thyroid bud. Some of the cells during this migration
form the thyroglossal duct. At E11.5 the thyroglossal
duct disappears, and at E13.5 the thyroid migration is
complete.
In humans, the process of thyroid morphogenesis is very
similar, lasting from the 3rd to 16th week of gestation (6).
The molecular mechanisms controlling the regulation of
thyroid cells precursor migration and their proliferation
are still largely unknown, but several genes have been
suggested to play an important role, including those en-
coding for the transcription factors Nkx2-1, Foxe1, Nkx2-
5, Pax8.
Starting from E8.5 in mouse, the cells fated to become
TFC in the primitive pharynx are univocally characterized
by the simultaneous expression of Nkx2-1 (7), Foxe1 (8),
Pax8 (9), and Hhex (10). These factors are also present in
other embryonic tissue, but all four are co-expressed on-
ly in the thyroid anlage, suggesting that their contem-
porary expression is required for early stages of thyroid
morphogenesis. Therefore, alterations in any of these
genes can be responsible for an abnormal thyroid gland
morphogenesis and thyroid dysgenesis.
THYROID DYSGENESIS
The most critical events in thyroid organogenesis occur
during the first 60 days of gestation in man and the first
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15 days in mice. It is likely that alterations in the molec-
ular events occurring during this period can be associat-
ed to TD.
The absence of TFC in orthotopic or ectopic location is
called athyreosis. This condition can either be the con-
sequence of lack of formation of the thyroid bud or re-
sults from alterations in any of the step following the
specification of the thyroid bud and determining a de-
fective survival and/or proliferation of the precursors of
the TFC.
The ectopic thyroid is the consequence of a failure in the
descent of the developing thyroid from the thyroid an-
lage to its definitive location in front of the trachea. An
ectopic thyroid can be found in any location along the
path of the developing gland migration from the fora-
men caecum to the mediastinum. In the majority of cas-
es, the ectopic thyroid appears as a mass in the back of
the tongue (lingual thyroid, usually functioning). Sublin-
gual ectopic tissues are less frequent; in this case, thy-
roid tissue is present in a midline position above, below
or at the level of the hyoid bone.
Orthotopic and hypoplastic thyroid is reported in 5% of
CH cases. Thyroid hypoplasia is probably a genetically
heterogeneous form of thyroid dysgenesis. It could be
due to defects in any of the genes that control the num-
ber of thyroid cells (2).
Thyroid hemiagenesis is a rare congenital abnormality,
in which one of the thyroidal lobes fails to develop. Thy-
roid hemiagenesis is often associated with mild and or
transient hypothyroidism but several patients were found
to be in euthyroid state. Thyroidal hemiagenesis is pre-
dominantly seen in females with an incidence to 0.2% in
healthy children. In the large majority of the cases, it is
the left lobe to be absent (11). The causes of thyroid
hemiagenesis are still unclear and it is unknown whether
the disturbance of the lobulation process is due to inter-
ference of environmental factors or to genetic abnor-
mality.
GENES INVOLVED IN THYROID MORPHOGENESIS
TD occurs mostly as a sporadic disease; however, a ge-
netic cause of the disease has been demonstrated in
about 5% of the reported cases.
TD presents a clear female prevalence (12) and epi-
demiological studies demonstrated a different incidence
of the disease in different ethnic groups (13, 14) sug-
gesting that the genetic background plays a role in this
affection. In addition, among the first-degree relatives of
patients with sporadic TD, there is a significantly higher
rate of asymptomatic thyroid developmental anomalies
compared to the normal populations (15). By contrast,
against the notion of heritable TD is the finding reported
by Perry et al., showing a discordance for TD in 12 of 13
monozygotic twin pairs (16).
Studies on thyroid development in normal and mutated
mouse embryos indicate that the simultaneous pres-
ence of Pax8, Nkx2-1, Foxe1, and Hhex is required for
thyroid morphogenesis. Indeed, thyroid dysgenesis is
present in animal models with mutations in these genes,
and mutations in the same genes have been identified
in patients with congenital hypothyroidism associated
with TD.
NKX2-1
NKX2-1 (also known as TTF1) is a transcription factor con-
taining a homeodomain. The human gene maps to chro-
mosome 14q13 and it is formed by 3 exons. In mouse
embryos Nkx2-1 is expressed in the thyroid, in the pitu-
itary, in the lung and in the ventral forebrain. Its expres-
sion in TFC is constant during all stages of thyroid de-
velopment and in adulthood (7).
In differentiated TFC, NKX2-1 controls thyroglobulin and
thyroperoxidase expression (17). In lung cells it is re-
sponsible for the production of the surfactant proteins
(18) and in the hypothalamus NKX2-1 acts as transcrip-
tional regulator of genes encoding neuromodulators and
hypophysiotrophic peptides, controlling circadian oscil-
lations in GnRH gene transcription (19).
Nkx2-1 null mice die at birth. They are characterized by
impaired lung morphogenesis, lack of thyroid and pi-
tuitary, and severe alterations in the ventral region of
the forebrain (20). Other studies, performed at earlier
stage of development demonstated that in Nkx2-1–/–
embryos the thyroid primordium forms in its correct po-
sition but subsequently undergoes degeneration and
eventually disappears, probably because Nkx2-1 is re-
quired to prevent the initiation of apoptotic process
(21). Hence, Nkx2-1 is essential for the survival of thy-
roid cells precursor, but it is not necessary for their ini-
tial formation.
NKX2-1mutations have been described in several patients
with primary CH, respiratory distress and benign heredi-
tary chorea, which are manifestations of the “Brain-Thy-
roid-Lung Syndrome” (BLTS, OMIM # 610978) (Table 1). In
the majority of cases haploinsufficiency has been consid-
ered to be responsible for the phenotype (22). Only few
mutations produce a dominant negative effect on the wild
type NKX2-1 (23-25) and among those in two cases it has
been reported a promoter-specific dominant negative ef-
fect (24, 25).
All the published NKX2-1 mutations have variable func-
tional effects, even if the mutations occur in similar re-
gions of the protein. The clinical features of the patients
carrying NKX2-1mutations are reported in Table 1. Phe-
notypes are very variable and there is no correlation be-
tween the clinical manifestations and the molecular al-
terations (22).
Pax8
PAX8 is a transcription factor belonging to the mam-
malian family of PAX proteins, characterized by the pres-
ence of a paired domain (Prd). The human gene encod-
ing for PAX8maps to chromosome 2q12-q14 and it con-
sists in ten exons (9, 26).
Homozygous Pax8–/– mice are alive at birth but show
growth retardation and die within 2-3 weeks if not treat-
ed with thyroid hormones (27). The thyroid gland in these
mice is severely altered and no follicles and TFC can be
detected, while calcitonin-producing C cells are present.
In Pax8–/– mice at E11.5, thyroid primordium appears
smaller (hypoplastic thyroid) than in wild-type mice, and
at E12.5 follicular cells are essentially undetectable, in-
dicating that Pax8, similarly to Nkx2-1, is required for the
survival of thyroid cell precursors but not for their speci-
fication (28).
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Mutation Type of Mechanism of Thyroid Other Ref.
mutation action of the mutation Phenothype disorders
DNA Protein
CH: congenital hypothyroidism; Tg: thyroglobulin.
Table 1 - NKX2-1 mutations in patients with thyroid dysgenesis.
2.6-Mb deletion
Large deletion
del 14q11.2q13.3
del 14q12-13.3
del 14q12-13.3
del 14q13-21
c.374-1G >A
c.376-2A>G
c.255insG
g.1302C>A
c.609C>A
c.470_479delinsGCG
c.493C>T
c.493delC
g.2519C>A
c.523G>T
c.526C>G
c.532C>T
g.2595_2597insGG
c.605C>T
g.2626G>T
c.613G>T
c.619A>T
c.621C>G
c.629A>C
c.650C>A
c.713G>T
c.727C>A
c.745C>T
c.786_787del2
c.825delC
c.859_860insC
c.908_909delG
p.0
p.0?
p.G86fs*322
p.C87*
p.S145*
p.P157fs*196
p.R165W
p.R165Gfs*32
p.S169*
p.E175*
p.L176V
p.R178*
p.A195fs*4
p.P202L
p.V205F
p.V205F
p.I207F
p.I207M
p.Q210P
p.S217*
p.W238L
p.R243S
p.Q249*
p.L263fs
p.P275fs*74
p.Q287fs*121
p.G303fs*77
Deletion
Splice site
mutation
Frameshift
Non sense
Frameshift
Missense
Frameshift
Non sense
Missense
Non sense
Frameshift
Missense
Non sense
Missense
Non sense
Frameshift
Not tested
Haploinsufficiency
Not tested
Haploinsufficiency
Haploinsufficiency;
Reduced binding and
transactivation of Tg
Haploinsufficiency
Haploinsufficiency
Dominant positive on SP-C;
Reduced transactivation of Tg
Decreased binding of Tg
Reduced transactivation
of Tg and SP-C;
Dom negative only
on Tg but not on SP-C
Haploinsufficiency
Not tested
Dom. negative on Tg
Decrease binding and
reduced transactivation of Tg;
not dominant negative on Tg
Haploinsufficiency
Reduced transactivation of Tg;
rescue of activity by
co-trasfection with Pax8
Decreased DNA binding on Tg
Not tested
Reduced transactivation, dom.
negative and decreased DNA
binding capacity on Tg and SP-B
Not tested
Reduced transactivation of Tg
Not tested
Haploinsufficiency
Haploinsufficiency
Not tested
Dom. negative on SP-B
and SP-C
Dom. negative on Tg but
not on SP-C
Not tested
Haploinsufficiency
Respiratory problems
and psychomotor delay
Multisistem disorder of the basal
ganglia, salivary glands, bowels
and teeth. Respiratory problems
and psychomotor delay
Respiratory problems and
psychomotor delay
Respiratory problems,
severe developmental delay
and psychomotor delay
Psychomotor delay
Respiratory problems and
psychomotor delay
Respiratory problems and
psychomotor delay
Respiratory problems
Respiratory problems
Respiratory problems and
psychomotor delay
Respiratory problems and
psychomotor delay
Respiratory problems
and psychomotor delay
Respiratory problems and
psychomotor delay
Respiratory problems and
psychomotor delay
Respiratory problems
Respiratory problems and
psychomotor delay
Psychomotor delay
Respiratory problems and
psychomotor delay
Psychomotor delay
Psychomotor delay
Psychomotor delay
Psychomotor delay
Respiratory problems and
psychomotor delay
Psychomotor delay
Respiratory problems
Respiratory problems
Psychomotor delay
Respiratory problems,
psychomotor delay and psychosis
Psychomotor delay
Psychomotor delay
Psychomotor delay
Respiratory problems and
mild psychomotor delay
Psychomotor delay
Respiratory problems and
psychomotor delay
Psychomotor delay
(48)
(49)
(50)
(51)
(52)(53)
(54)(55)
(56)
(55)
(57)
(58)
(50)
(22)
(59)
(23)
(25)
(50)
(60)
(55)
(61)
(50)
(55)
(50)
(48)
(62)
(63)
(55)
(64)
(52)
(52)
(65)
(23)
(24)
(66)
(52)
Absent
Primary hypothyroidism
associated with
hypoparathyroidism
and osteoporosis.
CH (Hypoplasia)
CH (Normal thyroid)
Absent
CH (Normal thyroid)
CH (Hypoplasia)
CH (Athyreosis)
CH (Hemiagenesis)
CH (Normal thyroid)
CH (Normal thyroid)
CH (Agenesis)
CH (Normal thyroid)
CH (Normal thyroid)
CH (Normal thyroid)
Subclinical
hypothyroidism
CH (Hypoplasia)
CH (Hypoplasia/
Hemiagenesia)
CH (Hypoplasia)
Absent
CH (Normal thyroid)
CH (Normal thyroid)
CH (Hypoplasia)
CH (not defined)
CH (Normal thyroid)
CH (Normal Thyroid)
CH (Hypoplasia)
CH (not defined)
CH (not defined)
Absent
Absent
CH (Normal thyroid)
CH (Normal thyroid)
CH (not defined)
Absent
©20
3, E
ditr
i e
Kur
tis
FOR
PER
SON
AL U
SE O
NLY
I.C. Nettore, V. Cacace, C. De Fusco, et al.
657
The involvement of PAX8 has been described in sporadic
and familial cases of CH with TD (Table 2). All affected
individuals are heterozygous for the mutations and au-
tosomal dominant transmission with incomplete pene-
trance and variable expressivity has been described for
the familial cases. In the majority of cases CH is due to
thyroid hypoplasia; however, three patients with athyre-
osis and two with thyroid ectopy have been described
(Table 2). This indicates that in humans, contrary to mice
models, both PAX8 alleles are necessary for correct thy-
roid morphogenesis, and a reduced dosage of the gene
product (haploinsufficiency) causes dysgenesis.
The molecular mechanisms by which PAX8 mutations
lead to TD are still unclear. A recent work describes and
functionally characterizes two novel PAX8 mutations lead-
ing to TD by two different mechanisms. Both mutations
(S54R and R133Q) determined a significant reduction in
the transcription induction of thyroglobulin and thy-
Mutation
Region Effect of the mutation Thyroid Phenothype Ref.
DNA Protein
c.-456C > T (*) p.0? Promoter Loss of protein binding capacity on the mutant promoter Athyreosis (43)
and decreased transcriptional activity
c.287G>A p.R31H Paired domain Completely lack of DNA binding and transcriptional Hypoplasia (67, 68)
activity on TPO promoter
c.286C>T p.R31C Decreased binding to DNA Severe hypoplasia (69)
c.119A>C p.Q40P Completely lack of DNA binding and transcriptional Hypoplasia (70)
activity on TPO promoter
c.143C>T p.S48F No p300 recruitment and decreased transcriptional Normal or Athyreosis (71)
activity on Tg promoter
c.155G>C p.R52P Completely lack of binding to Tg promoter Hypoplasia (72)
c.160A>G(**) p.S54G Decreased binding to TPO promoter and reduced Hypoplasia (73)
synergism with NKX2-1 on Tg promoter
c.162C>G p.S54R Decreased DNA binding and transcriptional activity Severe hypoplasia (29)
on Tg and TPO promoter
c.165T>G p.H55Q Decreased transcriptional activity on Tg promoter Hypoplasia (74)
c.170G>A p.C57Y Completely lack of transcriptional activity on TPO promoter Hypoplasia (75)
c.380T>G p.L62R Decreased DNA binding and transcriptional activity Hypoplasia (67)
on TPO promoter
c.238_252dup p.K80-A84dup Decreased DNA binding and transcriptional Hypoplasia (76)
activity on Tg promoter
c.517C>T p.R108* Completely lack of DNA binding and transcriptional Hypoplasia and Ectopia (67)
activity on TPO promoter
c.398G>A p.R133Q Decreased transcriptional activity on Tg and TPO promoter Severe hypoplasia (29)
c.674C>T p. T225M C-terminus NO Decreased transcriptional activity on Tg promoter Ectopia (77)
c.1006G>A p.G336S NO Decreased transcriptional activity on Tg promoter Athyreosis (78)
c.989-992delACCC p.T277fs*1 Decreased transcriptional activity on CP5-CAT promoter Normal or Hypoplasia (79)
*The patient carrying the c.-456C > T mutation also has a NKX2-5 (p.S265R) mutation. **The patient also displayed unilateral kidney agenesis. CH: con-
genital hypothyroidism; Tg: thyroglobulin; TPO: thyroperoxidase.
Table 2 - PAX8 mutations in patients with thyroid dysgenesis.
Mutation
Mechanism of action of the mutation Human phenotype Ref.
DNA Protein
c.169G>A p.S57N Partial lack of DNA binding and CH, athyreosis, cleft palate (80)
transcriptional activity on the Tg promoter
c.194C>T p.A65V Complete lack of DNA binding and CH, athyreosis cleft palate, (38, 81)
transcriptional activity on the Tg promoter choanal atresia, bifid epiglottis
c.289T>C p.W97R Loss of function of the gene product CH, thyroid hypoplasia, cleft palate, (82)
spiky hair and optional choanal atresia
c.304C>T p.R102C Complete lack of DNA binding CH, severe thyroid hypoplasia, (83)
and transcriptional activity on the TPO promoter cleft palate, choanal atresia.
c.394A>G p.N132D Slight reduction in binding capability and 5% CH, athyreosis, tongue-tied (84)
loss transcriptional activity on the TPO promoter since birth, poor attention span
c.410T>C p.F137S Complete lack of DNA binding and CH, severe thyroid hypoplasia, (82)
transcriptional activity on the TPO promoter cleft palate, and spiky hair
CH: congenital hypothyroidism; Tg: thyroglobulin; TPO: thyroperoxidase.
Table 3 - FOXE1 mutations.
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roperoxidase promoters, but while the S54R mutant pre-
sented an impaired DNA binding, the DNA-binding
properties of R133Q mutation are not affected and the
R133Q has no dominant negative effect on the WT pro-
tein in vitro (29).
Hemiagenesis of the thyroid is a frequent observation in
mice double heterozygous for Nkx2-1+/– and Pax8+/– (30),
but, to date, in humans no genetic alterations have been
found in patients with thyroid hemiagenesis.
TSHR
In late stage of thyroid organogenesis, at E15.5, the thy-
rotropin receptor (Tshr) starts to be expressed in TFC.
The binding of TSH to its receptor results in signaling
pathway that regulates many functions of the adult thy-
roid but also during thyroid organogenesis.
TSHR belongs to the G-protein coupled receptors su-
perfamily. The gene encoding TSHR maps to human
chromosome 14q31 and to mouse chromosome 12. It
consists in ten exons and codify for a 764 aminoacid pro-
tein.
The role of the TSHR in thyroid differentiation was first
identified in Tshrhyt/hyt mice, affected by primary hy-
pothyroidism with elevated TSH and hypoplastic thyroid,
as a consequence of a loss of function mutation in the
fourth transmembrane domain of TSHR (pro556Leu),
which abolishes the cAMP response to TSH (31).
Several patients with homozygous or compound het-
erozygous loss-of-function TSHR mutations have been
reported (Table 4). The disease, known as resistance to
TSH (OMIM #275200) is inherited as an autosomal re-
cessive trait, and patients are characterized by elevated
serum TSH levels, absence of goiter with a normal or hy-
poplastic gland, and normal to very low serum levels of
thyroid hormones. The clinical manifestations are very
variable spanning from euthyroid hyperthyrotropinemia
to severe hypothyroidism (32).
FOXE1
FoxE1, also called TTF-2, is a transcription factor con-
taining a forkhead domain and a polialanine stretch of
variable length (33-35). The human gene maps to chro-
mosome 9q22 and encodes for a 42kDa protein (33).
In mouse, at an early stage of development, FoxE1 is pre-
sent in the posterior stomatodeum, in the buccopharyn-
geal membrane and in Rathke’s pouch. At later stages, it
appears in the secondary palate, in the definitive choane
and in the whiskers and hair follicles (36). In the adult,
FoxE1 is still present in the thyroid, whereas the expres-
sion in the esophagus is faint.
Homozygous FoxE1 knock-out mice are born at the ex-
pected ratio but die within 48 h. These mice have no thy-
roid in its normal location and absence of thyroid hor-
mones. Furthermore, the mice show a severe cleft palate,
probably responsible for the perinatal death, and ele-
vated TSH levels in the bloodstream (37).
Studies at the early stages of thyroid morphogenesis
demonstrate that at E9.5 in FoxE1 null embryos, thyroid
precursor cells are still on the floor of the pharynx, where-
as in wild-type embryos they are detached from the phar-
ynx cavity and begin to descend. At later stages of de-
velopment, mutant mice exhibit either a small thyroid
remnant still attached to the pharyngeal floor or no thy-
roid gland. It is worth noting that the non-migrating thy-
roid cells are able to complete their differentiation pro-
cess as demonstrated by the presence of thyroglobulin.
Hence, FoxE1 plays an essential role in the control of the
migration of TFC precursors.
Homozygous mutations in FOXE1 gene have been report-
ed in patients affected by Bamfort’s syndrome (Table 3).
This syndrome is characterized by cleft palate, bilateral
choanal atresia, spiky hair and athireosis (38). All the af-
fected members carry homozygous missense mutations in
conserved amino acids of FOXE1, and themutant proteins,
when tested in vitro, show a reduction in both DNA bind-
ing and transcriptional activity.
While in mice the absence of FoxE1 causes either athyre-
osis or ectopia (37), in humans FOXE1 mutations have
never been associated to thyroid ectopy.
NKX2-5
In addition to Nkx2-1, other genes of the Nkx2 family are
present in the primitive pharynx and the thyroid anlage,
such as Nkx2-3, Nkx2-5, Nkx2-6.
The gene encoding NKX2-5 in humans is located on
chromosome 5q34 and consists of two exons encoding
for a 324 aminoacids protein. In early phases of devel-
opment, Nkx2-5 is expressed in the ventral region of the
pharynx and in thyroid bud; later Nkx2-5 transcript dis-
appears from the thyroid bud, while its expression per-
sists in the heart region (39).
In Nkx2-5–/– embryos the thyroid bud is smaller when
compared to the wild type, suggesting that Nkx2-5 is re-
quired for thyroid development (40).
In humans, NKX2-5 is essential for normal heart morpho-
genesis, myogenesis, and function (41), and several loss of
function mutations in NKX2-5 have been described in pa-
tients with congenital heart diseases (42). In addition, het-
erozigous mutations in NKX2-5 have been associated to
the human ectopic thyroid (40). Functional studies demon-
strated that these mutants exhibited a significant func-
tional impairment, with reduction of transactivation prop-
erties and dominant negative effect (Table 5).
Recently, it has been reported a girl with athyreosis pre-
senting heterozygous mutations in both NKX2-5, and
PAX8 genes (43).
Haploinsufficiency, monoallelic expression, or imprinting
could all have an impact on the phenotype (44) and again
patients carrying NKX2-5 mutations show a phenotypic
variability in both heart and thyroid phenotype.
HHEX
Hhex is a homeodomain-containing transcription factor,
first identified in multipotent hematopoietic cells. It is en-
coded by a gene located on chromosome 19 in mice and
chromosome 10q23.32 in humans. In embryos, at early
stages of development, Hhex is detected in the primi-
tive and definitive endoderm. It is then expressed in the
primordium of several organs derived from the foregut,
including the thyroid bud (10).
Studies of Hhex–/– embryos showed that this gene plays
a critical role in the development of the liver, forebrain,
heart and thyroid (45). In Hhex null embryos at E9, the
thyroid anlage is present and the expression of Nkx2-1,
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Position Protein domain Mutation Molecular effects of the mutation Genotype Thyroid phenotype Ref.
Exon 1 Extracellular p.Q8fsX62 Extremely low expression HET Normal (85)
domain at the cell surface.
Reduced cAMP production
p.Q33PfsX46 Nonfunctional protein HET Not described (86)
p.C41fsX61 Premature stop with HET Not described (87, 88)
no in vitro expression
p.P27T Extremely low expression HET Not described (87)
at the cell surface.
Reduced cAMP production
p.C31X Truncated protein HET Hypoplasia (89)
p.E34K Reduced cAMP production HET Not described (87, 90)
p.C41S Intracellular tapping C-HET(p.F525L) Normal (91)
and decreased binding to TSH
p.R46P No cAMP production HET Not described (87)
Exon 2 Extracellular domain, Exon2del Nonfunctional protein HOMO Severe hypoplasia (92)
leucine-rich region p.P68S Decreased TSH binding C-HET(p.V653L) Normal (93)
Exon 3 p.Q90P^ Extremely low expression HOMO Normal (94)
at the cell surface C-HET (p.P264S)
Reduced cAMP production
Intron 3 g.IVS3+1G>A Splicing variant, non-functional protein HOMO Aplasia (92)
Exon 4 p.R109Q Reduced TSH binding C-HET (p.W546X) Normal (95)
Intron 4 g.IVS4+1G>A Splicing variant, non-functional protein HOM Thyroid Aplasia (92)
g.IVS4+2A>G Splicing variant, non-functional protein HET Not described (86)
Exon 5 p.G132R No TSH binding C-HET (p.R450H) Hypoplasia (96)
Partial activity HET Normal with decreased (97)
uptake of 99mTc
p.T145I Reduced coupling to Gs and Gq C-HET (p.R450H) Normal (98)
p.I152FsX157 Truncated protein HET Normal (87)
Intron 5 g.IVS5-1G>A Splicing variant, non-functional protein HOMO Severe Hypoplasia (99)
Exon 6 p.P162A Reduced biological activity C-HET (p.I167N) Normal (91, 100)
Mild destabilization of the molecule HOMO Normal (92)
and reduction of TSH binding C-HET (p.C600R) Hypoplasia (101)
p.P162L Defected Gq /11 signaling HET Not described (86)
HOMO Normal (102)
p.I167N No biological activity C-HET (p.P162A) Normal thyroid (100)
Exon 7 p.A204V Decreased TSH binding HET Normal thyroid (96)
Exon 9 p.G245S Partial activities HET Normal with decreased (103)
uptake of 99mTc (97)
p.L252P Low expression at the cell surface. HET Normal (87, 104)
Reduced TSH binding and
cAMP production
p.P264S Low expression at the cell surface. C-HET (p.Q90P) Normal (94)
Reduced cAMP production Associated with
TPO mutation
Exon 10 Extracellular p.R310C Reduced TSH binding HOMO Normal (105)
domain HET Normal (89)
p.Q324X Truncated protein C-HET (p.D410N) Slightly enlarged (91)
p.C390W Reduced TSH binding C-HET(p.W546X) Slightly enlarged (91)
HET Normal (89)
p.D403N Low cAMP production HET Hypoplasia (87, 90, 106)
C-HET (p.R450H) Not described (87, 89, 90)
p.N406fsX424 Truncated protein, C-HET (p.C390W) Hypoplasia (107)
no cell surface expression
p.D410N No cAMP production C-HET (p.G324X) Slightly enlarged (91)
HET Normal (85)
Intracellular loop #1 p.Y444X No cell surface expression, HOMO Hypoplasia (108)
non-functional protein
Table 4 - TSHR mutations.
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Position Protein domain Mutation Molecular effects of the mutation Genotype Thyroid phenotype Ref.
p.R450H Slight reduction in TSH binding C-HET (p.G498H) Hypoplasia (109)
HOMO Normal (110)
HET Normal (111)
C-HET (p. D403N) Not described (106)
C-HET (p. T145I) Not described (98)
C-HET (p. I661fsX) Not described
C-HET (p.V473I) Not described (111)
C-HET (p.R519C) Not described
C-HET (p.R519G) Not described (112)
C-HET (p.G132R) Hypoplastic
Transmembrane p.Y466C Reduce cell surface expression. HET Not described (86)
region #2 Reduce Gs and Gq/11 signaling.
p.L467P No cAMP production HET Normal (101)
p.V473I Normal TSH binding, C-HET (p.R450H) Not described (112)
Decrease cAMP and IP response
Extracellular loop #1 p.T477I Low expression at the cell surface. HOMO Severe Hypoplasia (113)
Reduced cAMP production
p.W488R No cAMP production HET Not described (87, 88, 90)
p.Q489H Misfolding of the receptor, HOMO Athyreosis (114)
immature protein.
Transmembrane p.G498S Low expression at cell surface C-HET (p.R450H) Hypoplasia (109)
region #3
Intracellular loop #2 p.R519G Reduced cAMP and IP production C-HET (p.R450H) Not described (112)
p.R519C Reduced cAMP and IP production C-HET (p.R450H) Not described (112)
p.W520X Truncated protein HET Not described (88)
p.F525L No cAMP production C-HET (p.G324X) Normal (91)
p.F525S Partial residual activity HET Normal with decreased (97)
uptake of 99mTc
p.M527T Reduced cAMP production HET Not described (87, 88)
Normal (89, 90)
p.R531Q Not described HOMO Hypoplasia (102)
p.R531W Structural change and/ HET Normal (92)
or reduced basal activity
Transmembrane p.W546X Non-functional protein C-HET (p.C390W) Slightly enlarged (91)
region #4 C-HET (p.R109Q) Normal size (95)
HOMO Normal size (115)
C-HET (p.A553T) Athyreosis (116)
p.A553T Low expression at cell surface HOMO Severe hypoplasia (117)
Not described C-HET (p.R546X) Athyreosis (116)
Not described HET Normal (89)
Unstable protein, HOMO Severe hypoplasia (92)
no intermolecular contacts
p.P556R Unstable protein, HOMO Aplasia (92)
no intermolecular contacts
Transmembrane p.I583T Reduced Gq/11 signaling HET Not described (86)
region #5 p.A593V Minimal reduction of TSH function HOMO Normal (118)
p.C600R No cAMP production C-HET (p.P162A) Hypoplasia (101)
p.Y601H No basal activity; Reduced IP productionHET Hypoplasia (119-121)
Intracellular loop #3 p.T607I Reduced Gq/11 signaling HET Not described (86)
p.R609Q Reduced Gq/11 signaling HET Not described (86)
p.R609X Truncated non-functional protein HOMO Athyreosis/ (122, 123)
Severe hypoplasia
Extracellular loop #3 p.L653V No IP but normal cAMP production HOMO Normal (124)
C-HET (p.P68S) Not described (93)
p.T655fsX657 Truncated protein C-HET Athyreosis/ (125)
(g.IVS6+3G>C) severe hypoplasia
HET Normal (101)
Transmembrane p.I661fsX Reduction in coupling to Gs and Gq C-HET (p.R450H) Normal (98)
region #7
Intracellular tail p.V689G Not described HET Not described (103)
HOMO: homozygous; HET: heterozygous, C-HET: compound heterozygous.
Table 4 - Continued.
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Pax8, and Foxe1 is not affected. At E10, in the absence
of Hhex, thyroid budding is severely impaired and the
thyroid primordium is represented only by a few non-mi-
grating cells which do not express Ttf1, Pax8, or Foxe1
mRNA. At later stages, the primordium disappears. These
data strongly suggest that Hhex has no role in thyroid
specification but is involved in the survival of already de-
termined thyroid precursors. Since Hhex is required to
maintain Nkx2-1, Pax8, and Foxe1 expression in the de-
veloping thyroid, cannot be excluded that the absence of
these factors is the direct cause of the thyroid phenotype
displayed by Hhex–/– embryos.
To date, no HHEX mutations in humans have been de-
scribed.
CONCLUSIONS
This review shows that, in some cases, abnormalities in
thyroid morphogenesis are due to alterations in genes
that regulate the thyroid development. The molecular
etiology of the majority of cases of TD still remains large-
ly unclear, and mutations have been identified in only a
few cases (46), with a high discrepancy between geno-
type and phenotype. This discrepancy can be the con-
sequence of different mechanisms of action of the mu-
tation in the different tissues, by the influence of modu-
lating genes (30), but also of the complex interactions
between other genetic and/or environmental factors that
may modulate the phenotype, as also suggested in ani-
mal models (47).
The identification and functional characterization of nov-
el mutations in thyroid transcription factor, known and/or
still unknown, may help to understand the transmission
mode of disease and provide crucial evidence for genetic
counseling.
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Identification and Functional Characterization
of a Novel Mutation in the NKX2-1 Gene:
Comparison with the Data in the Literature
Immacolata Cristina Nettore,1 Paola Mirra,2 Alfonso Massimiliano Ferrara,1 Annarita Sibilio,1
Valentina Pagliara,1 Claudia Suemi Kamoi Kay,3 Paulo Jose` Lorenzoni,3 Lineu Cesar Werneck,3
Isac Bruck,4 Lucia Helena Coutinho dos Santos,4 Francesco Beguinot,2 Domenico Salvatore,1
Paola Ungaro,2 Gianfranco Fenzi,1 Rosana Herminia Scola,3 and Paolo Emidio Macchia1
Background: NKX2-1 mutations have been described in several patients with primary congenital hypothyroidism,
respiratory distress, and benign hereditary chorea, which are classical manifestations of the brain–thyroid–lung
syndrome (BTLS).
Methods: The NKX2-1 gene was sequenced in the members of a Brazilian family with clinical features of BTLS,
and a novel monoallelic mutation was identified in the affected patients. We introduced the mutation in an
expression vector for the functional characterization by transfection experiments using both thyroidal and
lung-specific promoters.
Results: The mutation is a deletion of a cytosine at position 834 (ref. sequence NM_003317) (c.493delC) that
causes a frameshift with formation of an abnormal protein from amino acid 165 and a premature stop at
position 196. The last amino acid of the nuclear localization signal, the whole homeodomain, and the carboxy-
terminus of NKX2-1 are all missing in the mutant protein, which has a premature stop codon at position 196
(p.Arg165Glyfs*32). The p.Arg165Glyfs*32 mutant does not bind DNA, and it is unable to transactivate the
thyroglobulin (Tg) and the surfactant protein-C (SP-C) promoters. Interestingly, a dose-dependent dominant
negative effect of the p.Arg165Glyfs*32 was demonstrated only on the Tg promoter, but not on the SP-C
promoter. This effect was also noticed when the mutation was tested in presence of PAX8 or cofactors that
synergize with NKX2-1 (P300 and TAZ). The functional effect was also compared with the data present in the
literature and demonstrated that, so far, it is very difficult to establish a specific correlation among NKX2-1
mutations, their functional consequence, and the clinical phenotype of affected patients, thus suggesting that
the detailed mechanisms of transcriptional regulation still remain unclear.
Conclusions: We describe a novel NKX2-1 mutation and demonstrate that haploinsufficiency may not be the
only explanation for BTLS. Our results indicate that NKX2-1 activity is also finely regulated in a tissue-specific
manner, and additional studies are required to better understand the complexities of genotype–phenotype
correlations in the NKX2-1 deficiency syndrome.
Introduction
NK2 homeobox 1 (NKX2-1, also called TTF-1; MIM#600635) was initially identified in rat thyroid cells as a
42 kDa phosphorylated nuclear protein able to bind to the
thyroglobulin (Tg) promoter (1). It belongs to the NKX2
class of transcription factors and is encoded by a three-
exon structured gene located on chromosome 14q13. Dur-
ing human development, the gene is expressed in the
ventral diencephalon, telencephalon, lung bud, and the
thyroid primordium (2,3). Nkx2-1 null mice lack thyroid
and pituitary glands, have lung hypoplasia with se-
vere respiratory failure, and have defects in the ventral
forebrain (4).
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The association of choreoathetosis, hypothyroidism, and
pulmonary alterations was linked to mutations in the gene
encoding NKX2-1 in the so-called brain–thyroid–lung syn-
drome (BTLS).
A novel NKX2-1 mutation was identified and function-
ally characterized in a family with five affected patients in
two generations showing hypothyroidism, benign heredi-
tary chorea, and respiratory distress. All the affected
members presented a heterozygous deletion of the cytosine
at position 834 (ref. sequence NM_003317) of the NKX2-1
gene (c.493delC). The mutation is responsible for a frame-
shift that produces an abnormal protein from amino acid
165 with a premature stop codon at position 196.
Materials and Methods
Patients
The family included five affected patients in two genera-
tions living in Curitiba, Brazil (Fig. 1). All family members
gave their informed consent for the study. The study was
approved by the ethical committee of each participating in-
stitution. The clinical characteristics of the affected members
of the family are reported in the Results section.
DNA amplification and sequencing
Genomic DNA was extracted from peripheral blood
leukocytes of all family members. The three exons of the
NKX2-1 gene were amplified by polymerase chain reaction
(PCR) as previously described (5). PCR products were pu-
rified with Antarctic phosphatase-exonuclease I (New
England BioLabs, Ipswich, MA) at 37C for 15 minutes and
80C for 15 minutes for the enzyme activation and inacti-
vation respectively and the products were bidirectionally
sequenced with a 377 ABI sequencer (Applied Biosystems,
Foster City, CA). The genes encoding PAX8 (6), NKX2.5 (7),
and TAZ (8) were also amplified and sequenced as previously
described. To exclude the presence of polymorphysms, 100
normal subjects were also screened as controls.
Mutagenesis
The mouse Nkx2-1 gene from the p3XFLAG-CMV-10-
NKX2-1 vector was used as template in a PCR with the sense
primer 5¢-CCG CCG GAA GCG CGG GTG CTC TTC T-3¢ and
the antisense primer 5¢-GAG AAG AGC ACC CGC GCT TCC
GGC-3¢ using the QuikChange Site-Directed Mutagenesis kit
(Agilent Technologies, La Jolla, CA) according to the manu-
facturer’s procedure. The presence of the mutation in the
obtained vector was confirmed by direct sequencing.
Western blot
HEK293 cells were transiently transfected with 10 lg of
either wild-type (WT)-Nkx2-1 or c.493delC-Nkx2-1 plasmids
using the FuGene 6 Transfection Reagent (Roche, Indiana-
polis, IN) according to the manufacturer’s instructions. After
48 hours, cells were scraped in phosphate-buffered saline (pH
7.4) and centrifuged at 1792 g for 5 minutes at 4C. Pellets
were frozen and stored at -80C until used to prepare nuclear
or total extracts as previously described (5).
Ten micrograms and 40 lg each of nuclear and total extracts
were boiled in Laemmli buffer and resolved on a 12% SDS-
PAGE gel. The gel was blotted on Immobilon P (Millipore
Corp., Bedford, MA) for 90 minutes at a constant current of
100 mA. Immunodetection of NKX2-1 was performed by
using a monoclonal anti-FLAG antibody (M2; Sigma, St.
Louis, MO) diluted 1:3000 in Tris-buffered saline containing
5% nonfat milk (Bio-Rad Laboratories, Inc., Richmond, CA),
and the filter was treated with a 1:3000 dilution of goat anti-
mouse IgG conjugated to horse radish peroxidase (Bio-Rad).
Electrophoretic mobility shift assay
The binding to DNA of the c.493delC mutant was studied
by electrophoretic mobility shift assay (EMSA) using double-
stranded end-labeled oligonucleotide C for the Tg promoter
as described (9), and double-stranded end-labeled oligonu-
cleotide C2 for the surfactant protein C (SP-C) promoter (10).
Cell culture and in vitro functional assays
HEK293 and HeLa cells were maintained in Dulbecco’s mod-
ified Eagle’s medium supplemented with 2 mM L-glutamine,
4.5 g/L D-glucose, 50 U/mL penicillin, 50lg/mL streptomycin,
and 10% fetal bovine serum under humidified 5% carbon
dioxide/95% air at 37C and grown in 24-well plates to
70%–80% confluence (i.e.,*5 · 104 cells per well).
HeLa cells were transfected with the reporter plasmid
(0.1 lg of pTg-Luc, 0.3 lg of SP-C-Luc 0.32) plus 3 ng of
CMV-Ren as an internal control vector, and different doses
of effector plasmids. HEK293 cells were transfected with
0.1 lg of the reporter pTg-Luc plasmid and 1.5 ng of CMV-
Ren internal control vector plus different doses of effector
plasmids. In each set of transfection experiments, the total
amount of transfected DNA was normalized using an empty
vector.
Transfections were performed with the TurboFect in vitro
Transfection Reagent (Fermentas Life Sciences, Pittsburgh,
PA), using a DNA/Turbofect ratio of 1:2 in all experiments.
Cells were harvested after 36–48 hours and analyzed se-
quentially for firefly and Renilla luciferase activities (Dual-
Luciferase Reporter Assay System, Promega, Madison, WI).
FIG. 1. Pedigree of the
studied family. The family
members carrying the
c.493delC mutation
(p.Arg165Glyfs*32) and
showing the clinical manifes-
tation of brain–thyroid–lung
syndrome (BTLS) are in black.
The proband (III-6) is indi-
cated by an arrow.
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The ratios between the measured firefly and Renilla lucifer-
ase activities were expressed relative to the ratios obtained in
cells transfected with the reporter and an empty expression
vector (CMV-Flag) only. Transfection experiments were
performed in duplicate and repeated at least three times.
Data are shown as mean – SD. Statistical analysis was per-
formed using Student’s t-test.
Results
Patients
The family included five affected patients in three gen-
erations (Fig. 1). Collection of clinical information was dif-
ficult because the members of the family live in different
towns; therefore, some of the clinical characteristics were
missing.
The proband (III-6) was the fifth child of nonconsanguine-
ous parents. He was born at term with a birth weight of 2820 g,
but a delay in motor development was soon evident: he took
his first steps at 24 months of age. During infancy, the proband
showed moderate generalized choreiform movements and
cerebellar ataxia that remained stable thereafter, accompanied
by several episodes of respiratory insufficiency that were di-
agnosed either as asthma or pneumonia. Routine blood
chemistry and hematology tests and electrocardiograms were
normal. Brain MRI, electromyography, and muscle biopsy
were also normal.
When the proband was 13 years old, his thyroid function
tests (TFTs) revealed subclinical hypothyroidism: serum
thyrotropin (TSH) was 9.1 mU/L (normal range 0.35–
4.94 mU/L), free thyroxine (FT4) was 1.07 ng/dL (normal
range 0.7–1.48 ng/dL) and triiodothyronine (T3) was
127.55 ng/dL (normal range 58–159 ng/dL). Serum anti-
thyroid antibodies tests were negative.
The proband’s mother (II-1) presented with short stature,
mild generalized choreiform movements since infancy, sub-
clinical hypothyroidism (TSH 8.51 mU/L, FT4 1.07 ng/dL, T3
109.46 ng/dL), and episodes of respiratory insufficiency (di-
agnosed as asthma) in childhood.
Subject III-2, a brother of the proband, presented with
cervical dystonia, moderate generalized choreiform move-
ments, and hypothyroidism (TFT not available) at the age of
22 years.
Subject III-4 (the oldest sister of the proband) was diag-
nosed with a mild choreiform movement disorder at the age
of 17 years. At that time, subclinical hypothyroidism (TSH
8.13 mU/L, FT4 1.1 ng/dL, T3 122.08 ng/dL) was also noticed.
She was treated with 25 lg/d of L-thyroxine, which normal-
ized serum TSH levels.
The proband’s youngest sister (III-5) presented with mod-
erate generalized choreiform movements, mild cognitive
deficit, and subclinical hypothyroidism (TSH 5.43 mU/L, FT4
1.19 ng/dL, T3 126.60 ng/dL) at the age of 14 years.
All the other members in the family (I-1, I-2, II-2, II-3, III-1,
III-3, III-7, III-8, III-9) had normal TFTs and normal thyroid
morphology on ultrasound examination.
Sequencing
Sequencing of the NKX2-1 coding region of the proband’s
DNA revealed a new monoallelic deletion of the cytosine at
position 834 (accession no. NM_003317.3). The mutation is
responsible for a frameshift that produces an abnormal pro-
tein from amino acid 165. The last amino acid of the nuclear
localization signal (NLS), the whole homeodomain, and the
carboxy-terminus of NKX2-1 are all missing in the mutant
protein, which has a premature stop codon at position 196
(p.Arg165Glyfs*32). The mutant protein has an approximate
molecular weight of 20 kDa.
The same mutation (TRANSNP_1331899076), never de-
scribed before, was present in all the affected members of the
family but not in any of the unaffected members of the family
or in the 100 normal controls.
No mutations were detected in the coding sequences of
PAX8, NKX2-5, and TAZ genes in the family members or in
the 100 normal controls.
Nuclear localization
Since the c.493delC mutation occurs in the codon encoding
for the last amino acid of the NLS of NKX2-1, we tested the
effect on the nuclear localization. To this aim, HeLa cells were
transfected with either the WT-Nkx2-1 or the c.493delC-Nkx2-
1. After 24 hours, both nuclear and cytoplasmatic proteins
were extracted from transfected cells and Western blot results
are shown in Figure 2.
As expected, WT-NKX2-1 was synthesized and migrated
into the nucleus, disappearing from the cytosolic extracts.
Despite the alteration of the nuclear localization signal, the
c.493delC was able to migrate into the nucleus.
These results indicate that the p.Arg165Glyfs*32 was syn-
thesized and was capable of migrating into the nucleus.
DNA binding capacity
DNA binding properties of the c.493delC mutant were also
analyzed by EMSA using a short DNA stretch corresponding
to the NKX2-1 binding site within the Tg promoter (oligo C)
(9) and the SP-C promoter (oligo C2) (10). The results are
shown in Figure 3. A retarded band could be detected with the
WT, while the c.493delC NKX2-1 was, as expected, unable to
bind to DNA because of the absence of the homeodomain.
Moreover, the addition of the same or double amount of
c.493delC extracts did not reduce the binding of WT-NKX2-1.
This indicates that c.493delC-NKX2-1 was unable to physi-
cally interact and modulate WT-NKX2-1 binding to DNA. The
specificity of all the observed complexes was demonstrated in
competition experiments adding a 100-fold excess of cold
oligos.
FIG. 2. Western blot analysis with the anti-FLAG anti-
bodies of cytosolic and nuclear extract of the cells transfected
with both wild-type (WT) and c.493delC (p.Arg165Glyfs*32)
cloned into the p3XFLAG-CMV-10 plasmid. The c.493delC is
normally synthesized and able to migrate into the nucleus.
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Transactivation capacity of mutated
and WT NKX2-1 proteins
The transcriptional properties of both WT- and c.493delC-
NKX2-1 were investigated by co-transfection assays as pre-
viously described. As expected, the c.493delC mutant was
unable to activate both the Tg (11) and the SP-C promoters
(12).
Thereafter co-transfection experiments were performed
using both WT and the c.493delC mutant on the same pro-
moters. Interestingly we were able to demonstrate a dose-
dependent dominant negative effect of the c.493delC mutant
on the WT-NKX2-1 when used with the Tg promoter (Fig.
4A), but no dominant negative effect could be demonstrated
on the SP-C promoter (Fig. 4B), indicating that the c.493delC
mutant produced a dominant-negative effect on the wild-type
NKX2-1 in a promoter-specific manner.
To further understand the dominant-negative action and
investigate the c.493delC effects, co-transfection experi-
ments were performed with PAX8, P300, and TAZ on the
Tg promoter.
PAX8 (Paired Box Gene 8) is a transcription factor ex-
pressed in the thyroid but not in the lung. It synergizes with
NKX2-1 to stimulate Tg and thyroperoxidase promoter ac-
tivities (13).
P300 (E1A-Binding Protein), a general transcriptional
coactivator, plays a pivotal role in the activity of many tran-
scription factors, either by bridging sequence-specific DNA-
binding factors with elements of the basal transcriptional
machinery, such as transcription factor IIB and polymerase 2,
or by its intrinsic histone acetyltransferase activity. NKX2-1,
PAX8, and P300 physically interact with each other (13–15),
and the functional synergism may involve the direct cooper-
ation of all three factors. The addition of P300 increases the
transactivation properties of PAX8, NKX2-1, and both factors
together.
TAZ (transcriptional co-activator with a PDZ-binding
motif, also known as WWTR1) is also present in thyroid tissue
and in differentiated thyroid cell lines (16), thus acting as a
potent co-activator for both PAX8 (16) and NKX2-1 (17).
As previously shown (13), we were able to demonstrate
that PAX8 synergized with the WT protein and increased Tg
promoter activity. The co-transfection with the c.493delC did
not modify the PAX8 basal activity, and the dominant nega-
tive effect was also present when both WT and c.493delC
proteins were transfected with PAX8 (Fig. 5).
FIG. 3. DNA binding capability of the c.493delC mutant
(p.Arg165Glyfs*32). Electrophoretic mobility shift assay
(EMSA) was performed with nuclear extracts of HEK293
cells transfected with WT and c.493delC constructs on the
thyroglobulin (Tg) promoter (A) and surfactant protein C
(SP-C) promoter (B). Arrowheads indicate the bound NKX2-
1 to the oligos. The co-transfection of the WT-Nkx2-1 with the
same (+/+) or double (+/+ +) amount of the mutant
c.493delC does not reduce the binding of the WT. Extracts
were also incubated with a large excess (100-fold) of cold
oligos as a competitor that produced a significant displace-
ment of the bound labeled probe.
FIG. 4. Transcriptional activation of Tg and the SP-C pro-
moters. (A) Effects of transfection of WT-NKX2-1 and
c.493delC-NKX2-1 on the Tg promoter. Addition of increas-
ing amounts (12.5, 25, 50 ng) of c.493delC to a constant
amount (50 ng) of the WT produced a significant decrease in
the promoter activity (***p< 0.001). (B) Effects of transfection
of WT-Nkx2-1 and c.493delC-Nkx2-1 on the SP-C promoter.
Contrary to what was observed for Tg, addition of increasing
amounts (12.5, 25, 50 ng) of c.493delC to a constant amount
(50 ng) of the WT did not reveal a dominant negative effect.
FIG. 5. Synergism with PAX8. Transcription activation of
the Tg promoter by WT-NKX2-1 and c.493delC-NKX2-1 in
the interaction with PAX8. HeLa cells have been transfected
with 50 ng of each plasmid and 100 ng of the reporter. The
addition of WT produced a significant (***p< 0.001) increase
in the PAX8 activity, while the addition of the c.493delC had
no effect. If both WT-Nkx2-1 and c.493delC-Nkx2-1 were
transfected, the dominant negative effect of the mutant on
the WT protein was still present. The presence of PAX8 did
not rescue the dominant negative effect on the Tg promoter.
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To further study the interplay of P300, PAX8, and both WT
and c.493delC proteins, co-transfection experiments were
performed in HEK293 cells, since these cells lack the endo-
genous P300 (18). Again, if the c.493delC was added to the
cells, there was no increase in the activation produced by
PAX8 and/or P300, suggesting that this truncated protein did
not interfere with the complex. Finally, when all four factors
were present (WT, c.493delC, PAX8 and P300), a slight de-
crease in the activity could be observed compared with the
multiprotein complex of NKX2-1/PAX8/P300 (Fig. 6).
These results indicate that the dominant negative effect can
also be observed when a multifactorial complex is present,
and PAX8 or P300 are unable to rescue the effect of the
mutation.
Similar results were obtained when the coactivator TAZ
was used in HeLa cells (data not shown).
Discussion
Mutations in NKX2-1 have been demonstrated to be re-
sponsible for several cases of BTLS, and in this article we
describe a novel mutation in the gene encoding for NKX2-1 in
a family with the clinical manifestations of benign hereditary
chorea, hypothyroidism, and respiratory distress. The muta-
tion c.493delC results in a protein of 196 amino acids. The
mutant protein contains a frameshift and differs from the WT
beginning at position 165, which corresponds to the last
amino acid of the NLS. Transfection experiments with the
mutant protein demonstrate that the c.493delC protein is
synthesized and translocates into the nucleus, but it is unable
to bind DNA since it completely lacks the homeodomain. The
c.493delC mutant was responsible for a clear dose-dependent
dominant negative effect on the WT NKX2-1 when tested on
the Tg promoter, whereas when functional assays were per-
formed on the lung SP-C promoter, the c.493delC mutant
showed no dominant negative effect.
Several mutations in NKX2-1 have been reported (5,19–38),
and in the majority of cases haploinsufficiency has been con-
sidered to be responsible for the phenotype, as also sug-
gested by the finding of motor abnormalities and mild
hyperthyrotropinemia in the Nkx2-1 heterozygous knockout
mice (19). Only a few mutations (Table 1) produce a dominant
negative effect on the WT NKX2-1 (20,21), and there is only
one case among them describing a promoter-specific domi-
nant negative effect (22). In this last case, contrary to what was
observed for the c.493delC, the mutant protein contained the
homeodomain and could bind to DNA. The authors sug-
gested that the possible interference of the mutant NKX2-1
(p.P275fs*74) with the cooperative interaction between
NKX2-1 and PAX8 or NKX2-1 and other cofactors on the Tg
promoter is the cause of the promoter-specific dominant
negative effect. Since our mutant did not bind to DNA, it is
probable that the amino terminus of NKX2-1 binds to other
factors that are relevant for its activity on the Tg promoter,
thus excluding them from the transcriptional complex and
reducing the activity of the WT NKX2-1. In fact, tissue-specific
transcriptional regulation is achieved by the combined inter-
action among transcription factors, co-regulators, and other
components regulating basal transcription. In the thyroid,
NKX2-1 physically interacts with both PAX8 (13) and TAZ
(16). In addition P300, a ubiquitous transcriptional cofactor,
has been demonstrated to play an important role for the
NKX2-1/PAX8 synergy (14,39). PAX8, P300, and TAZ were
tested to see whether they could influence the transactivation
of NKX2-1 on its target promoters. The presence of these co-
factors increased the activation of the Tg and SP-C promoters,
but did not change the thyroid-specific dominant negative
effect. In addition, no rescue of the NKX2-1/PAX8 synergism
was observed, contrary to what was previously reported in
the case of a PAX8 mutation (39).
It has been suggested that NKX2-1 binds to DNA as a dimer
(40) and that the interaction with PAX8 occurs via the amino
terminus of the NKX2-1 protein (13). Several other factors, most
of which not yet defined, may be involved in the regulation of
transcription. We believe that the truncated NKX2-1 mutant
described in this article interferes with the activity of WT-
NKX2-1, decreasing the activity of the multiprotein transcrip-
tional complex. It is likely that PAX8 plays a critical role in
modulating this effect in thyroid cells. In lung cells, where
PAX8 is absent, the dominant negative effect can not be ob-
served. Even if HeLa cells do not express PAX8, it has been
previously suggested that other proteins with a similar activity
may replace the function of PAX8 on the Tg promoter (22).
Very recently Silberschmidt and coworkers (41) produced
mice lacking one of the two redundant activation domains of
Nkx2-1, or having defective phosphorylation of the protein.
They demonstrated that each mutant shows a distinct phe-
notype. They also revealed a level of complexity that could
not be predicted by experiments carried out in cultured cells
and stressed the discrepancy between the results in the cell
models and in those that can be obtained in whole organisms
(41). In this context, the major molecular effect of our mutation
on the Tg promoter is dominant, while hypothyroidism is
only mild (subclinical) in all the affected members of our
FIG. 6. Effect of P300. HEK293 cells were co-transfected
with WT-Nkx2-1 (50 ng), c.493delC-Nkx2-1 (50 ng), PAX8
(50 ng), and P300 (300 ng) expression vectors, and the pTg-
Luc reporter (100 ng) in the indicated combinations. The
addition of P300 significantly increased the activity of the Tg
promoter in response to WT-NKX2-1 and PAX8, but had no
effects on the activity of c.493delC. The cooperation between
WT, PAX8, and P300 produced an additional increase in the
activity, while the activation of the complex c.493delC/PAX8
did not differ from the activation observed when PAX8 was
co-transfected with P300 alone. Finally, when all the factors
were present, there was a reduction of the activation com-
pared with the WT +PAX8 complex, as a consequence of the
dominant negative effect of the c.493delC mutant on the WT.
Significant differences between the samples with and with-
out P300 are indicated: ***p < 0.001.
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family. This discrepancy can be the consequence of different
mechanisms of action of the mutation in the different tissues,
but also of the complex interactions between other genetic
and/or environmental factors that may modulate the pheno-
type. All the reported NKX2-1 mutations (summarized in Table
1) have variable functional effects, even if the mutations occur
in similar regions of the protein. Indeed, the clinical features of
the affected families and family members described in the lit-
erature are very variable, and there is no correlation between
the clinical and the molecular phenotype. Mutations that pro-
duce major alterations in the protein structure may be associ-
ated with only minor neurological signs (19,26), while primary
hypothyroidism has been linked to NKX2-1 mutations in 81%
of the cases (25/31) (19,20,22,27–38).
In conclusion, a novel NKX2-1 mutation in a family pre-
senting the clinical findings of the BTLS is described. The
c.493delC mutant migrates into the nucleus but is not able to
transactivate the Tg or SP-C promoters. These results indicate
that NKX2-1 activity is finely regulated by the interaction of
several factors that are still largely unknown. The mecha-
nisms regulating gene expression are different in each tissue.
Additional studies are required to better understand the
complexities of the genotype–phenotype correlation in the
NKX2-1 deficiency syndrome.
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ABSTRACT. Context: Congenital hypothyroidism (CH) is a
common endocrine disorder with an incidence of 1:3000-
4000 newborns. In 80-85% of cases, CH is caused by defects
in thyroid organogenesis, resulting in absent, ectopically lo-
cated, and/or severely reduced gland, all conditions indicat-
ed as “thyroid dysgenesis” (TD). A higher prevalence of con-
genital heart diseases has been documented in children with
CH compared to the general population. This association sug-
gests a possible pathogenic role of genes involved in both
heart and thyroid development. Among these, it can be in-
cluded Isl1, a transcription factor containing a LIM home-
odomain that is expressed in both thyroid and heart during
morphogenesis. Objective: In the present study, we investi-
gate the role of ISL1 in the pathogenesis of TD. Settings and
patients: By single stranded conformational polymorphism,
we screened for mutations the entire ISL1 coding sequence
in 96 patients with TD and in 96 normal controls. Results: No
mutations have been found in patients and controls. Con-
clusion: Our data indicate that, despite the relevant role of
ISL1 in thyroid and heart morphogenesis, mutations in its
coding region are not associated with TD in our group of pa-
tients.
(J. Endocrinol. Invest. 34: e149-e152, 2011)
©2011, Editrice Kurtis
INTRODUCTION
Primary congenital hypothyroidism (CH) is the most fre-
quent endocrine metabolic disease in the infancy, with
an incidence of 1/3000-4000 live birth. In about 15% of
cases, the disease is caused by inborn errors in the mech-
anisms required for thyroid hormone biosynthesis, a con-
dition known as dysormonogenesis. In the remaining 85%
of the cases, CH is caused by alterations occurring during
the thyroid gland organogenesis, that results in a thyroid
that is completely absent (athyreosis), severely reduced in
size (hypoplasia) or located in abnormal position (ectopy).
All these entities are grouped under the term of “thyroid
dysgenesis” (TD) (1).
Several genes have been found mutated in patients with
TD, including NKX2.1, FOXE1, PAX8, TSHR, and NKX2.5,
suggesting that in a small percentage of cases TD is a
genetic disorder (2).
Congenital malformations, mostly cardiac, have higher
frequency in children with CH than in the general popu-
lation (3-5), and we recently demonstrated that NKX2.5,
a transcription factor that plays a crucial role in heart mor-
phogenesis (6-8) and found altered in patients with con-
genital heart disease (9-12), can also be associated to TD
(13). These observations suggest that genes expressed
during embryogenesis of both thyroid and heart can be
good candidates in the pathogenesis of TD. One of these
is the gene encoding for ISL1, a LIM homeodomain tran-
scription factor originally proven to be necessary for the
differentiation of both exocrine and endocrine pancreas
(14). Pancreatic organogenesis requires Isl1 activity in en-
doderm progenitors as well as in the mesenchymal tis-
sues surrounding the dorsal pancreatic bud. A similar ex-
pression pattern of Isl1 has been demonstrated in the an-
terior foregut and adjacent cardiogenic mesoderm in ear-
ly steps of mouse (15) and Drosophila cardiogenesis (16).
Isl1 knock out mice show severe malformations of the
heart and of the cardiac outflow tract that leads to em-
bryonic lethality around E10.5 (15). Since thyroid pro-
genitor cells assemble in this portion of the endoderm, it
can be hypothesized that Isl1 might also play a role in
this process. This possibility is also suggested by recent
findings demonstrating that Isl1-regulated cardiac mor-
phogenesis is mediated via Sonichedgehog (Shh) (17)
and that Shh null mice exhibit thyroid malformations (18,
19). Finally, Isl1 has previously reported to be expressed
in the early thyroid placode in chicken (20) and in the
adult rat thyroid gland, although only C-cells showed Isl1
immunoreactivity in this study (21).
Very recently, it has been showed that, in mouse embryo,
Isl1 is widely expressed in the anterior foregut endoderm
including the thyroid primordia. During further develop-
mental steps, Isl1 expression is maintained in all thyroid
progenitor cells until the anlagen fuse at 13.5. Therefore
Isl1 expression seems to be restricted to the C-cells pre-
cursors, and it is down-regulated in the presumptive fol-
licular cells. The adult thyroid contains only few Isl1-pos-
itive cells, but their number is in clear minority compared
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to the total number of C-cells. These data suggest that
Isl1 is a putative transcriptional regulator of both follicu-
lar and C-cell during thyroid organogenesis (22).
Given the foregoing, we considered ISL1 as a good can-
didate gene for TD. In the present work, ISL1 mutation-
al screening was carried out in a group of 96 patients
with TD but no mutation has been identified.
MATERIALS AND METHODS
Patient recruitments
Ninety-six patients with permanent CH (35 with ectopy, 31 with
hypoplasia, 30 with athyreosis), were included in the study. For
all of them, together with blood sample, pediatricians provide a
questionnaire with several clinical informations. With the ex-
ception of 3 cases, no congenital heart defects have been indi-
cated in the questionnaire, suggesting that patients did not pre-
sented relevant cardiac alterations. In 3 patients minor heart
congenital defects have been reported: 2 patients (1 with thyroid
ectopy and the other 1 with thyroid hypoplasia) with patent fora-
men ovale at birth that resolved spontaneously and 1 (with thy-
roid ectopy) with minor pulmonary valve insufficiency. Screening
for mutations in other genes associated to TD (NKX2.1, FOXE1,
PAX8, TSHR) and in NKX2.5 (associated with TD and congenital
heart disease) was negative in all the patients. Also 96 healthy
subjects with no thyroid-related disorders were also enrolled as
controls. The study was approved by the Ethics Committees of
the participating Institutes. All individuals, or parents of minors,
gave their informed consent.
Single stranded conformational polymorphism
The entire ISL1 coding region was screened for mutations on
genomic DNA extracted from peripheral blood lymphocytes.
Oligonucleotide primers (sequence available upon request) were
designed on the human ISL1 cDNA (NM_002202) and genom-
ic sequences to produce PCR products suitable for single strand-
ed conformational polymorphism (SSCP) analysis (Fig. 1). PCR
reactions were carried out in 10 µl reaction volume with the fol-
lowing cycling parameters: 94 C, 8 min; 94 C, 45 sec; the spe-
cific temperature for each exon, 30 sec; 72 C, 45 sec for 35 cy-
cles; 72 C, 15 min. Samples were denatured 1:1 in denaturing
solution (99% formamide, 1% xylene cyanol solution, 0.1% bro-
mophenol blue) at 95 C for 5 min and thereafter directly placed
on ice to prevent reannealing of the single stranded product.
Six µl of each sample were applied to a nondenaturing gel of
acrylamide (GeneGel TM Excel 12.5/24 Kit, GE Healthcare Bio-
Sciences AB, Sweden) and run on a GenePhorTM Elec-
trophoresis Unit (GE Healthcare Bio-Sciences AB, Sweden). The
running conditions were the following: plate temperature: 15 C,
600 V, 25 mA, 15 W. The running was stopped when bro-
mophenol blue reached the anode buffer strip (at least 80 min).
Following separation, we stained nucleic acids in acrylamide gel
using the PlusOneTM DNA Silver Staining Kit (GE Healthcare
Bio-Sciences AB, Sweden), following producer’s protocol.
Direct sequencing
PCR products of the samples showing an abnormal migration
at the SSCP were purified with Antartic Phosphatase-Exonucle-
ase I (New England BioLabs, USA) at the following conditions: 37
C for 15 min and 80 C for 15 min, respectively for enzymes ac-
tivation and inactivation, and then, directly sequenced bi-direc-
tionally with a 377 ABI sequencer.
Statistical analysis
Statistical analysis were performed using the 2×2 contingency
table available on line at http://graphpad.com/quickcalcs
/contingency1.cfm. p values were calculated using the Fisher’s
exact test.
RESULTS
SSCP method was used as first approach to screen for
mutations the ISL1 coding sequence in patients with TD
using specific primer-pairs. Examples of the SSCP are
Fig. 1 - Panel A shows a schematic rep-
resentation of the human WWTR1 gene
and the location of the primers used for
single stranded conformational poly-
morphism (SSCP) analysis. In panel B, the
PCR product length and the annealing
temperature of the respective PCR am-
plification are reported for each DNA ex-
on. In panel C, typical results of SSCP
analysis are shown. Please note in SS-
CP4a the different migration patterns of
samples 1 and 3 compared to samples 2
and 4. They correspond to a heterozy-
gous CCA to CCG change in the triplet
encoding for proline at position 168 of
ISL1.
1
A
B C
SSCP 1
SSCP 1
SSCP 4a
SSCP 5
SSCP 4b
SSCP 6
SSCP 2 SSCP 3
2 3 5 64
SSCP 3 SSCP 4b SSCP 5
SSCP 2 SSCP 4a SSCP 6
SSCP PCR length Annealing T
1 337 bp
2 287 bp
3 367 bp
4a 338 bp
59 C
4b 248 bp
5 228 bp
6 235 bp 51.2 C
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shown in Figure 1. No mutations have been identified in
DNA extracted from either patients or controls. We found
a silent polymorphism corresponding in a CCA to CCG
change in the triplet encoding for proline at position 168
in 8 patients (4 with ectopy and 4 with hypoplasia) in het-
erozygous state and in 10 patients (5 with athyreosis, 2
ectopy, 1 with thyroid ectopy and patent foramen ovale
and 2 with CH not further characterized) in homozygous
state. The same polymorphism was found in 28 controls
(8 in heterozygous state and 20 in homozygous state).
This polymorphysm has been previously reported
(http://www.genecards.org). Statistical analysis (Fisher’s
exact test) demonstrated no significant difference be-
tween patients and controls.
DISCUSSION
The genetic origin of TD is still wildly discussed, despite
several genetic factors have been demonstrated as cause
of CH in animal models and in a small percentage of pa-
tients with TD.
Since TD is frequently associated to other congenital mal-
formations, mostly cardiac (3-5), it is possible to hypoth-
esize that genes involved in heart organogenesis might
also participate to thyroid development. The ventral pha-
ryngeal endoderm, from which the thyroid follicular cells
originate, lies in close opposition to the heart mesoderm,
and the role of the endoderm in the “specification” and
differentiation of myocardial cells has been already de-
fined (23). Conversely, the influence of the developing
heart on thyroid organogenesis has not been demon-
strated, although a recent work identify a critical role of
developing arteries on thyroid development (18). The hy-
pothesis of close relationship between developing heart
and thyroid is also confirmed by the recent identification
of mutation in the NKX2.5 gene, a transcription factor crit-
ical for the heart morphogenesis, in patients with TD (13).
Based on these findings, we are investigating the possible
role of genes involved in heart development for their role
in thyroid organogenesis, and ISL1 could be considered
an attractive candidate in the pathogenesis of TD.
Cai et al. showed that Isl1 null mice die at approximate-
ly E10.5 because of severe cardiovascular malformations.
These are determined by the lack of Isl1-expressing car-
diogenic progenitor cells in embryonic heart and as con-
sequence of a decreased cell proliferation and increased
apoptosis in the endoderm and in the adjacent splanch-
nic mesoderm in Isl1 null mice embryos (15).
More recently Wendl et al. demonstrated a role for car-
diac mesoderm in early thyroid development (24): thy-
roid progenitor cells were missing and the thyroid failed
to develop in zebrafish mutants deficient of Hand2, a
transcriptional factor involved in heart development.
Since Hand2 was suggested to function downstream of
Isl1 in the developing heart (25), it might be possible that
the Isl1-dependent signals in the pharyngeal mesoderm
might also influence the growth of the thyroid bud.
Westerlund et al. speculated that Isl1 might be an inter-
esting gene involved in the control of the early phases
thyroid formation (thyroid specification), and demon-
strated that Nkx2.1-positive thyroid progenitor cells ex-
press Isl1 during evagination from the pharyngeal endo-
derm at E10.75 and when the thyroid is completely de-
tached at E11.5 (22). Moreover, Isl1 is expressed in the
endoderm of the 4th pouches at E10.75 and in the com-
pletely detached E12.5 ultimobranchial bodies, from
which calcitonin-producing cells (C-cells) originate. At
E13, Isl1 expression is present in the trachea, in the ulti-
mobrachial bodies, in midline thyroid primordium, and
in the mesenchyme surrounding the trachea, but, after
the fusion of the cells deriving from the ultimobrachial
bodies with the midline precursors of the follicular thy-
roid cells at E13.5, Isl1 is present only in the thyroid, while
its expression is markedly decreased in the midline meso-
derm and trachea. Isl1 expression disappears when the
number of C-cells gradually increase between E15.5 and
E17.5 (22). Of note, starting from E9.5 the thyroid pla-
code is significantly smaller in Isl1–/– mice when compared
wild type embryos, and the thyroid follicular cells at this
stage present a normal Nkx2.1 and Pax8 expression (22).
Finally, in cardiac progenitors Nkx2.5 is transcriptionally
regulated by Isl1 (26). Takeuchi and coworkers studied
the upstream regulatory regions of the proximal Nkx2-5
enhancer and identified a conserved Isl1-binding site,
adjacent to the Gata site required for NKX2.5 expression
in the anterior heart field. Mutations in this Isl1-binding
site abolish Nkx2.5 expression in the right ventricle and
in the outflow tract. We previously demonstrated the as-
sociation between NKX2.5 mutation and thyroid dysge-
nesis (13), and Takeuchi’s data clarify the strong interac-
tion between these two transcription factors, at least in
the developing heart.
All these observations allow to hypothesize a possible
role of ISL-1 also in the thyroid development. In the pre-
sent study, the entire coding region of the ISL1 gene was
screened for mutations in patients with CH due to thy-
roid dysgenesis in order to evaluate the potential role of
this gene in the pathogenesis of TD. We were not able to
demonstrate mutations in the ISL1 coding sequence in
96 patients with TD as well as in 96 healthy normal con-
trols.
The absence of ISL1 mutations in our patients well cor-
relate with the complex phenotype observed in Isl1
knock-out mice, were the severe cardiac malformations
are responsible for early embryonic lethality (22), and it is
possible to hypothesize that alterations in this gene are
not compatible with life also in humans as well as in mice.
Our results do not exclude the potential role of ISL1 in
the pathogenesis of TD, since we have not investigated
other genes potentially necessary for ISL1 activity, in-
cluding cofactors or cell-specific co-activators. Moreover,
mutation(s) in the ISL1 promoter responsible for a de-
crease in the expression of the gene, would have been
undetected in this study as well as mutations occurring in
intronic regions of the gene that can produce inactive
splice variants.
In conclusion, despite the fact that ISL1 was a good can-
didate for TD, we did not find mutations in the coding
region of this gene in patients with TD alone as well as in
the 3 patients with TD and congenital heart disease. Our
results could be explained by the essential role of this
factor in embryonic heart development. As described in
mouse models, it should be hypothesized that patients
with ISL1mutations die before birth because of heart ma-
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jor defects. In these patients TD might be not diagnosed
and the detection of ISL1 mutations lost.
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